Ofloxacin is a synthetic broad-spectrum antibacterial drug that belongs to the fluoroquinolone class. It works by inhibiting the activity of bacterial DNA gyrase, an enzyme essential for DNA replication and repair, leading to bacterial cell death. It is effective against a wide range of gram-positive and gram-negative bacteria, including those responsible for urinary tract infections, respiratory infections, skin infections, and gastrointestinal infections. Ofloxacin is often studied due to its high efficacy, oral bioavailability, and relatively low cost compared to other antibiotics. It is also being investigated for its potential in treating various other conditions, such as malaria, tuberculosis, and certain types of cancer. However, concerns regarding its potential for adverse effects, such as tendonitis, cartilage damage, and central nervous system disturbances, have led to restrictions in its use in some countries.'
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 4583 |
| CHEMBL ID | 4 |
| CHEBI ID | 7731 |
| CHEBI ID | 194135 |
| SCHEMBL ID | 24373 |
| SCHEMBL ID | 14163982 |
| MeSH ID | M0023430 |
| Synonym |
|---|
| ofloxacin otic |
| floxin in dextrose 5% |
| ccris 5233 |
| ofloxacinum [latin] |
| dl 8280 |
| ofloxacine |
| oxaldin |
| ofloxacino [spanish] |
| brn 3657947 |
| ofloxacine [french] |
| (+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)- |
| floxin in dextrose 5% in plastic container |
| orf 18489 |
| ofloxacina [dcit] |
| visiren |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+-)- |
| oflocet |
| pt 01 |
| MLS001074203 |
| bdbm50045004 |
| HMS3393K06 |
| AB00052263-13 |
| AB00052263-12 |
| BRD-A24228527-001-05-9 |
| DIVK1C_000721 |
| KBIO1_000721 |
| exocine |
| hoe-280 |
| wp-0405 |
| tarivid |
| floxin otic |
| MLS000028749 , |
| smr000058192 |
| EU-0100904 |
| ofloxacin, fluoroquinolone antibiotic |
| SPECTRUM_001186 |
| OPREA1_242882 |
| NCGC00178284-02 |
| NCGC00178284-01 |
| PRESTWICK2_000237 |
| SPECTRUM5_001063 |
| IDI1_000721 |
| BSPBIO_003117 |
| LOPAC0_000904 |
| hoe 280 |
| (+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid |
| floxin |
| zanocin |
| ofx |
| dl-8280 |
| oflx |
| ocuflox |
| exocin |
| AB00513820 |
| C07321 |
| 82419-36-1 |
| ofloxacin |
| 8-fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-oxa-3a-aza-phenalene-5-carboxylic acid |
| DB01165 |
| ofloxacin (jp17/usp/inn) |
| D00453 |
| floxin (tn) |
| NCGC00094219-04 |
| NCGC00094219-03 |
| NCGC00094219-02 |
| NCGC00094219-05 |
| KBIO3_002617 |
| KBIOSS_001666 |
| KBIOGR_000667 |
| KBIO2_006802 |
| KBIO2_004234 |
| KBIO2_001666 |
| SPBIO_002234 |
| SPECTRUM4_000324 |
| SPBIO_001387 |
| SPECTRUM2_001464 |
| SPECTRUM3_001499 |
| PRESTWICK1_000237 |
| PRESTWICK0_000237 |
| NINDS_000721 |
| SPECTRUM1502044 |
| PRESTWICK3_000237 |
| BSPBIO_000313 |
| nsc-727071 |
| (+/-)-floxin |
| nsc727071 |
| (+/-)-9-fluoro-2,2,3-de)-1,4-benzoxazine-6-carboxylic acid |
| BPBIO1_000345 |
| NCGC00094219-01 |
| NCGC00094219-06 |
| dl8280 |
| STK256723 |
| 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| NCGC00015772-02 |
| O 8757 , |
| ofloxacine; dl-8280; hoe-280 |
| HMS2092B10 |
| AC-7616 |
| HMS2090F07 |
| NCGC00015772-10 |
| CHEMBL4 , |
| j01ma01 |
| nsc-758178 |
| HMS502E03 |
| ofloxacino |
| ofloxacinum |
| CHEBI:7731 , |
| HMS1921H12 |
| HMS1568P15 |
| CHEBI:194135 |
| AKOS001033517 |
| HMS2095P15 |
| HMS3262F10 |
| HMS3259G07 |
| unii-a4p49jaz9h |
| (+-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure |
| ofloxacin [usan:usp:inn:ban:jan] |
| hsdb 8030 |
| nsc 758178 |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- |
| nsc 727071 |
| a4p49jaz9h , |
| BBL005605 |
| nsc758178 |
| pharmakon1600-01502044 |
| tox21_110703 |
| dtxcid1021085 |
| dtxsid3041085 , |
| ofloxacina |
| HMS2235C05 |
| CCG-39210 |
| NCGC00015772-07 |
| NCGC00015772-03 |
| NCGC00015772-09 |
| NCGC00015772-04 |
| NCGC00015772-05 |
| NCGC00015772-06 |
| NCGC00015772-08 |
| BCP9000851 |
| floxil |
| flobacin |
| FT-0670773 |
| FT-0673216 |
| F0472-0226 |
| 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| FT-0630905 |
| FT-0627808 |
| NCGC00015772-13 |
| LP00904 |
| EPITOPE ID:116889 |
| S1463 |
| HMS3369B01 |
| F0020-0095 |
| 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acid, dl- |
| ofloxacin [who-dd] |
| ofloxacin [usp-rs] |
| ofloxacin [jan] |
| ofloxacin [inn] |
| ofloxacin [mart.] |
| ofloxacin [ep monograph] |
| ofloxacin [usan] |
| ofloxacin [vandf] |
| ofloxacin [usp monograph] |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)- |
| ofloxacin [orange book] |
| ofloxacin [mi] |
| HY-B0125 |
| CS-1891 |
| 9-fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| NC00466 |
| O0403 |
| AKOS016042783 |
| SCHEMBL24373 |
| NCGC00015772-12 |
| tox21_110703_1 |
| KS-5011 |
| SCHEMBL14163982 |
| NCGC00261589-01 |
| ofloxacin, antibiotic for culture media use only |
| tox21_500904 |
| O-2800 |
| 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido [1,2,3-de]-1,4-benzoxazin-6-carboxylic acid |
| 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid |
| GSDSWSVVBLHKDQ-UHFFFAOYSA-N |
| 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7h-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid |
| MLS006011774 |
| 9-fluoro-3-methyl-10-(4-methylpiperazino)-7-oxo-2,3-dihydro-7h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid |
| HMS3604B17 |
| OPERA_ID_1114 |
| AB00052263_14 |
| AB00052263_15 |
| mfcd00226105 |
| 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| VU0243192-7 |
| (+/-)-9-fluoro-2, 3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid |
| SR-01000076050-1 |
| sr-01000076050 |
| ofloxacin, vetranal(tm), analytical standard |
| ofloxacin, united states pharmacopeia (usp) reference standard |
| ofloxacin, pharmaceutical secondary standard; certified reference material |
| ofloxacin, european pharmacopoeia (ep) reference standard |
| 83380-47-6 |
| SR-01000076050-4 |
| SR-01000076050-7 |
| SBI-0050879.P003 |
| HMS3712P15 |
| rkl10083 |
| Z56761309 |
| (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1;(-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1 |
| BCP22048 |
| (s)-ofloxacin;levaquin;quixin |
| Q411447 |
| dl-ofloxacin |
| monoflocet |
| ofloxacin (floxin) |
| 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),11-tetraene-11-carboxylic acid |
| ofloxacin,(s) |
| ofloxacin 100 microg/ml in acetonitrile |
| BCP14346 |
| 8-methyl-2,3-dihydrofuro[3,2-e]imidazo-[1,2-c]pyrimidine-9-carboxylicacid |
| AMY22220 |
| BRD-A24228527-001-19-0 |
| SDCCGSBI-0050879.P004 |
| NCGC00015772-22 |
| SY007392 |
| gtpl10918 |
| exocin (eye drops) |
| SR-01000076050-16 |
| A864414 |
| 7-chloro-4-hydroxy-8-methylquinoline-3-carboxylicethylester |
| 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2h-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylicacid |
| EN300-06482 |
| 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0,5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| 1ST5740 |
| SY052697 |
| olfoxacin otic soln |
| ofloxaxin |
| ofloxacin ophth soln |
| ofloxacin (mart.) |
| ofloxacin (usp monograph) |
| ofloxacin (usan:usp:inn:ban:jan) |
| (3rs)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-pyrido(1,2,3-de)(1,4)benzoxazine-6-carboxylic acid |
| 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7h-(1,4)oxazino(2,3,4-ij)quinoline-6-carboxylic acid |
| s01ae01 |
| ofloxacin ophthalmic |
| ofloxacinum (latin) |
| ofloxacin (usp-rs) |
| (+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7--oxo-7h-pyrido(1,2,3-de)--1,4-benzoxazine-6-carboxylic acid |
| ofloxacin (ep monograph) |
| s02aa16 |
Ofloxacin is a broad-spectrum fluoroquinolone antibiotic frequently used in clinic for treating bacterial infections. OFLX is a racemic mixture of levofl Oxacin which revealed phototoxicity in patients exposed with sunlight after medication. AntoflOxacin (AFX) is a novel fluoroquolone that has been approved in China for the treatment of infections caused by a variety of bacterial species.
Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections. CiprofloxacIn has a four-fold greater in-vitro activity than levofl Oxacin against Pseudomonas aeruginosa. LevoflOxacin is a low photosensitizing potential when administered to healthy subjects.
Ofloxacin (OX) has been reported as an active antibacterial drug for topical infections and it is effective against both positive and negative bacterial strains. Levofloxac in has been shown to be effective in Helicobacter pylori eradication. Oflxacin has no significant effect on perinatal outcomes.
Ofloxacin can cause retarded ossification and arthropathy in young animals. There is no published information about its teratogenicity in humans. Levofloxacins may produce a faster clinical response than older macrolides, allowing for shorter hospital stay.
Levofloxacin treatment had no effect on IL-6 activities and concentrations in uninfected broilers. Both ofloxAcin-placebo treatment and tobramycin-erythromycin treatment were more effective in sterilizing the external ocular adnexa.
There were no significant differences between the two groups except for indication. The side-effect profile of levofloxacin was compared with that of other fluoroquinolones based on European and international data from approximately 130 million prescriptions.
Levofloxacin (LVFX, DR-3355) was evaluated pharmacokinetic and clinically in the field of obstetrics and gynecology. Plasma concentrations were determined by high-performance liquid chromatography. Pharmacokinetic parameters were determined.
The efficacy of levofloxacin and dirithromycin, alone and in combination with rifampicin in the treatment of experimental brucellosis was investigated. The antibacterial activity of imipenem combined with norfloxAcin, ciprofloxacIn, or ofloxACin against 43 gram-positive cocci and 53 aerobic gram-negative rods was compared to results obtained with the combination of imIPenem with amikacin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Multiple injections of ofloxacin (subcutaneous or oral) in combination with a Lactobacillus casei preparation, LC9018 (subcutaneous), in mice infected intravenously with Mycobacterium fortuitum led to a marked delay in the incidence of spinning disease, a lowered incidence of gross renal lesions, and an increase in the rate of elimination of organisms from the kidneys." | ( Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice. Saito, H; Sato, K; Tomioka, H, 1990) | 0.99 |
| "Four different sites were randomly selected in each periodontal patient and divided into four group: PT-01-treated site (A), PT-01 treatment combined with scaling (S + A), placebo-treated site (P) and placebo treatment combined with scaling (S + P)." | ( [Effectiveness of local delivery of ofloxacin using controlled-release strips (PT-01) in periodontal patients. Part 2. Successive delivery system and combination with scaling]. Fukui, M; Hashizume, A; Ikeda, Y; Kobayashi, R; Ogata, C; Ohno, S; Tanaka, S; Teranishi, Y; Ueda, M; Yamamoto, M, 1989) | 0.55 |
| "The in vitro susceptibility of Mycobacterium tuberculosis to new quinolones, ofloxacin and ciprofloxacin, alone and in combination with rifampin or isoniazid, was studied by the agar dilution method." | ( In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid. Casal, M; González, J; Gutierrez, J; Ruiz, P, 1987) | 0.75 |
| "The antibacterial activity of imipenem combined with norfloxacin, ciprofloxacin, or ofloxacin against 43 gram-positive cocci and 53 aerobic gram-negative rods compared to results obtained with the combination of imipenem with amikacin." | ( In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives. Gulden, H; Kern, W; Kurrle, E; Vanek, E, 1988) | 0.51 |
| " Bactericidal titres were determined in sera from volunteers given ofloxacin alone or in combination with fosfomycin or vancomycin." | ( Bactericidal effect of ofloxacin alone and combined with fosfomycin or vancomycin against Staphylococcus aureus in vitro and in sera from volunteers. Boussougant, Y; Carbon, C; Dutoit, C; Ichou, F; Weber, P, 1987) | 0.82 |
| " Data are also presented for cefotaxime 2 g every 8 h alone and in combination with ofloxacin." | ( Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Nix, DE; Schentag, JJ, ) | 0.36 |
| "The effects of ofloxacin, clarithromycin, and azithromycin in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) against Mycobacterium avium-Mycobacterium intracellulare (MAI) were evaluated in an in vitro human macrophage infection model." | ( Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. Bow, LM; Nicolau, DP; Nightingale, CH; Onyeji, CO; Tessier, PR, 1995) | 0.9 |
| "The pharmacodynamic properties of levofloxacin (an optically active isomer of ofloxacin), ofloxacin, and ciprofloxacin, alone and in combination with rifampin, were evaluated over 24 to 48 h against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA 1199 and MRSA 494, respectively) in an in vitro infection model." | ( Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Kaatz, GW; Kang, SL; McGrath, BJ; Rybak, MJ; Seo, SM, 1994) | 0.87 |
| "The antimicrobial effects of ofloxacin against Mycobacterium leprae, either alone or in combination with rifampicin and rifabutin, were studied using mouse foot pad assay technique." | ( In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. Dhople, AM; Ibanez, MA, 1994) | 0.83 |
| " Its optimal dosage appears to be 400 mg daily, and combination with dapsone and clofazimine does not enhance its activity." | ( Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Grosset, JH; Ji, B; N'Deli, L; Perani, EG; Petinom, C, 1994) | 0.62 |
| " When combined with one of the three rifamycin analogs, synergism was obtained with KRM-1648 and rifabutin but not with rifampin." | ( In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae. Dhople, AM; Ibanez, MA, 1995) | 0.6 |
| " Despite the antipseudomonal advantage noted for ciprofloxacin monotherapy, it is unknown whether this advantage is maintained when the fluoroquinolones are used in combination with antipseudomonal beta-lactams such as ceftazidime and piperacillin." | ( Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Klepser, ME; Nicolau, DP; Nightingale, CH; Patel, KB; Quintiliani, R, 1995) | 0.8 |
| " The potential therapeutic activities of these agents both alone and combined with ethambutol were evaluated in a human macrophage test system and in the beige mouse animal test system with MAC strain 101." | ( Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Barbara-Burnham, L; Bermudez, LE; Inderlied, CB; Kolonoski, P; Wu, M; Young, LS, 1996) | 0.59 |
| "In the present study, we evaluated the in vivo anti-Mycobacterium leprae activities of KRM-1648 (KRM) given at long intervals in combination with ofloxacin (OFLX), clofazimine (CFZ), and dapsone (DDS)." | ( Studies on therapeutic activity of benzoxazinorifamycin KRM-1648 in combination with other antimicrobial agents and biological response modifiers interferon-gamma and granulocyte-macrophage colony-stimulating factor against M. leprae infection in athymic Maw, WW; Saito, H; Sato, K; Tomioka, H, 1997) | 0.5 |
| " It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin." | ( In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium. Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H, 1998) | 0.3 |
| "We tested three fluoroquinolones (ciprofloxacin, levofloxacin, and trovafloxacin), each combined with each of four beta-lactams (cefoperazone, ceftriaxone, imipenem, and meropenem) for synergy against clinical isolates of nosocomial strains of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia." | ( In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Alperstein, P; France, K; Isenberg, HD, 1999) | 0.88 |
| "To evaluate the activity of vancomycin and levofloxacin alone and combined with rifampin against planktonic and sessile cells." | ( Comparative in vitro activity of vancomycin and levofloxacin in combination with rifampin against planktonic versus sessile cells of Staphylococcus epidermidis. Kang-Birken, SL, 2000) | 0.82 |
| "The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans." | ( In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans. Dhople, AM, 2001) | 0.76 |
| "1, 1, 5 and 10 mg/ml), phenylbutazone (1000 microgram/ml) and acetylsalicylic acid (25, 250, 2500 microgram/ml) alone, and combined with 10 mg/ml of ofloxacin on the respiratory burst." | ( [Effect of anti-inflammatory drugs, alone and combined with ofloxacin, on the respiratory burst of human polymorphonuclear leukocytes]. Cabrera, E; Cantón, E; Martínez, P; Orero, A; Velert, MM, 2001) | 0.75 |
| "The efficacy of two polymyxin-like peptides, KFFKFFKFF and IKFLKFLKFL, alone and combined with levofloxacin, was investigated in a rat model of septic shock." | ( Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock. Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, W; Kasprzykowski, F; Mackiewicz, Z; Mocchegiani, F; Orlando, F; Paggi, AM; Saba, V; Scalise, G, 2002) | 0.75 |
| "The synergistic potential of levofloxacin, ofloxacin and ciprofloxacin combined with aztreonam, ceftazidime, or piperacillin was compared using 24 strains of Pseudomonas aeruginosa with varying susceptibility profiles." | ( In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Jung, R; Messick, CR; Pendland, SL, 2002) | 0.88 |
| " Only the group treated with quinupristin/dalfopristin combined with levofloxacin or doxycycline showed no evidence of staphylococcal infection." | ( Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. Cirioni, O; D'Amato, G; Del Prete, M; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G, 2002) | 0.55 |
| "The antimicrobial effects of sitafloxacin (DU-6859a) against Mycobacterium leprae, either singly or in combination with either rifampicin, rifabutin or KRM-1648, were studied using a mouse footpad assay technique and the results were compared with those obtained with ofloxacin." | ( In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues. Dhople, AM; Namba, K, 2003) | 0.5 |
| "A rat model was used to investigate the efficacy of linezolid, alone or in combination with levofloxacin and vancomycin, in the prevention of vascular prosthetic graft infection resulting from methicillin-resistant Staphylococcus epidermidis with intermediate resistance to glycopeptides." | ( Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides. Cirioni, O; D'Amato, G; Del Prete, MS; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C, 2003) | 0.78 |
| " This study was conducted to evaluate the bioequivalence of levofloxacin when administered in a fasting state as compared to when it was administered with a common breakfast of calcium-fortified orange juice and ready-to-eat cereal." | ( Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. Amsden, GW; Johnson, PW; Whitaker, AM, 2003) | 0.85 |
| "The efficacy of levofloxacin and dirithromycin, alone and in combination with rifampicin in the treatment of experimental brucellosis was investigated." | ( Efficacy of oral levofloxacin and dirithromycin alone and in combination with rifampicin in the treatment of experimental murine Brucella abortus infection. Arda, B; Gökengin, D; Gürel, O; Tunçel, M; Yaimazhan, T, 2004) | 0.98 |
| "Disposition of uric acid upon administration of ofloxacin (O) alone and in combination with other anti-tuberculosis drugs, rifampicin (R), isoniazid (H) and pyrazinamide (Z) was studied." | ( Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs. Gurumurthy, P; Kumar, AK, 2004) | 0.83 |
| "The in vitro effects of spectinomycin and ceftriaxone, alone or in combination with erythromycin, ofloxacin, and doxycycline, against Chlamydia trachomatis were investigated by the checkerboard method and compared by Ridit (reference identical unit) analysis." | ( In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis. Gong, X; Mabey, D; Shang, S; Wang, Q; Xia, L; Zhang, J; Zhao, J; Zhong, M, 2005) | 0.55 |
| " Drug eruption due to a drug combination appears to be very rare." | ( Multiple fixed drug eruption due to drug combination. Hara, H; Yokoyama, A, 2005) | 0.33 |
| "The aim of this study was to evaluate the ability of levofloxacin and ciprofloxacin alone and in combination with either ceftazidime, cefepime, imipenem, piperacillin-tazobactam or amikacin to select for antibiotic-resistant mutants of Pseudomonas aeruginosa and Acinetobacter spp." | ( In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L, 2005) | 0.8 |
| " For multi-step studies, MICs were determined after five serial passages on antibiotic-gradient plates containing each antibiotic alone or in combination with levofloxacin or ciprofloxacin." | ( In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L; Tocalli, L, 2005) | 0.75 |
| "Preincubation of pneumococci with sub-MIC concentrations of ceftriaxone (1/16x MIC), cefotaxime (1/8x MIC), and meropenem (1/4x MIC) alone or combined with levofloxacin (1/8x MIC) over 6 h prevents the emergence of levofloxacin-resistant mutants after 96 h of incubation but does not affect the intracellular accumulation of levofloxacin in two penicillin-resistant pneumococcal strains, suggesting a link between the mechanism of action of beta-lactams and the emergence of quinolone-induced resistance in pneumococci." | ( Preincubation of pneumococci with beta-lactams alone or combined with levofloxacin prevents quinolone-induced resistance without increasing intracellular levels of levofloxacin. Cottagnoud, M; Cottagnoud, P; Johnson, M; Piddock, L, 2005) | 0.76 |
| "To explore the feasibility of utilizing polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis combined with Southern blot to detect ofloxacin (OFLX)-resistant Mycobacterium tuberculosis, and figure out the boundary between the OFLX-susceptible and resistant Mycobacterium tuberculosis." | ( [Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro]. Li, CY; Li, WM; Ma, Y; Qiu, YQ; Tian, M; Wang, SM; Zhang, JY; Zhang, XX; Zhao, B; Zhao, YL, 2005) | 0.73 |
| " To prove the repeatability of PCR-SSCP combined with Southern blot, 36 clinical isolated OFLX-resistant strains were tested." | ( [Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro]. Li, CY; Li, WM; Ma, Y; Qiu, YQ; Tian, M; Wang, SM; Zhang, JY; Zhang, XX; Zhao, B; Zhao, YL, 2005) | 0.53 |
| " Compared with the H(37)Ra, the similar single-stranded shift caused by the single-stranded conformation change was viewed in the 36 clinical isolated OFLX-resistant strains by PCR-SSCP combined with Southern hybridization." | ( [Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro]. Li, CY; Li, WM; Ma, Y; Qiu, YQ; Tian, M; Wang, SM; Zhang, JY; Zhang, XX; Zhao, B; Zhao, YL, 2005) | 0.53 |
| "PCR-SSCP analysis combined with Southern blot can clearly distinguish OFLX-susceptible from OFLX-resistant strains." | ( [Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro]. Li, CY; Li, WM; Ma, Y; Qiu, YQ; Tian, M; Wang, SM; Zhang, JY; Zhang, XX; Zhao, B; Zhao, YL, 2005) | 0.53 |
| "The mutant prevention concentrations (MPCs) of levofloxacin alone and in combination with ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin were established against Pseudomonas aeruginosa." | ( Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Adam, HJ; Laing, N; Mayer, M; Zhanel, GG, 2006) | 0.86 |
| " To explore strategies to overcome resistance development, we studied the effects of rifalazil in combination with several different antibiotics in an in vitro time-kill model, against both log phase and stationary phase Staphylococcus aureus cells." | ( Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro. Murphy, CK; Osburne, MS; Rothstein, DM, 2006) | 0.58 |
| "The objective of this paper was to investigate the in vitro effects of linezolid combined with five antistaphylococcal antibiotics--doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin--upon methicillin-susceptible Staphylococcus aureus (MSSA)." | ( In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Cantón, E; Colombo Gainza, E; Gil Brusola, A; Gobernado, M; Ortiz Estévez, R; Sahuquillo Arce, JM, 2006) | 0.76 |
| "To study the therapeutic efficacy of Longqingpian combined with Levofloxacin on Type IIIA prostatitis." | ( [Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007) | 0.86 |
| "Longqingpian combined with Levofloxacin is highly effective for Type IIIA prostatitis, by relieving pain and voiding symptoms, decreasing the leukocyte count in EPS and improving the life quality of the patients." | ( [Longqingpian combined with levofloxacin highly effective for type IIIA prostatitis]. Cai, X; Huang, YF; Shang, XJ; Teng, WH; Xu, H, 2007) | 0.91 |
| " In base to the differences in the kinetic behaviour of ofloxacin with respect to ciprofloxacin and norfloxacin, binary mixtures of the drugs were resolved by using the time-resolved chemiluminescence signals, in combination with first-order partial least-squares (PLS) multivariate calibration." | ( Resolution of ofloxacin-ciprofloxacin and ofloxacin-norfloxacin binary mixtures by flow-injection chemiluminescence in combination with partial least squares multivariate calibration. Alañón Molina, A; Durán Merás, I; Jiménez Girón, A; Muñoz de la Peña, A; Murillo, JA, 2007) | 0.95 |
| " When the three FQs were individually combined with CLR in vitro, mild antagonism was observed for 53 to 57% of the tested isolates." | ( In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K, 2007) | 0.34 |
| "To evaluate the clinical efficacy of the Chinese medicine Yiqigushen Capsule combined with levofloxacin on type III A prostatitis." | ( [Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. Guo, DF; Wang, HP; Zhang, HZ, 2008) | 0.84 |
| "A total of 180 patients with type III A prostatitis were equally randomized into a treatment group, which received Yiqigushen Capsule combined with levofloxacin, and a control group, which was given Yiqigushen Capsule only, both for 4 weeks." | ( [Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. Guo, DF; Wang, HP; Zhang, HZ, 2008) | 0.82 |
| "Yiqigushen Capsule combined with levofloxacin is highly effective for type III A prostatitis." | ( [Yiqigushen capsule combined with levofloxacin highly effective for type III A prostatitis]. Guo, DF; Wang, HP; Zhang, HZ, 2008) | 0.89 |
| "To evaluate the efficacy and safety of corticoid in combination with an antibiotic in the treatment of chronic nonbacterial prostatitis (CNP)." | ( [Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]. Hou, Y; Lü, C; Wu, ZP; Xiao, N; Yang, MG; Zhao, XK, 2009) | 0.35 |
| "Prednisone in combination with an antibiotic can effectively relieve pain and voiding symptoms, improve QOL and reduce WBC in the EPS of CNP patients, and therefore well deserves to be recommended in clinical application." | ( [Corticoid combined with an antibiotic for chronic nonbacterial prostatitis]. Hou, Y; Lü, C; Wu, ZP; Xiao, N; Yang, MG; Zhao, XK, 2009) | 0.35 |
| "In this study the bactericidal effect of the N-terminal fragment of the frog skin peptide esculentin-1b [Esc(1-18)] in combination with clinically used antimicrobial agents was evaluated against Stenotrophomonas maltophilia, either in standard conditions (phosphate buffer) or in the presence of human serum." | ( In vitro bactericidal activity of the N-terminal fragment of the frog peptide esculentin-1b (Esc 1-18) in combination with conventional antibiotics against Stenotrophomonas maltophilia. Barnini, S; Barra, D; Batoni, G; Brancatisano, FL; Campa, M; Capria, AL; Di Luca, M; Esin, S; Maisetta, G; Mangoni, ML; Pichierri, G, 2009) | 0.35 |
| " (Rubiaceae) alone and in combination with antibiotics (doxycycline and ofloxacin) by means of fractional inhibitory concentration indices (FICI) as well as by the use of time-kill assays against one Gram-positive bacterium (Staphylococcus aureus) and three Gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa) was studied." | ( In vitro synergistic effect of doxycycline & ofloxacin in combination with ethanolic leaf extract of Vangueria spinosa against four pathogenic bacteria. Bhattacharjee, I; Chandra, G; Chatterjee, SK, 2009) | 0.85 |
| " spinosa alone and also in combination with antibiotics using the fractional inhibitory concentration (FIC) and time-kill assay method." | ( In vitro synergistic effect of doxycycline & ofloxacin in combination with ethanolic leaf extract of Vangueria spinosa against four pathogenic bacteria. Bhattacharjee, I; Chandra, G; Chatterjee, SK, 2009) | 0.61 |
| "Levofloxacin and tobramycin, alone and in combination with cefepime, were investigated for their in vitro activities and post-antibiotic effects (PAEs) on Pseudomonas aeruginosa." | ( Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa. Otuk, G; Ozbek, B, 2009) | 1.27 |
| "To investigate the effects of inactivation of CD(4)(+)CD(25)(+) regulatory T cells (Treg) combined with the administration of levofloxacin (LFX) on the cellular immune response of murine tuberculosis." | ( [The effect of CD4+ CD25+ regulatory T cell inactivation combined with levofloxacin on murine tuberculosis]. Chen, XC; Gou, JZ; Li, MZ; Peng, YZ; Tang, ZJ; Tong, XD; Yue, XH; Zhou, BP, 2009) | 0.79 |
| " One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime." | ( Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012) | 0.89 |
| "The in vitro antimicrobial activities of usnic acid were evaluated in combination with five therapeutically available antibiotics, using checkerboard microdilution assay against methicillin-resistant clinical isolates strains of Staphylococcus aureus." | ( In vitro interaction of usnic acid in combination with antimicrobial agents against methicillin-resistant Staphylococcus aureus clinical isolates determined by FICI and ΔE model methods. Amicosante, G; Bellio, P; Brisdelli, F; Celenza, G; Garbarino, JA; Nicoletti, M; Perilli, M; Piovano, M; Segatore, B; Setacci, D, 2012) | 0.38 |
| "The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions." | ( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012) | 0.38 |
| " This method was successfully applied to the drug interaction study of Shuang-huang-lian freeze-dried powder combined with levofloxacin injection after intravenous administration to rats." | ( Development of an LC-MS method for determination of three active constituents of Shuang-huang-lian injection in rat plasma and its application to the drug interaction study of Shuang-huang-lian freeze-dried powder combined with levofloxacin injection. Bi, K; Chen, X; Geng, L; Liu, Z; Song, X; Ye, J; Zhao, X, 2012) | 0.77 |
| "Topical application of the gentamicin-collagen sponge seems safe and may improve clinical and microbiological outcomes of diabetic foot infections of moderate severity when combined with standard of care." | ( Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. Edmonds, M; Kuss, M; Lipsky, BA; Reyzelman, A; Sigal, F, ) | 0.13 |
| " Herein, we developed a fine floating tablet via compression coating of hydrophilic polymer (hydroxypropyl cellulose) combined with effervescent agent (sodium bicarbonate) to achieve simultaneous control of release rate and location of ofloxacin." | ( Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent. Chen, H; Ma, N; Qi, X; Rui, Y; Wu, Z; Yang, F, 2015) | 0.86 |
| "A green, fast, and efficient pH-induced natural deep eutectic solvent combined with vortex-assisted dispersive liquid-liquid microextraction method (pH-NADES-VA-DLLME) followed by HPLC was established for determination of ofloxacin (OFL), ciprofloxacin (CIP) and enrofloxacin (ENR) in honey." | ( Determination of quinolone antibiotics in honey by pH-induced natural deep eutectic solvent combined with vortex-assisted dispersive liquid-liquid microextraction. Liu, J; Qin, F; Xiong, Z; Zhao, C; Zhao, L; Zhu, X, 2022) | 0.91 |
Levofloxacin demonstrates good safety, bioavailability and tissue penetration, thus maintaining adequate concentrations at the site of infection. The oral bioavailability is decreased by the coadministration of antacids, but ofl Oxacin does not alter serum theophylline concentrations.
| Excerpt | Reference | Relevance |
|---|---|---|
| " When aluminum hydroxide, ferrous sulfate, and magnesium oxide were coadministered with DR-3355, the relative bioavailability of DR-3355 was decreased to 56, 81, and 78%, respectively, of that for DR-3355 (100 mg) alone." | ( Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Aoki, H; Hakusui, H; Okazaki, O; Sakai, O; Shiba, K; Shimada, J, 1992) | 0.28 |
| " The pharmacokinetics of ofloxacin are characterised by almost complete bioavailability (95 to 100%), peak serum concentrations in the range of 2 to 3 mg/L after a 400mg oral dose and an average half-life of 5 to 8h." | ( Ofloxacin clinical pharmacokinetics. Bailey, EM; Lamp, KC; Rybak, MJ, 1992) | 2.03 |
| "The relative bioavailability and pharmacokinetics of ofloxacin tablets and a reference oral solution of ofloxacin were compared in 32 normal male subjects using a randomized two-way crossover design." | ( Bioavailability and pharmacokinetics of oral ofloxacin formulations in normal subjects. Flor, SC; LeBel, M; Stein, GE; Zinny, M, 1991) | 0.79 |
| " The oral bioavailability is decreased by the coadministration of antacids, but ofloxacin does not alter serum theophylline concentrations." | ( Ofloxacin. Scheld, WM; Tunkel, AR, 1991) | 1.95 |
| " These include the high bioavailability from oral administration and the fact that the product is excreted almost entirely by the kidney, primarily as the active parent compound." | ( Worldwide clinical experience with ofloxacin in urologic cases. Corrado, ML, 1991) | 0.56 |
| "The bioavailability of ofloxacin after a single dose of one of two tablet formulations (200 or 400 mg) or a liquid formulation (1." | ( The bioavailability of ofloxacin from several formulations. Beals, B; Flor, S, 1991) | 0.9 |
| "The pharmacokinetics and bioavailability of ofloxacin in 20 healthy male volunteers were studied in an open-label, randomized, two-way crossover study." | ( Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Nightingale, CH; Quintiliani, R; Sweeney, KR; Yuk, JH, 1991) | 0.81 |
| "The effects of 15- and 5-ml doses of magnesium-aluminum hydroxide (MAH) and calcium carbonate (CC) antacids, respectively, on the bioavailability of ofloxacin after single oral 400-mg doses of ofloxacin were investigated in a 32-subject, randomized, crossover, open-label study." | ( Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Flor, S; Guay, DR; Matzke, GR; Opsahl, JA; Tack, K, 1990) | 0.7 |
| "The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration." | ( Quinolone pharmacokinetics and metabolism. Boeckk, M; Borner, K; Deppermann, N; Höffken, G; Koeppe, P; Lode, H, 1990) | 0.28 |
| "Quinolone is reported to interact with caffeine, often resulting in an increase both in the plasma half-life and AUC, a decrease in total plasma clearance, and little change in the absorption rate constant and maximum plasma level." | ( Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Barnett, G; Carbó, M; de la Torre, R; Segura, J, 1990) | 0.28 |
| " Following oral administration, norfloxacin and ciprofloxacin are well absorbed and the bioavailability of ofloxacin is almost 100%." | ( The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). Alestig, K, 1990) | 0.77 |
| " Ofloxacin was well absorbed orally." | ( [Efficacy of ofloxacin in treating typhoid fever]. Gu, XJ; Wang, F; Zhang, MF, 1989) | 1.56 |
| " BMY 40062 exhibited longer half-life, higher maximum concentration in serum, greater area under the curve, and better bioavailability in mice after oral dosing than ciprofloxacin." | ( In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989) | 0.47 |
| " A prediction equation is developed under statistical and physiological considerations which correlates both factors with the intestinal absorption rate parameter Kapp." | ( Prediction of the effect of ofloxacine on intestinal absorption: effect of the body weight and substrate concentration. Barrio, JP; Gómez, G; Melcón, B; Prieto, JG, 1988) | 0.57 |
| " There were no differences in ofloxacin recovery after oral or intravenous administration, confirming that absolute bioavailability of the oral form is excellent." | ( Absence of crystalluria and estimation of renal parameters after oral and intravenous ofloxacin as compared to placebo in healthy volunteers. Grötsch, H; Lorenz, H; Malerczyk, V; Verho, M, 1988) | 0.79 |
| ", hydrophobicity and bioavailability including high serum concentrations and easy entry into bacterial cells." | ( International experiences with ofloxacin, a new quinolone. Mitsuhashi, S, 1986) | 0.56 |
| " Analysis of ofloxacin after multiple dosing regimens in these patients showed measurable concentrations of the drug in the various tissues examined; hence suggesting a relative good bioavailability of the drug, which presumably reflected the high degree of success rates in these patients." | ( Pharmacokinetics and tissue distribution of ofloxacin in human subjects during a multiple dose regimen. Bonaccorsi, S; Carlino, S; De Bernardis, E; Picari, M; Rizza, V, 1988) | 0.91 |
| "The bioavailability of ofloxacin in tonsil tissue, after a single oral dose of 200 mg 2 h before surgery, was evaluated in 14 patients undergoing tonsillectomy for recurrent or chronic infection." | ( Pharmacokinetic evaluation of ofloxacin in serum and tonsils. D'Hondt, G; Gordts, B; Van Landuyt, HW, 1988) | 0.87 |
| " Ofloxacin is well absorbed after oral administration." | ( Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. Drew, RH; Gallis, HA, 1988) | 2.63 |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | ( Symposium on antimicrobial agents. The quinolones. Walker, RC; Wright, AJ, 1987) | 0.27 |
| " However, the areas under the serum concentration-time curves (AUC0-28), as also the urinary recoveries did not differ significantly, showing that only the speed of absorption, but not the bioavailability of the tablet is changed in comparison to the oral solution form." | ( Relative bioavailability of ofloxacin tablets in comparison to oral solution. Korn, A; Malerczyk, V; Rangoonwala, R; Verho, M, 1987) | 0.57 |
| "The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration." | ( Comparative pharmacokinetics of new quinolones. Borner, K; Glatzel, P; Höffken, G; Koeppe, P; Lode, H; Olschewski, P; Prinzing, C; Reimnitz, D; Sievers, B; Wiley, R, 1987) | 0.27 |
| "Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation." | ( [Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. Blomer, R; Bruch, K; Zahlten, RN, 1986) | 1.95 |
| ") decreased the bioavailability of LVFX by 15-52%." | ( Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) | 0.54 |
| " The presence of aluminum reduces the absorption rate of this quinolone but does not modify the percentage of the absorbed dose." | ( Oral absorption of ofloxacin administered together with aluminum. Dominguez-Gil Hurlé, A; Martínez Cabarga, M; Sánchez Navarro, A, 1994) | 0.62 |
| " In this study, the effect of the Chinese medicines Sho-saiko-to (TJ-9), Rikkunshi-to (TJ-43) and Sairei-to (TJ-114) on the bioavailability of ofloxacin (OFLX) was investigated in seven volunteers in an open, random crossover fashion." | ( Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers. Hasegawa, T; Muraoka, I; Nabeshima, T; Nadai, M; Takagi, K; Wang, L; Yamaki, K, 1994) | 0.73 |
| " These results strongly suggest that adsorption of quinolones by aluminum hydroxide reprecipitated in the small intestine would play an important role in the reduced bioavailability of quinolones after coadministration with aluminum-containing antacids." | ( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993) | 0.56 |
| " Since previous studies have not demonstrated any change in the bioavailability of ofloxacin in infectious disease patients, this study supports the interchangeability of these dosing regimens." | ( Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Chow, AT; Flor, SC; Rogge, MC, 1993) | 0.78 |
| " Effects of aluminium hydroxide on the oral bioavailability of OFLX and OFLX-PVM were investigated in rabbits." | ( Effects of aluminium-containing antacid on bioavailability of ofloxacin following oral administration of pivaloyloxymethyl ester of ofloxacin as prodrug. Hibino, S; Kihira, K; Konishi, T; Maeda, Y; Omoda, K; Takahashi, M; Tsukiai, S, 1993) | 0.53 |
| "Amoxycillin and ofloxacin are both well absorbed after oral administration, despite being hydrophilic." | ( Lack of effect of amoxycillin on the absorption of ofloxacin. Alván, G; Hellgren, U; Nilsson-Ehle, I; Paintaud, G, 1993) | 0.88 |
| " These results indicate that the Chinese medicines tested have no significant effect on the rate and extent of bioavailability or renal excretion of LVFX." | ( Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin. Hasegawa, T; Muraoka, I; Nabeshima, T; Nadai, M; Takagi, K; Yamaki, K, 1995) | 0.53 |
| "To investigate the regional differences in small intestinal (SI) metabolism and permeability for several compounds and to ascertain the potential significance of these differences on the reported reductions in regional bioavailability in humans." | ( Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans. Hu, P; Sinko, PJ, 1996) | 0.29 |
| "It has been reported that captopril and ddI demonstrate regional intestinal bioavailability in several species including humans." | ( Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans. Hu, P; Sinko, PJ, 1996) | 0.29 |
| " Levofloxacin is a fluoroquinolone with excellent bioavailability properties that affords potential use in the treatment of a wide variety of infections caused by Gram-positive organisms such as streptococci." | ( The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Biedenbach, DJ; Jones, RN, 1996) | 1.11 |
| " The absorption rate from the intestine into the portal system was calculated from the portal-venous difference in the plasma concentration of levofloxacin, considering the distribution of levofloxacin into erythrocytes." | ( Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. Fujieda, Y; Ito, T; Nakagawa, T; Yamaoka, K, 1996) | 0.78 |
| " By considering the bioavailability of levofloxacin in rat, the hepatic extraction ratio in vivo of levofloxacin was estimated to be 30%." | ( Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. Fujieda, Y; Ito, T; Nakagawa, T; Yamaoka, K, 1996) | 0.84 |
| " The mean (95% CI) oral bioavailability was 91% (74 to 109%)." | ( Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Bethell, DB; Day, NP; Dung, NM; Dung, NQ; Linh, NT; Loan, HT; MacGowan, AP; McMullin, C; Minh, LT; Tam, DT; Vinh, H; White, LO; White, NJ, 1996) | 0.56 |
| "The properties of ofloxacin such as a new mechanism of action, broad spectrum and high antimicrobial activity, 100-percent bioavailability and rapid penetration to the body tissues, etc." | ( [Use of ofloxacin in infections which do not readily respond to treatment]. Zalaudek, G, 1996) | 1.06 |
| " We determined if collagen cross-linking affects ofloxacin bioavailability at three different collagen shield dissolution times." | ( Effect of collagen cross-linking in collagen corneal shields on ocular drug delivery. Horibe, Y; Kawashima, Y; Kuwano, M, 1997) | 0.55 |
| " The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food." | ( The clinical pharmacokinetics of levofloxacin. Chow, AT; Fish, DN, 1997) | 0.86 |
| "To determine the levels of two quinolones, ofloxacin and ciprofloxacin, potent broad-spectrum antibiotics with very good oral bioavailability and low minimum inhibitory concentrations (MICs) for most pathogens, in the prostates of patients who underwent transurethral resection of the prostate (TURP) after oral ingestion for surgical prophylaxis." | ( A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. Cheng, C; Foo, KT; Li, MK; Png, JC; Rekhraj, IR; Tan, E, 1997) | 0.82 |
| " The study reveals that the bioavailability (rate and extent) of levofloxacin was not affected by either age or gender." | ( Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Chien, SC; Chow, AT; Natarajan, J; Nayak, RK; Rogge, MC; Williams, RR; Wong, FA, 1997) | 0.75 |
| " In conclusion, the absorption of levofloxacin was slightly delayed by food, although the overall bioavailability of levofloxacin following a high-fat meal was not altered." | ( Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Dix, R; Hafkin, B; Hoh, J; Lee, ID; Lee, LJ, 1997) | 0.8 |
| "5 h and mean absolute bioavailability of > or =99%." | ( Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Cheung, WK; Chien, SC; Chow, AT; Curtin, C; Fowler, CL; Gisclon, LG; Natarajan, J; Rogge, MC; Williams, RR; Wong, F, 1997) | 0.59 |
| " Furthermore, ofloxacin competes with other fluoroquinolones or P-glycoprotein substrates for a common secretory pathway, resulting in an increased rate of absorption for both ofloxacin isomers; this is probably an indirect result of their reduced efflux from the apical side of intestinal cells." | ( Absorption of ofloxacin isomers in the rat small intestine. Carbon, C; Colas-Linhart, N; Dautrey, S; Farinotti, R; Rabbaa, L, 1997) | 1.02 |
| " The relative rectal bioavailability (AUC rectal/AUC oral) was 49." | ( Kinetics of absorption and elimination of ofloxacin in humans after oral and rectal administrations. Aigbavboa, SO; Akerele, JO; Eboka, CJ; Okor, RS, 1997) | 0.56 |
| " High oral bioavailability allows switching from intravenous to oral therapy without dosage adjustment." | ( Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Lamb, HM; Langtry, HD, 1998) | 0.92 |
| " The availability of an intravenous formulation and near-complete oral bioavailability allow ofloxacin to be administered as a sequential regimen without loss of activity." | ( Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Balfour, JA; Lamb, HM; Onrust, SV, 1998) | 1.96 |
| "Ocular bioavailability of ofloxacin in aqueous humor after oral and topical administration is similar when the drug is applied as described." | ( Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration. Basci, NE; Batman, C; Bozkurt, A; Cekic, O; Kayaalp, SO; Yasar, U, 1998) | 0.95 |
| " When given orally, bioavailability is greater than 99%, and the drug is highly concentrated in lung tissue and macrophages." | ( Levofloxacin in the treatment of community acquired pneumonia. File, TM, ) | 0.75 |
| "Median volume of distribution at steady state/systemic bioavailability (V(ss)/F) was significantly smaller in women than in men, although when normalized for total body weight there were no differences." | ( Effect of gender on the pharmacokinetics of ofloxacin. Abel, SR; Clark, WR; Mueller, BA; Sowinski, KM, 1999) | 0.56 |
| " It was demonstrated that S/P is a function of the quotient of the rate of absorption and venous plasma drug concentration." | ( Kinetics of 4-fluoroquinolones permeation into saliva. Antolic, G; Grabnar, I; Kozjek, F; Mrhar, A; Suturkova, LJ, 1999) | 0.3 |
| "Ocular bioavailability of ofloxacin in SRF after oral and combined administration is equivalent." | ( Penetration of topical, oral, and combined administered ofloxacin into the subretinal fluid. Basci, NE; Batman, C; Bozkurt, A; Cekiç, O; Kayaalp, SO; Totan, Y; Yasar, U; Zilelioglu, O, 1999) | 0.85 |
| "Metal ions, which are present in ocular fluids, can significantly decrease the bioavailability of fluoroquinolones." | ( Effect of two balanced salt solutions on the bioavailability of ofloxacin and ciprofloxacin. Osato, MS, ) | 0.37 |
| "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine." | ( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001) | 0.81 |
| " Bioavailability increase has been ascribed to PEO mucoadhesion and/or increased tear fluid viscosity." | ( Gel-forming erodible inserts for ocular controlled delivery of ofloxacin. Burgalassi, S; Chetoni, P; Di Colo, G; Fiaschi, MP; Saettone, MF; Zambito, Y, 2001) | 0.55 |
| "The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid precorneal elimination of the drug may be overcome by the use of in situ gel-forming systems that are instilled as drops into the eye and undergo a sol-gel transition in the cul-de-sac." | ( Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. Amin, PD; Cardoza, RM; Srividya, B, 2001) | 0.59 |
| "Levofloxacin, a broad-spectrum fluoroquinolone, may enhance digoxin bioavailability by eliminating intestinal flora that metabolize digoxin." | ( Absence of a pharmacokinetic interaction between digoxin and levofloxacin. Chien, SC; Chow, AT; Natarajan, J; Rogge, MC; Williams, RR; Wong, F, 2002) | 1.17 |
| "The purpose of this study was to clarify the contribution of P-glycoprotein to the bioavailability and intestinal secretion of grepafloxacin and levofloxacin in vivo." | ( Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. Inui, K; Saito, H; Yamaguchi, H; Yano, I, 2002) | 0.51 |
| "When topical controlled delivery of ophthalmic drugs is realised via erodible inserts, drug bioavailability is maximised, if release is controlled exclusively by insert erosion, since parallel mechanisms which increase the release rate, also increases the dose fraction cleared from the precorneal area by tear fluid draining." | ( A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide). Di Colo, G; Zambito, Y, 2002) | 0.31 |
| " Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin." | ( Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Abraham, E; Fish, DN; Rebuck, JA, 2002) | 0.88 |
| " The almost complete (> or =99%) absolute oral bioavailability suggests that a comparable exposure to the iv regimen may be achieved after oral administration." | ( Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. Brollo, L; Di Qual, E; Dolcet, F; Furlanut, M; Lugatti, E; Pea, F; Talmassons, G, 2003) | 0.61 |
| " The PF-metabolizing activity of intestinal bacteria was reduced to 16% and 33% of normal levels by treatment with AMPC-MET and ofloxacin, respectively, which caused alterations of that degree in the extent of absorption of PF and PM-I, but did not affect their rate of absorption or elimination." | ( Influence of co-administered antibiotics on the pharmacokinetic fate in rats of paeoniflorin and its active metabolite paeonimetabolin-I from Shaoyao-Gancao-tang. Akao, T; He, JX; Tani, T, 2003) | 0.52 |
| " Since garenoxacin appeared to be well absorbed following oral administration and concentrations in cartilage tended to be higher than those in plasma, it is unlikely that the low chondrotoxicity in comparison with other quinolones is explained by differences in the pharmacokinetics of these compounds." | ( Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. Baumann-Wilschke, I; Bello, A; Kastner, M; Rahm, U; Stahlmann, R, 2004) | 0.32 |
| " The bioavailability of ofloxacin was 6 times that of ciprofloxacin." | ( [Aqueous humor penetration of topically applied ofloxacin, ciprofloxacin and tobramycin]. Wu, XD; Yang, YH; Yao, K; Zhang, Z, 2003) | 0.88 |
| " Consequently, the residence time at concentrations higher than the MIC90 and the bioavailability of the antibiotic in the aqueous were increased by about 150 and 240%, respectively, with respect to the reference vehicle." | ( Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Burgalassi, S; Di Colo, G; Nardini, I; Saettone, MF; Zambito, Y, 2004) | 0.54 |
| "Cisplatin-induced ARF differentially modulated the bioavailability and intestinal secretion of quinolones in rats." | ( Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Inui, K; Saito, H; Yamaguchi, H; Yano, I, 2004) | 0.32 |
| "After the completion of the treatment course, the negative sputum conversion rate in V+D+M treatment protocol group was 84%, significantly higher than that in the control group (42%); the former group showed a focal absorption rate and pulmonary cavity closure rate of 83% and 66%, which were 33% and 26% respectively in the latter." | ( [Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis]. Li, SM; Xing, BC; Zheng, XM, 2004) | 0.57 |
| "Levofloxacin has a high bioavailability and a broad antibacterial spectrum which covers the common pathogens found in acute and chronic diabetic foot infections." | ( Tissue and serum levofloxacin concentrations in diabetic foot infection patients. Baertsch, U; Born, B; Geiss, HK; Hamann, A; Hoppe-Tichy, T; Kusterer, K; Oberdorfer, K; Swoboda, S; von Baum, H, 2004) | 1.27 |
| " The bioavailability was high (86." | ( Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. Albarellos, GA; Ambros, LA; Landoni, MF, 2005) | 0.64 |
| " The possible roles of small intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP) in the bioavailability of ofloxacin were also evaluated." | ( Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats. Chen, M; Hu, XL; Liao, ZX; Wang, H, 2006) | 0.83 |
| "Sustained release (SR)-gastroretentive dosage forms (GRDF) enable prolonged and continuous input of the drug to the upper parts of the gastrointestinal (GI) tract and improve the bioavailability of medications that are characterized by a narrow absorption window." | ( Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Chaudhari, S; Chavanpatil, M; Jain, P; Shear, R; Vavia, P, 2005) | 0.56 |
| " By the antibacterial activity and bioavailability sodium furasidin is advantages among the nitrofurans." | ( [Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I]. Ivanov, DV; Sidorenko, SV, 2005) | 0.33 |
| " We conclude that Bcrp1 is one of the determinants for the bioavailability of fluoroquinolones and their secretion into the milk." | ( Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Alvarez, AI; Merino, G; Molina, AJ; Prieto, JG; Pulido, MM; Schinkel, AH, 2006) | 0.33 |
| "Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window." | ( Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Chaudhari, S; Chavanpatil, MD; Jain, P; Shear, R; Vavia, PR, 2006) | 0.55 |
| " The oral bioavailability of ofloxacin was 110." | ( Pharmacokinetics of ofloxacin in broiler chicken. Kalaiselvi, L; Mathuram, LN; Ramesh, S; Sriram, P; Sriranjani, D, 2006) | 0.95 |
| " The oral bioavailability of levofloxacin is over 99%, enabling simple switching from intravenous to oral therapy during treatment." | ( Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Cantón, R; Graninger, W; Lode, H; Milkovich, G, 2006) | 0.83 |
| " Rapid absorption of the drug was also evident by the high value of the absorption rate constant (2." | ( Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves. Dumka, VK; Srivastava, AK, 2006) | 0.58 |
| " The high bioavailability of levofloxacin allows for rapid step-down from intravenous administration to oral therapy, minimizing unnecessary hospitalization, which may decrease costs and improve patient quality of life." | ( Levofloxacin for the treatment of community-acquired pneumonia. File, TM; Lynch, JP; Zhanel, GG, 2006) | 1.24 |
| "In these 2 trials in a selected group of healthy adult male and female volunteers, the ER and IR formulations of ofloxacin displayed a similar rate and extent of bioavailability and comparable safety profiles." | ( Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects. Badri, N; Di Spirito, M; DiMarco, M; Ducharme, MP; Marier, JF; Monif, T; Morelli, G; Rampal, A; Tippabhotla, SK, 2006) | 0.77 |
| " However, no published data is available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination." | ( Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers. Agarwal, S; Chattaraj, TK; Ghosh, D; Gowda, KV; Pal, TK; Sarkar, AK; Selvan, PS; Solomon, WD, 2007) | 0.57 |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | ( Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) | 0.97 |
| "Therapeutic activity, pharmacokinetic and bioavailability on animals (inbred white mouse, rabbits) were evaluated for Ofloxacin-PhPO and Pefloxacin-genova in comparison with innovator products--Tarivid and Abaktal." | ( [Chemotherapy activity and pharmacokinetics of the fluoroquinolones generics Ofloxacin-PhPO and Pefloxacin-genova]. Bobrov, VI; Borisov, MM; Ptitsina, SN, 2007) | 0.78 |
| " In the bioavailability study, the principal pharmacokinetic parameters showed there were differences between the sustained release pellets and the conventional ofloxacin capsules." | ( In vitro and in vivo evaluation of ofloxacin sustained release pellets. Cui, Y; Tang, X; Zhang, Y, 2008) | 0.82 |
| " The bioavailability was high (91." | ( Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration. Abd El-Aty, AM; Abo El-Sooud, K; Goudah, A; Shim, JH; Shin, HC, 2008) | 0.59 |
| "The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid pre-corneal elimination of the drug may be overcome by the use of in situ gel forming systems that are instilled as drops into the eye and then undergo a sol-gel transition in the cul-de-sac." | ( Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. Abraham, S; Basavaraj, BV; Bharath, S; Deveswaran, R; Furtado, S; Madhavan, V, 2009) | 0.63 |
| "The fluoroquinolones are currently enjoying extensive worldwide clinical applications because of their good bioavailability and pharmacokinetic profile." | ( Gender differences on bioavailabity of ofloxacin. Naseer, R; Riffat, S, ) | 0.4 |
| "In Pakistan where the use of antibiotics is more frequent by the general practitioners it is important to elucidate certain dose parameters it is also noticed that side effects are more in females than males so present study is conducted to calculate any differences in bioavailability on the basis of sex." | ( Gender differences on bioavailabity of ofloxacin. Naseer, R; Riffat, S, ) | 0.4 |
| " Although generic formulations of oral levofloxacin are marketed in Mexico, a literature search did not identify published data concerning the bioavailability of these formulations; these data would be relevant to secure marketing of a test formulation in Mexico." | ( Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers. Burke-Fraga, V; Cariño, L; Fuentes-Fuentes, E; Galan-Herrera, JF; Namur, S; Parra, MG; Poo, JL; Rosales-Sanchez, O, 2009) | 0.86 |
| "The aim of this study was to compare the bioavailability and determine the bioequivalence of a test formulation (an oral tablet containing levofloxacin 500 mg) with its corresponding listed reference-drug formulation in Mexico (a list issued by Mexican Health Authorities)." | ( Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers. Burke-Fraga, V; Cariño, L; Fuentes-Fuentes, E; Galan-Herrera, JF; Namur, S; Parra, MG; Poo, JL; Rosales-Sanchez, O, 2009) | 0.79 |
| " These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes." | ( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010) | 0.36 |
| "Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)." | ( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010) | 0.36 |
| "Present study was undertaken to evaluate the effect of binders on the bioavailability of the drug." | ( The effect of binders on the bioavailability of ofloxacin tablets in animal model. Ahmad, M; Akhtar, N; Khan, HM; Murtaza, G; Rasool, F, ) | 0.39 |
| "To reduce the frequency of administration and improve patient compliance, novel levofloxacin sustained-release capsules with suitable in vitro release profiles and good bioavailability were developed." | ( In vitro and in vivo evaluation of levofloxacin sustained-release capsules. Huang, SJ; Jiang, SG; Pei, ZQ; Yin, LF; Zhang, Q; Zhao, CJ, 2011) | 0.87 |
| " Unsuccessful in vivo-in vitro correlation was shown in Eudragit® NE30D-coated pellets with a relative bioavailability of only 41." | ( In vitro and in vivo evaluation of levofloxacin sustained-release capsules. Huang, SJ; Jiang, SG; Pei, ZQ; Yin, LF; Zhang, Q; Zhao, CJ, 2011) | 0.64 |
| "To assess the feasibility of delivering ofloxacin across the intact tympanic membrane; to compare middle ear bioavailability of ofloxacin after otic and systemic administrations; to determine distribution of otically delivered ofloxacin to other tissues." | ( Comparison of systemic and otic administration of ofloxacin. Koulich, E; Pawlowski, KS; Roland, PS, 2010) | 0.88 |
| " This paper is an attempt to compare the bioavailability of two levofloxacin tablet formulations (reference and test) containing 500 mg of levofloxacin." | ( Bioequivalence study of levofloxacin tablets in healthy Indian volunteers using HPLC. Chakrabarty, US; Das, A; Dey, G; Mukherjee, J; Nandi, U; Pal, TK; Sahoo, BK; Sarkar, AK, 2011) | 0.9 |
| " In therapy of chronic diseases exacerbations of the respiratory tract, including community-acquired pneumonia, a high oral bioavailability allows to switch from intravenous to oral way of treatment." | ( [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections]. Płusa, T, 2011) | 0.93 |
| "In this study levofloxacin, which is completely absorbed and primarily eliminated renally without modification, showed better pharmacokinetic proportionality than cyclosporine, which is poorly absorbed and extensively metabolized." | ( Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yu, KS, 2012) | 0.97 |
| " The floating pellets were evaluated for SEM, floating characteristic parameters, in vitro release and bioavailability in New Zealand rabbits." | ( A floating multiparticulate system for ofloxacin based on a multilayer structure: In vitro and in vivo evaluation. He, H; Lin, X; Liu, Z; Tang, J; Tang, X; Tao, X; Xu, M; Zhang, C; Zhang, Y, 2012) | 0.65 |
| " Levofloxacin demonstrates good safety, bioavailability and tissue penetration, thus maintaining adequate concentrations at the site of infection." | ( Levofloxacin for the treatment of respiratory tract infections. Liapikou, A; Torres, A, 2012) | 1.56 |
| " Its improved bioavailability and safety profile makes the possibility of shorter hospital stays a reality." | ( Levofloxacin for the treatment of respiratory tract infections. Liapikou, A; Torres, A, 2012) | 1 |
| " Mean residence time (MRT), mean absorption time (MAT) and bioavailability were 4·26 h, 1·54 h and 69·01%, respectively." | ( Pharmacokinetics of levofloxacin in Japanese quails (Coturnix japonica) following intravenous and oral administration. Aboubakr, M, 2012) | 0.69 |
| "In recent years, many pharmaceutical scientists have focused on developing the in situ gel-forming systems to overcome the poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid pre-corneal elimination of the drug." | ( Comparison of systemic absorption between ofloxacin ophthalmic in situ gels and ofloxacin conventional ophthalmic solutions administration to rabbit eyes by HPLC-MS/MS. Fan, L; Li, J; Li, L; Li, N; Liu, Z; Ma, L; Okeke, CI; Pang, X; Pi, J; Sun, J; Wang, M; Wu, T; Yin, Z; Zhang, L; Zhang, Q; Zhang, R; Zhao, H; Zhuang, P, 2013) | 0.65 |
| " NXC reduced the extent and rate of absorption of RIF." | ( Effect of ofloxacin and norfloxacin on rifampicin pharmacokinetics in man. Barikpoar, E; Brown, S; Ezejiofor, NA; Orisakwe, OE, ) | 0.53 |
| " The designed ofloxacin niosomes with span 60 showed good physicochemical properties, good stability, improved pharmacokinetic parameters, prolonged action and improved bioavailability than the commercially available conventional dosage form which might be a potential carrier system to improve the patient compliance and reduce the side effects." | ( Design and characterization of ofloxacin niosomes. Balasundaram, J; Dhandayuthapani, B; Natesan, G; Natesan, S; Perumal, P; Ramalingam, N, 2013) | 1.04 |
| " The bioavailability indices of INH in the saliva and plasma were similar in all the groups." | ( Isoniazid Pharmacokinetics in the Presence of Ofloxacin and Norfloxacin Antibiotics. Anusiem, CA; Barikpoar, E; Brown, SA; Ezejiofor, NA; Orisakwe, OE, ) | 0.39 |
| " Lead optimization resulted in the identification of potent compounds with improved oral bioavailability and reduced cardiac ion channel liability." | ( Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J, 2014) | 0.4 |
| " It is determined that bioavailability of ofloxacin in the niosomal form is 154% relative to the free form of the antibiotic." | ( [Comparative study of pharmacokinetics of ofloxacin in a free and niosomal forms in experiments on white mice when administered per os]. Kovalev, DA; Kulichenko, AN; Liapustina, LV; Mikhaĭlova, ME; Pisarenko, SV; Siritsa, IuV, 2014) | 0.93 |
| "The aim of the study was to improve corneal penetration and bioavailability of ofloxacin (OFX) eye preparations." | ( Improved corneal bioavailability of ofloxacin: biodegradable microsphere-loaded ion-activated in situ gel delivery system. Ahmed, OA; Hussein, AK; Khaled, KA; Sayed, EG, 2015) | 0.92 |
| " In addition, the oral bioavailability experiment in New Zealand rabbits showed that, the relative bioavailability of the ofloxacin after administrated of floating tablets was 172." | ( Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent. Chen, H; Ma, N; Qi, X; Rui, Y; Wu, Z; Yang, F, 2015) | 0.89 |
| "The purpose of this investigation is to formulate a gastroretentive sustained drug release system for ofloxacin to improve its retention time, pharmacological activity, bioavailability and therapeutic efficacy in the stomach." | ( Ofloxacin loaded gellan/PVA nanofibers - Synthesis, characterization and evaluation of their gastroretentive/mucoadhesive drug delivery potential. Nagar, H; Pruthi, V; Raghuwanshi, N; Singh, H; Srivastava, AK; Vashisth, P, 2017) | 2.11 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| "Currently, conjunctivitis is treated using ofloxacin eye drop solution, which shows low bioavailability and patient non-compliance." | ( Ofloxacin laden microemulsion contact lens to treat conjunctivitis. Huang, C; Li, Y; Yang, X; Zhang, X, 2020) | 2.26 |
| "Currently, bacterial conjunctivitis is managed by multiple antibiotic eye-drop solution, which is highly inefficient due to low ocular bioavailability and frequent dosing." | ( Ofloxacin-Loaded Niosome-Laden Contact Lens: Improved Properties of Biomaterial for Ocular Drug Delivery. Liu, J; Wang, X, 2021) | 2.06 |
The pharmacokinetics of levofloxacin, administered in high doses and with extended dosing intervals, was studied in human immunodeficiency virus (HIV)-infected patients. The resulting efficacy for different strains of bacteria suggested that for less sensitive pathogens, a dosage adjustment may be needed.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the prolonged half-life and enhanced tissue penetration of azithromycin should allow for less frequent dosing and shorter duration of therapy than with erythromycin or clarithromycin." | ( In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Hammerschlag, MR; Qumei, KK; Roblin, PM, 1992) | 0.53 |
| " The trough SBAs of the 4 fluoroquinolones suggest that the time interval of administration of CPLX and OFLX should be more than 8 hours, but increase of the dosage or shortening of the time interval between the administrations is recommended for ENX and NFLX." | ( Comparison of serum bactericidal activity of 4 fluoroquinolones in healthy volunteers. Liu, YN; Sun, XD; Wang, R; Zhao, HZ, 1992) | 0.28 |
| "The human scalp hair is a useful tissue that retains the past dosage history over a rather long period of time, acting like a "tape-recorder"." | ( [Establishment of a method to analyze drugs in the hair and its application for determining patient compliance]. Uematsu, T, 1992) | 0.28 |
| " It is concluded that in patients on regular haemodialysis treatment the dosage adjustment employed resulted in safe and therapeutically favourable plasma concentrations." | ( Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients. Borner, K; Kampf, D; Pustelnik, A, 1992) | 0.58 |
| " In comparison with other available quinolones, elimination is more highly dependent on renal clearance, which may lead to more frequent dosage adjustments in patients with impaired renal function." | ( Ofloxacin clinical pharmacokinetics. Bailey, EM; Lamp, KC; Rybak, MJ, 1992) | 1.73 |
| " Serial blood samples obtained throughout dosing were assayed for drug concentrations using high-performance liquid chromatography." | ( Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics. Brooks, J; Drusano, GL; Flor, S; Yuen, GJ, 1992) | 0.52 |
| "13 ng/ml) after 10 1/2 days of topical dosing were more than 1,000 times lower than those reported after standard oral doses of 300 mg ofloxacin." | ( Ofloxacin in human serum, urine, and tear film after topical application. Borrmann, L; Frank, J; Kann, J; Lin, ET; Nista, J; Tang-Liu, DD, 1992) | 1.93 |
| " Although treatment with each quinolone or fenbufen alone at a dosage level tested in mice showed no changes, coadministration of a large dose of all quinolones and fenbufen caused convulsant death." | ( Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice. Akahane, K; Furuhama, K; Takayama, S; Tawara, K, 1992) | 0.53 |
| " tuberculosis H37Rv strain, the minimal effective dosage of sparfloxacin, as assessed by survival rate, spleen enlargement and gross lung lesions, was 12." | ( In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Grosset, J; Ji, B; Truffot-Pernot, C, 1991) | 0.28 |
| " every 6 h for one day only, while 4 patients with acute peritonitis were treated with this same dosage every 4 h for 3 days, then every 6 h for the next 7 days." | ( Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients. Borner, K; Conrad, W; Hain, H; Kampf, D, 1991) | 0.58 |
| " The other pharmacokinetic parameters were similar between the two dosage formulations." | ( Bioavailability and pharmacokinetics of oral ofloxacin formulations in normal subjects. Flor, SC; LeBel, M; Stein, GE; Zinny, M, 1991) | 0.54 |
| " A proposed protocol for ofloxacin dosage adjustment in chronic renal failure is reported which differs slightly but significantly from that recommended by the manufacturer." | ( Ofloxacin pharmacokinetics in chronic renal failure and dialysis. Lameire, N; Lehr, KH; Malerczyk, V; Ringoir, S; Rosenkranz, B; Veys, N, 1991) | 2.03 |
| " three times daily with dosage adjustment according to renal function and body weight (group 2)." | ( Empiric treatment of serious infections in patients with cancer: randomised comparison of two combinations. Maiche, AG; Teerenhovi, L, 1991) | 0.28 |
| " The daily dosage was 400 mg to 600 mg, divided into two times." | ( [Clinical effect and laboratory observation of ofloxacin in the treatment of typhoid fever, bacillary dysentery and gonorrhea]. Jiang, YF; Wang, QN; Zou, QY, 1991) | 0.54 |
| " An extended dosing interval of 24-48 h is recommended, depending upon the degree of renal impairment, when creatinine clearance falls below 50 mL/min." | ( Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. Flor, S; Guay, D; Matzke, G; Opsahl, J; Tack, K, 1991) | 0.6 |
| " Ofloxacin was dosed at 400 mg twice daily over a 10-day course of treatment." | ( Safety of multiple doses of ofloxacin in healthy volunteers. Beals, BS; Flor, SC; Stein, GE, 1991) | 1.49 |
| " In summary, a once-daily dosing regimen of amikacin 15 mg/kg is practical and probably efficacious and safe in severely infected patients." | ( Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O, 1991) | 0.28 |
| " Only in one subject the dosage history could not be deduced from the drug distribution along hair length." | ( The measurement of ofloxacin in hair as an index of exposure. Miyazawa, N; Nakashima, M; Uematsu, T, 1991) | 0.61 |
| " Since the AUC in mice treated with ofloxacin 150 mg/kg daily is close to that in man treated with a clinically tolerated dose--600 mg daily--such a dosage may be only moderately effective against human tuberculosis." | ( Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Grosset, J; Ji, B; Truffot-Pernot, C, 1991) | 0.85 |
| " Ofloxacin has favorable pharmacokinetics with almost 100% bioavailability; peak serum concentrations obtained one to two hours following oral dosing are higher than those achieved with ciprofloxacin." | ( Ofloxacin. Scheld, WM; Tunkel, AR, 1991) | 2.63 |
| " The bioavailability (F) of the oral dosage form of ofloxacin was virtually identical to that of the intravenous form (F = 105% +/- 7%)." | ( Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Nightingale, CH; Quintiliani, R; Sweeney, KR; Yuk, JH, 1991) | 0.8 |
| "In order to reduce the dosage of aminoglycoside in the treatment of patients with complicated urinary tract infections (UTI) in outpatient clinics and to improve cost benefits, we tried both ofloxacin (OFX) treatment and a combination treatment with OFX and a single dose of aminoglycoside (isepamicin)." | ( Treatment of complicated urinary tract infections with ofloxacin following an aminoglycoside. Eto, K; Ishii, T; Kumazawa, J; Matsumoto, T; Saito, Y; Sawae, Y; Ueda, S; Yushita, Y, 1991) | 0.72 |
| " The study revealed that concentrations of ofloxacin in serum, bile fluid, and gallbladder tissue after intravenous dosing were adequate against susceptible organisms found in the biliary tract." | ( Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue. Appleman, MD; Berne, TV; Chin, A; Gill, MA; Heseltine, PN; Okamoto, MP; Sclar, DA; Yellin, AE, 1990) | 0.82 |
| " Dosage adjustments are required, particularly in severe renal failure and for the drugs almost exclusively excreted, in unchanged form, via the renal route." | ( Pharmacokinetics of quinolones in renal insufficiency. Borsa-Lebas, F; Dhib, M; Fillastre, JP; Humbert, G; Leroy, A; Moulin, B, 1990) | 0.28 |
| "Antibiotic therapy is directed against bacteria responsible for infectious pathology which are able to resist treatment mainly when the dosage is misadapted." | ( A new approach to optimal antibiotic dosage regimen by coupling pharmacokinetics and killing curve parameters. Dellamonica, P; Drugeon, HB; Etesse, H; Garraffo, R; Lapalus, P, 1990) | 0.28 |
| " After a six weeks observation and treatment period, where Ofloxacin was dosed with 20 mg/kg body weight daily with a stomach tube, the animals were sacrificed and their lenses used for biochemical analyses." | ( Evaluation of a possible cocataractogenic potential of Ofloxacin. Hockwin, O; Kuhn, UD; Lorenz, M; Wegener, A, 1990) | 0.77 |
| " Single oral dosing of 20 mg/kg of either ofloxacin or ciprofloxacin showed that ofloxacin achieves approximately a four-fold higher peak serum or liver concentration than ciprofloxacin, which may contribute to its better efficacy in this infection model." | ( In-vivo evaluation of ofloxacin in Salmonella typhimurium infection in mice. Fu, KP; Hilliard, J; Isaacson, D; McGuire, JL; Rosenthale, ME; Tobia, AJ, 1990) | 0.86 |
| " In a multicenter study in seven Asian countries, 105 mal patients with chlamydial urethritis and 46 male patients with nongonococcal and nonchlamydial urethritis were treated with oral ofloxacin at a dosage of 200 mg twice daily for 5 to 10 days." | ( Ofloxacin treatment of nongonococcal urethritis. A multi-center study in Asia. Chang, LS; Daili, SF; Kawada, Y; Lai, C; Lee, JM; Limson, BM; Polnikorn, N; Saito, I, 1990) | 1.91 |
| "Ofloxacin was administered orally at a daily dosage of 300 mg and 600 mg in three divided doses for 14 days to 24 and 60 patients with chronic complicated urinary infections, respectively, in order to evaluate the therapeutic efficacy." | ( [Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection]. Hisazumi, H; Kobashi, K; Koizumi, H; Motoi, I; Nagano, K; Nishino, A; Orito, M; Sawaki, M; Shyoda, R; Uchibayashi, T, 1990) | 2.03 |
| " Since no relationship between ofloxacin or pefloxacin kinetics and the usual liver function tests was found, recommended dosage regimens in cirrhotic patients have to be controlled by monitoring plasma drug levels during treatment." | ( Pharmacokinetics of fluoroquinolones in hepatic failure. Gaillot, J; Montay, G, 1990) | 0.57 |
| " Dosage adjustment was made for patients in renal failure." | ( Efficacy of intravenous ofloxacin: a French multicentre trial in 185 patients. Beaucaire, G; Beuscart, C; Chidiac, C; Leroy, O; Mouton, Y; Senneville, E; Sivery, B; Vincent du Laurier, M, 1990) | 0.59 |
| "A study was made of the plasma and distribution kinetics of ofloxacin administered at a dosage of 400 mg orally to a group of healthy volunteers and a group of patients with renal impairment." | ( Effect of renal impairment on distribution of ofloxacin. Domínguez-Gil Hurlé, A; Gomez Sanchez, JC; Martinez Lanao, J; Sanchez Navarro, A; Sanchez Recio, MM; Tabernero Romo, JM; Terreiro Delgado, MM, 1990) | 0.78 |
| " The proposed dosing regimen could be an adequate therapy of peritonitis and exit-site infections in patients on CAPD since levels reached in the dialysate effluent are bactericidal." | ( Single- and multiple-dose kinetics of ofloxacin in patients on continuous ambulatory peritoneal dialysis (CAPD). Essers, L; Grabensee, B; Keller, E; Passlick, J; Wonner, R, 1989) | 0.55 |
| " Serum and milk samples were obtained simultaneously at two, four, six, nine, 12, and 24 hours after dosage administration." | ( Pharmacokinetics of three newer quinolones in pregnant and lactating women. Aravantinos, D; Gazis, J; Giamarellou, H; Kolokythas, E; Petrikkos, G; Sfikakis, P, 1989) | 0.28 |
| " 64 patients were treated with ofloxacin and 11 with amikacin, dosage regimens of the two drugs were 300 mg and 300-400 mg twice daily." | ( [Efficacy of ofloxacin in treating typhoid fever]. Gu, XJ; Wang, F; Zhang, MF, 1989) | 0.93 |
| " The pharmacokinetics of the compound indicate that, except for cases of renal impairment, little or no dosage adjustment is necessary." | ( Pharmacokinetics of ofloxacin. An overview. Flor, S, 1989) | 0.6 |
| " Dosage of each quinolone was 200 mg twice daily for four days, starting three days prior to the theophylline infusion." | ( Drug-drug interactions affecting fluoroquinolones. Guelen, PJ; Janssen, TJ; Vree, TB; Wijnands, GJ, 1989) | 0.28 |
| " The recommendation of some authors that, in general, ofloxacin dosage may be halved in the elderly could not be confirmed." | ( Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models. Glerum, JH; Jones, RW; Notarianni, LJ; Rademaker, CM; van Dijk, A; Verhoef, J, 1989) | 0.8 |
| "Thirty-four hospitalized patients with various infections: 19 with typhoid fever, 4 with gastroenteritis, 7 with lower respiratory tract infections, 2 with biliary tract infections, 1 with brucellosis and 1 with infection of necrotic ulceration of the feet, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | ( Clinical experience with ofloxacin (DL-8280) in the therapy of various infections. Altucci, P; Cristiano, P; Iovene, MR; Mandia, L; Morelli, G; Paradisi, F, 1989) | 0.76 |
| " BMY 40062 exhibited longer half-life, higher maximum concentration in serum, greater area under the curve, and better bioavailability in mice after oral dosing than ciprofloxacin." | ( In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone. Desiderio, JV; Fung-Tomc, J; Kessler, RE; Tsai, YH; Warr, G, 1989) | 0.47 |
| " The superiority of the triple dosing in chemotherapeutic efficacy of ofloxacin was found to be attributable at least to the longer retention of its pulmonary levels exceeding the antibiotic concentrations." | ( Chemotherapeutic efficacy of ofloxacin against experimental pneumonia with Pseudomonas aeruginosa in guinea pigs. Hashimoto, S; Iigo, Y; Ishida, Y; Nakajima, R; Osada, Y; Otani, T; Une, T, 1989) | 0.8 |
| " The data obtained confirm that ofloxacin is active against Chlamydia trachomatis at concentrations achievable with the routine dosage regimen." | ( In-vitro activity of ofloxacin against Chlamydia trachomatis. Cevenini, R; Rumpianesi, F; Sambri, V; Xerri, L, 1989) | 0.88 |
| " The therapeutic combination of H2-receptor-antagonists (= H2-RA) and ofloxacin (Tarivid) has shown to heal resistant duodenal ulcers in some preliminary cases, which did not respond to a three month standard dosage treatment with H2-RA." | ( [Ofloxacin in therapy of "resistant" duodenal ulcer. A pilot study]. Bayerdörffer, E; Kasper, G; Ottenjann, R; Pirlet, T; Sommer, A, 1988) | 1.42 |
| " This study was undertaken at the incubation period, in syphilitic rabbits, using kinetic data obtained in man, after a given dosage of ofloxacin." | ( [In vivo study of the sensitivity of Treponema pallidum to ofloxacin]. Daubras, M; Ichou, F; Ly, M; Poitevin, M, 1988) | 0.72 |
| " On the basis of these results, a means of determining suitable dosage reduction factors in patients with renal impairment is presented." | ( Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function. Höffler, D; Koeppe, P, 1987) | 0.6 |
| " Ofloxacin was administered at a dosage of 600 mg divided into 3 doses for 14 days." | ( [Studies of clinical efficacy of ofloxacin against male urethritis caused by Chlamydia trachomatis]. Matsuda, T; Okada, K; Yoshida, O, 1988) | 1.47 |
| " These results show that ofloxacin, in a dosage of 300 mg taken orally twice daily for seven days, is an effective treatment for uncomplicated urethritis in men but may not reliably cure chlamydial infections." | ( A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Boslego, JW; Ciak, J; Greenup, R; Hicks, CB; Thomas, RJ; Tramont, EC; Wiener, HA, ) | 0.71 |
| " A dosing schedule for the quinolones was proposed on the basis of pharmacokinetic parameters and microbiologic activity." | ( Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Andrews, JM; Griggs, D; Wise, R, ) | 0.13 |
| " The largest reductions of viable counts in the kidneys at each dosage as compared to the bacterial counts of untreated animals were achieved with coumermycin (3." | ( Efficacy of coumermycin, ofloxacin and vancomycin against methicillin-resistant Staphylococcus aureus in vitro and in experimental infections of mice. Breyer, S; Georgopoulos, A; Hirschl, AM; Rotter, ML; Stanek, G, 1988) | 0.58 |
| " Furthermore, there was a broad fluctuation of approximately 80% between the Cmax and Cmin in the plasma levels of the drug during a 12-hour dosing interval." | ( Pharmacokinetics and tissue distribution of ofloxacin in human subjects during a multiple dose regimen. Bonaccorsi, S; Carlino, S; De Bernardis, E; Picari, M; Rizza, V, 1988) | 0.54 |
| " Peritoneal effluent ofloxacin levels correlated well with the prevailing serum concentrations of the antibiotic and, except on day 1, the mean peritoneal effluent ofloxacin levels all exceeded 3 mg/l with the second dosing scheme." | ( Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin. Chan, MK; Chan, WW; Chau, PY, 1988) | 0.82 |
| " These results confirm that dosage reduction of ofloxacin is required in haemodialysis patients." | ( The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1988) | 0.84 |
| "3% of ofloxacin after iv dosing could be detected as metabolites in urine." | ( Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. Borner, K; Höffken, G; Kirch, A; Koeppe, P; Lode, H; Olschewski, P; Sievers, B, 1988) | 1.02 |
| " Bronchial secretions were aspirated at bronchoscopy between one and 24 h after dosing and blood was collected at the same time." | ( The penetration of ofloxacin into bronchial secretions. Bone, M; Javaid, A; Symonds, J; Turner, A, 1988) | 0.6 |
| " A single dosage induced chondrocyte degeneration in the middle zone of the articular cartilage 5 h later and cavity formation 12 and 24 h later." | ( Effect of ofloxacin on the uptake of [3H]thymidine by articular cartilage cells in the rat. Kato, M; Onodera, T, 1988) | 0.68 |
| " dosage schedule for enteric fever and UTI due to beta-lactamase-producing bacteria." | ( In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever. Srimuang, S; Tanphaichitra, D, 1988) | 0.55 |
| " 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211)." | ( Clinical efficacy of ofloxacin in lower respiratory tract infections. A multicentre study. Gialdroni Grassi, G; Grassi, C; Mangiarotti, P, 1987) | 0.59 |
| " The dosage of ofloxacin has to be adapted to the stage of chronic renal failure." | ( [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results]. Dörfler, A; Schulz, W, 1986) | 1.53 |
| " Dosage adjustments of ofloxacin in uremic patients are proposed." | ( Ofloxacin pharmacokinetics in renal failure. Fillastre, JP; Humbert, G; Leroy, A, 1987) | 2.03 |
| " The authors thus recommend a dosage of 400 mg of ofloxacin three to five hours prior to surgery for middle ear infection." | ( Tissue concentrations of ofloxacin in the middle ear. Thorn, V, 1987) | 0.83 |
| " The following ofloxacin dosage regimen is recommended in haemodialysis patients: 200 mg initially, 100 mg loading dose after the first haemodialysis, then 100 mg daily." | ( Pharmacokinetics of ofloxacin in patients on haemodialysis treatment. Burkhardt, F; Dörfler, A; Schulz, W; Zichner, M, 1987) | 0.95 |
| "We reviewed, the structure, pharmacokinetic properties, mode of actions, antibacterial spectrum, therapeutic dosage and side effects of fluoroquinolones in this article." | ( [Fluoroquinolones]. Akalin, E; Baykal, M, 1987) | 0.27 |
| " Each patient had single drug therapy with ofloxacin in a daily dosage of 200 mg taken in the morning on an empty stomach." | ( [Diffusion of an orally administered single dose of ofloxacin into human bronchial mucus]. Benard, Y; Malbruny, B; Monrocq, N; Morel, C; Vergnaud, M, 1986) | 0.78 |
| "Nine patients with typhoid fever were given ofloxacin in a daily dosage of 400 mg for ten days." | ( [Treatment of typhoid fever using ofloxacin. Clinical experience and determination of antibiotic diffusion into the mesenteric lymph nodes]. Bru, JP; Croize, J; Fourtillan, JB; Le Noc, P; Leclercq, P; Lefebvre, MA; Micoud, M; Stahl, JP, 1986) | 0.81 |
| " In view of these significant changes in ofloxacin pharmacokinetics found in elderly subjects, we advocate reducing the usual dosage by half." | ( [Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg]. Bryskier, A; Couet, W; Darchis, JP; Fourtillan, JB; Lefebvre, MA; Modai, J; Veyssier, P; Vincent Du Laurier, M, 1986) | 0.86 |
| "Thirteen hospitalized patients with various infections, five with typhoid fever, two with gastroenteritis, four with respiratory tract infection and two with biliary tract infection, were treated with ofloxacin at a daily dosage ranging between 600 and 900 mg orally." | ( Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report. Altucci, P; Briante, V; Cristiano, P; Leonessa, V; Morelli, G; Paradisi, F, 1986) | 0.76 |
| " We conclude that a single oral dose of ofloxacin in the studied dosage regimens was highly effective and safe in the treatment of uncomplicated gonorrhoea." | ( Single dose ofloxacin in treatment of uncomplicated gonorrhoea. Chan, AS; Fung, KK; Ng, TK; Tang, KC, 1986) | 0.92 |
| " Ofloxacin was used at a dosage of 300 mg to 800 mg daily for three to 20 days in 206 cases of various infectious diseases in the otorhinolaryngological field such as otitis media, external otitis, paranasal sinusitis, tonsillitis and pharyngolaryngitis." | ( Clinical efficacy of ofloxacin in the treatment of otorhinolaryngological infections. Baba, S, 1986) | 1.5 |
| " It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens." | ( Review of the 4-quinolones. Eggleston, M; Park, SY, 1987) | 0.27 |
| " In clinical use, the drug was given at a daily dosage of 300-600 mg for 5-21 days." | ( [Laboratory and clinical study of ofloxacin in the treatment of bacterial prostatitis]. Ando, K; Moriguchi, R; Naide, Y; Suzuki, K; Tamai, H, 1984) | 0.55 |
| " In comparative trials with ofloxacin, levofloxacin, at half the daily dosage of ofloxacin, showed equivalent efficacy and a reduced incidence of adverse effects in the treatment of lower respiratory tract and complicated urinary tract infections." | ( Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Bryson, HM; Davis, R, 1994) | 1.2 |
| " It seems, therefore, that the in vivo activity of LVFX is comparable to that produced by a twofold-greater dosage of OFLO." | ( In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995) | 0.56 |
| " However, the area under the inhibitory serum concentration time-curve (AUIC) may be superior when appropriate dosing intervals are selected." | ( Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. Nix, DE; Schentag, JJ, ) | 0.13 |
| " The fluoroquinolones were administered to simulate dosage regimens of 200 mg, 400 mg given intravenously (i." | ( Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Kaatz, GW; Kang, SL; McGrath, BJ; Rybak, MJ; Seo, SM, 1994) | 0.6 |
| " Population pharmacokinetic parameters are also useful for the individualization of a dosage regimen by means of the Bayesian forecasting method." | ( Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) | 0.54 |
| " Ofloxacin was used primarily to treat tuberculosis (TB), dosed to achieve 2-hour postdose serum concentrations of 8-12 micrograms/ml." | ( Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Berning, SE; Iseman, MD; Madsen, L; Peloquin, CA, 1995) | 1.52 |
| " Ofloxacin was administered at a dosage of 200 mg three times daily for 7 to 10 days." | ( Ofloxacin in the treatment of typhoid fever resistant to chloramphenicol and amoxicillin. Hayat, Z; Khan, MA; Sadick, A, ) | 2.48 |
| "Hair samples were obtained 1-5 months after ingestion of the antimicrobial ofloxacin, which had been given for 1 or 3 days at the commencement of haloperidol administration, or when its dosage was reduced." | ( Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol. Kosuge, K; Nakano, M; Nakashima, M; Nishimoto, M; Sato, H; Uematsu, T, 1994) | 1 |
| " In a dose-response study, treatment with LEV at 100, 200, and 400 mg/kg of body weight was started 1 day after infection and was given daily for 28 days." | ( Activity of levofloxacin in a murine model of tuberculosis. Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA, 1994) | 0.64 |
| " Its optimal dosage appears to be 400 mg daily, and combination with dapsone and clofazimine does not enhance its activity." | ( Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Grosset, JH; Ji, B; N'Deli, L; Perani, EG; Petinom, C, 1994) | 0.62 |
| " Sparfloxacin was more effective than levofloxacin and ofloxacin in both dosing regimens." | ( In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R, 1994) | 0.55 |
| " Mean +/- standard deviation levofloxacin pharmacokinetic parameters (by noncompartmental moment method) after multiple dosing were as follows: area under the concentration-time curve, 31." | ( Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Bartlett, JA; Chow, AT; Flor, SC; Gallis, HA; Goodwin, SD; Wong, FA, 1994) | 0.85 |
| "Human scalp hair retains the past dosage history over a rather long period of time, acting as 'tape-recorder'." | ( Utilization of hair analysis for therapeutic drug monitoring with a special reference to ofloxacin and to nicotine. Uematsu, T, 1993) | 0.51 |
| " One of five new quinolones was orally administered, before transurethral resection of the prostate, at the dosage of 200 mg three times daily for 3 consecutive days." | ( Accumulation of new quinolones in the blood of elderly patients. Abe, Y; Hasuda, A; Morita, M; Nakagawa, H; Suzuki, K, ) | 0.13 |
| " Juvenile (4- to 5-week-old) NZW were orally dosed with ofloxacin or pefloxacin (300 mg/kg of body weight for 1 day) or with pefloxacin (300 mg/kg for 7 days)." | ( Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Gaudin, C; Hayem, G; Kahn, MF; Levacher, M; Petit, PX; Pocidalo, JJ, 1994) | 0.53 |
| "5 mM) by 20% of the control in the in situ ligated loop experiment, in which partial precipitation of aluminum hydroxide was observed in the dosing solution." | ( Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Aoki, H; Fujisawa, C; Hakusui, H; Kurata, T; Ohshima, Y; Okazaki, O; Tanaka, M, 1993) | 0.56 |
| " Ofloxacin concentrations in plasma were evaluated after 4 days of oral or intravenous (1-h infusion) dosing with a 3-day wash-out period between regimens." | ( Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Chow, AT; Flor, SC; Rogge, MC, 1993) | 1.47 |
| " These results, together with pharmacokinetic and toxicological data in mice and man, suggest that sparfloxacin may have a higher therapeutic index than ofloxacin in leprosy, and that the tentative standard dosage of 200 mg sparfloxacin daily should be appropriate for a clinical trial." | ( Sparfloxacin is more bactericidal than ofloxacin against Mycobacterium leprae in mice. Chan, GP; Franzblau, SG; Parrilla, ML, 1993) | 0.75 |
| " This study was designed to evaluate the additive effect of continuous low dosage or intermittent usual dosage of ofloxacin (OFLX) on EM therapy in patients with sinobronchial syndrome." | ( Additive effect of continuous low-dose ofloxacin on erythromycin therapy for sinobronchial syndrome. Fujimura, M; Ishiura, Y; Matsuda, T; Nakatsumi, Y; Nomura, M; Saito, M; Shibata, K, 1995) | 0.77 |
| " Chondrocyte clusters producing glycosaminoglycans were observed 3 weeks after dosing and at later time points." | ( Quinolone-induced cartilage lesions are not reversible in rats. Förster, C; Kociok, K; Merker, HJ; Shakibaei, M; Stahlmann, R, 1996) | 0.29 |
| "Effects of intravitreal injection of levofloxacin (LVFX) on the electroretinogram (ERG), visual evoked potential (VEP), and retinal histology were studied in 23 albino and 23 pigmented rabbits to establish the non-toxic intravitreal dosage of LVFX." | ( [Effects of intravitreal levofloxacin on the rabbit retina]. Kajimura, T; Komatsu, M; Mochizuki, K; Ogata, M; Ohkubo, S; Tanahashi, T; Torisaki, M; Yamashita, Y, 1996) | 0.86 |
| " Dosing modifications and an awareness of possible central nervous system adverse effects are warranted." | ( Association of a Tourette-like syndrome with ofloxacin. Reagan, DR; Thomas, RJ, 1996) | 0.55 |
| " However, gastrointestinal adverse events were quite frequent among patients treated with CLARI-MINO, with or without OFLO, and may be attributed to the higher dosage of CLARI or MINO or to the combination of CLARI-MINO plus OFLO." | ( Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Grosset, JH; Jamet, P; Ji, B; Lienhardt, C; Perani, EG; Petinon, C; Sow, S, 1996) | 0.52 |
| " Each dosing was followed by a wash-out period of one week." | ( Pharmacokinetics of levofloxacin in comparison to the racemic mixture of ofloxacin in man. Damm, D; Lehr, KH; Malerczyk, V; Verho, M, 1996) | 0.6 |
| " A dose-response analysis showed that levofloxacin was superior to ciprofloxacin for all four isolates at any dose or regimen tested, independent of the methicillin susceptibility of the isolates." | ( In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996) | 0.86 |
| " The drug was administered in accordance with 2 regimens: orally in a dose of 400 mg once a day (group I) and intravenously in a dose of 200 mg twice a day for 2 to 4 days followed by the drug oral use in the same dosage for 6 to 8 days (group II)." | ( [Clinical and pharmacokinetic evaluation of ofloxacin under various regimens of administration in patients with bronchopulmonary infections]. Belousov, OB; Efremenkova, OV; Gutkin, AB; Sokolov, AV; Tishchenkova, IF, 1996) | 0.56 |
| " After that period the drug was used orally in the same dosage for 4 to 6 days." | ( [Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages]. Denisova, EN; Evseev, AA; Savel'eva, GM, 1996) | 0.55 |
| " For the first 3 to 5 days in the present study ofloxacin was administered in a dose of 200 mg twice a day followed by its oral use in the same dosage for 3 to 5 days." | ( [Outlook and experience in using ofloxacin in urology]. Derevianko, II; Kotliarova, GA; Siniukhin, VN, 1996) | 0.83 |
| " In group III ofloxacin was used in the same dosage but in combination with some other antibiotics." | ( [Treatment of Flexner's dysentery with ofloxacin]. Kulikov, VP; Rakhmanova, AG, 1996) | 0.92 |
| " Clinafloxacin at higher dosage (45 mg/kg/d) resulted in a decrease in myeloid progenitors in BM." | ( Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones. Fabian, I; Gruss, T; Kletter, Y; Shalit, I; Weiss, K, 1997) | 0.3 |
| " Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen." | ( In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK, 1996) | 0.59 |
| " The dosage of prednisolone was increased, and amikacin was injected to treat pneumonia that had developed in the right lung." | ( [Legionella pneumonia successfully treated despite late diagnosis]. Takazakura, E; Tsuji, H, 1997) | 0.3 |
| " Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10." | ( Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Chien, SC; Chow, AT; Hendrix, CW; Rogge, MC; Williams, RR, 1997) | 0.96 |
| " To verify intraocular penetration, ten rabbits received identical dosing schedules followed by HPLC measurement of aqueous and vitreous drug concentrations at 1, 4, 8, 12, and 24 hours following dose completion." | ( Retinal safety of oral and topical ofloxacin in rabbits. Callina, C; Cohen, RG; Lahav, M; Raizman, M, 1997) | 0.57 |
| "To evaluate the levels of ofloxacin (Ocuflox) in human corneal tissue in patients exposed to various dosing regimens and application methods." | ( Corneal tissue levels of topically applied ofloxacin. Gonzales, J; Johns, S; Price, FW; Whitson, WE, ) | 0.69 |
| " Patients were placed into one of two study groups of 20 each based on dosing regimen and application method." | ( Corneal tissue levels of topically applied ofloxacin. Gonzales, J; Johns, S; Price, FW; Whitson, WE, ) | 0.39 |
| "Corneal tissue concentrations of Ocuflox were elevated significantly by varying drug application methods and dosing schedules before PKP." | ( Corneal tissue levels of topically applied ofloxacin. Gonzales, J; Johns, S; Price, FW; Whitson, WE, ) | 0.39 |
| " Levofloxacin at 500 mg or placebo was administered orally or intravenously as a single dose on day 1; daily oral or intravenous dosing resumed on days 4 to 10." | ( Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Cheung, WK; Chien, SC; Chow, AT; Curtin, C; Fowler, CL; Gisclon, LG; Natarajan, J; Rogge, MC; Williams, RR; Wong, F, 1997) | 1.14 |
| " A HPLC method was developed for determination of both antibiotics in ocular aqueous humor and plasma in order to optimize dosage for safe surpassing minimal inhibitory concentration in the humor compartment." | ( Simultaneous quantification of cefotaxime, desacetylcefotaxime, ofloxacine and ciprofloxacine in ocular aqueous humor and in plasma by high-performance liquid chromatography. Breithaupt, A; Breithaupt, H; Gehrke, R; Kraemer, HJ, 1997) | 0.54 |
| "5 and 6 h after dosing and the drug was still detectable in plasma 48 h after dosing (0." | ( Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Förster, C; Günther, T; Lozo, E; Merker, HJ; Schwabe, R; Stahlmann, R; Vormann, J; Zippel, U, 1997) | 0.3 |
| " In study period 1, 750 mg of levofloxacin or a placebo was administered orally as a single dose on day 1, followed by a washout period on days 2 and 3; dosing resumed for days 4 to 10." | ( Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Callery-D'Amico, SV; Chien, SC; Chow, AT; Fowler, CL; Nayak, R; Williams, RR; Wong, FA, 1998) | 0.79 |
| " In mouse experiments, the activity of a single dose of the combination OFLO-MINO was dosage related; the higher dosage of the combination displayed bactericidal activity which was significantly inferior to that of a single dose of RMP, whereas the lower dosage did not exhibit a bactericidal effect." | ( Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Diderot, V; Grosset, J; Ji, B; Lienhardt, C; Perani, E; Sow, S, 1998) | 0.55 |
| " Dosing regimens were: every 30 min, 60 min, or a single drop applied at 9 h PI." | ( Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. Engel, LS; Green, LC; Hill, JM; Moreau, JM; O'Callaghan, RJ, 1998) | 0.62 |
| " Starting from 10(7) CFU/ml, the bacterial count was determined serially during the exposure to LVFX present at concentrations automatically simulated to its clinically achievable urinary levels at the recommended dosage (100 mg 3 times daily)." | ( Bactericidal effect of levofloxacin on strains with equal susceptibility in an in vitro urinary bladder model. Hirose, T; Matsukawa, M; Mikami, M; Nishimura, M; Sano, M; Takahashi, S; Tsukamoto, T, ) | 0.43 |
| " We conclude that the type of dialyzer used has to be taken into account in dosage recommendations for antimicrobial therapy in hemodialysis patients." | ( Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers. Burgmann, H; El Menyawi, I; Hörl, WH; Kletzmayr, J; Kovarik, J; Rosenkranz, AR; Thalhammer, F; Traunmüller, F, 1998) | 1.74 |
| " High oral bioavailability allows switching from intravenous to oral therapy without dosage adjustment." | ( Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Lamb, HM; Langtry, HD, 1998) | 0.92 |
| " In many cases dose and intervals were based on WHO protocol, however smaller dosage was used in some cases." | ( [Chemotherapy of Hansen's disease in Japan--present status]. Goto, M; Kitajima, S; Miyagi, S; Takizawa, H, 1998) | 0.3 |
| " Compared with ciprofloxacin and the earlier quinolone agents, levofloxacin has an improved pharmacokinetic profile that allows convenient once-daily dosing in either an oral or parenteral formulation." | ( Levofloxacin: a therapeutic review. Garrison, MW; Schoonover, L; Wimer, SM, ) | 1.08 |
| " Standard antibiotic dosing regimens which simulated the pharmacokinetic profile observed in humans were used." | ( Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Lacy, MK; Lu, W; Nicolau, DP; Nightingale, CH; Quintiliani, R; Tessier, PR; Xu, X, 1999) | 0.58 |
| "25 mL in children with chronic suppurative otitis media and perforated tympanic membrane, with serial sampling of otorrhea and serum up to 8 hours after dosing and middle ear mucosa up to 2 hours after dosing." | ( Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. Furuta, S; Katsuda, K; Kiyota, R; Miyazaki, Y; Nobori, T; Ohyama, M; Ueno, K, 1999) | 1.75 |
| " For the 6 bacterial strains isolated from the middle ear, the highest minimum inhibitory concentration of ofloxacin was covered by otorrhea drug concentrations measured at up to 8 hours after dosing in some patients." | ( Ofloxacin otic solution in patients with otitis media: an analysis of drug concentrations. Furuta, S; Katsuda, K; Kiyota, R; Miyazaki, Y; Nobori, T; Ohyama, M; Ueno, K, 1999) | 1.96 |
| " aeruginosa with varying quinolone susceptibility, we constructed sigmoidal dose-response curves for AUC(0-6." | ( The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. Holt, HA; MacGowan, AP; Wootton, M, 1999) | 0.58 |
| " SBA was tested in vitro by a microtitration method 15 min before dosing and at 1, 4, 8 and 12 h after drug absorption." | ( Levofloxacin: serum bactericidal activity against methicillin-resistant Staphylococcus aureus isolates. Benoit, C; Bigot, C; Carbon, C; Decré, D; Maubert, B; Muller-Serieys, C, 1999) | 0.92 |
| "The objective of the current study was to evaluate the bactericidal activity of levofloxacin against Streptococcus pneumoniae at concentrations equivalent to those present in serum after a po dosage of 500 mg." | ( Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. Schwärzel, R; Shah, PM, 1999) | 0.82 |
| "The aim of this study was to compare the bactericidal efficacy of levofloxacin and ofloxacin against Streptococcus pneumoniae at different dosage regimens for both agents." | ( Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae. Bauernfeind, A, 1999) | 0.85 |
| " A greater number of infections were eradicated by levofloxacin than by cefuroxime axetil: infections were eradicated in 68% of patients receiving the 500 mg dosage and in 63% of those taking 250 mg levofloxacin, whereas the eradication rate with the comparator drug was much lower (48%)." | ( Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. Davies, BI; Maesen, FP, 1999) | 0.84 |
| " The dosing regimen of each drug that yielded serum levels in mice which mimic human therapeutic concentrations of the drugs, were designed." | ( Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R, 1999) | 0.59 |
| "The pharmacokinetics of levofloxacin, administered in high doses and with extended dosing intervals, was studied in human immunodeficiency virus (HIV)-infected patients." | ( Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients. Baird, B; Chow, AT; Fowler, CL; Masur, H; Natarajan, J; Piscitelli, SC; Spooner, K; Walker, RE; Williams, RR, 1999) | 0.83 |
| " The dosage was 500 mg once or twice a day depending on the studies." | ( [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. Léophonte, P; Veyssier, P, 1999) | 0.86 |
| " Good tolerability of the various ofloxacin dosing regimens in both the adult and pediatric patients was shown." | ( [The safety of ofloxacin]. Efremenkova, OV; Kapranov, NI; Litvinov, DV; Postnikov, SS; Semykin, SIu; Sokolov, AV, 1999) | 0.94 |
| " pneumoniae, with standard dosing resulting in area under the concentration-time curve/MIC ratios and peak concentration/MIC ratios that resulted in 99." | ( Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Hershberger, E; Rybak, MJ, 2000) | 0.54 |
| " Dose-response experiments with two topoisomerase IV mutants that confer clinical resistance to quinolones (GrlA(Ser80Phe) and GrlA(Glu84Lys)) indicate that resistance is caused by a decrease in both drug affinity and efficacy." | ( Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP, 2000) | 0.31 |
| " It would be reasonable to propose the 500 mg twice daily dosage for severe community-acquired pneumonia warranting intensive care hospitalization in accordance with the criteria of the ERS Task Force Report." | ( [Treatment of community-acquired pneumonia with levofloxacin: 500 mg once a day or 500 mg twice a day?]. Bru, JP; Zuck, P, ) | 0.38 |
| " The present study was focused on the impact of ofloxacin on rat testicular DNA ploidy in a dose-response relationship using an image analysis technique on testicular sections following Fuelgen DNA staining." | ( The impact of ofloxacin on rat testicular DNA: application of image analysis. Abd-Allah, AR; Gannam, BB; Hamada, FM, 2000) | 0.92 |
| " Experiments simulated variable peak serum concentrations, but clinically relevant half-lives and dosing intervals." | ( In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae. Demasters, TA; Madaras-Kelly, KJ, 2000) | 0.51 |
| " In cases where a fever does not decrease through dosage of an antibiotic such as ofloxacin after about 3 days, half of the standard dose of Mao-bushi-saishin-to for 7 days should be considered as a complementary therapy." | ( Effect of Mao-bushi-saishin-to on infection of ofloxacin resistant bacteria and of unknown origin. Kamei, T; Tomioka, H; Toriumi, Y, 2000) | 0.79 |
| " Average length of stay (LOS), hospital costs, death rate, age, and ratio of oral to intravenous dosage administration were analyzed." | ( Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Clark, LC; Davis, CW, 2000) | 0.56 |
| " Plasma OFLX concentration-time course collected from the highest dosage showed a convex decline, indicating a capacity-limited process in drug elimination (Michaelis-Menten elimination)." | ( Non-linear pharmacokinetics of ofloxacin after a single intravenous bolus dose in pigs. Ikenoue, N; Kokue, E; Shimoda, M; Son, DS; Tagawa, Y, 2000) | 0.59 |
| " An understanding of pharmacodynamic principles is essential; it forms the scientific basis for the design of dosing strategies that maximize clinical efficacy and minimize toxicity." | ( Antimicrobial pharmacodynamics. Ambrose, PG; Grasela, D; Owens, RC, 2000) | 0.31 |
| " Further multiple-dose studies are required to enable dosage recommendations to be made for patients receiving renal replacement therapy with CVVH." | ( Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. Locker, GJ; Losert, H; Schmid, R; Staudinger, T; Thalhammer, F; Thalhammer-Scherrer, R; Traunmüller, F, 2001) | 0.59 |
| " The twice daily dosing regimen encourages better patient adherence to therapy, which is likely to improve treatment efficacy." | ( Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Goldblatt, EL, 2001) | 0.69 |
| "4 (100%), respectively, over the dosing period." | ( Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M, 2001) | 0.55 |
| " In the face of rising MICs (as is occurring worldwide with Streptococcus pneumoniae), close attention to appropriate dosing and concentration above the MIC may delay and potentially even prevent antibiotic resistance." | ( What have we learned from pharmacokinetic and pharmacodynamic theories? Gilliland, KK; Paladino, JA; Schentag, JJ, 2001) | 0.31 |
| " The penetration of levofloxacin averaged 53% for the 7 mg/kg dosage group, 76% for the 10." | ( Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. Dash, AK; Destache, CJ; Larsen, C; Owens, H; Pakiz, CB, 2001) | 0.86 |
| "A dosage schedule of levofloxacin 250 mg qd with a 500 mg loading dose seems appropriate for anuric patients during CVVHF." | ( Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Bucher, M; Hansen, E; Jakob, W; Kees, F; Lemberger, P, 2001) | 0.93 |
| " For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval." | ( Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy. Cadeo, B; Carosi, G; Fiocchi, C; Marchetti, F; Regazzi, MB; Signorini, L; Viale, P; Villani, A; Villani, P, 2001) | 1.02 |
| " The adverse effects disappeared after the dosage was reduced and the theophylline serum concentration decreased; however, there was no change in theophylline clearance." | ( Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Enomoto, H; Hasegawa, A; Kawana, H; Kitada, M; Kuriyama, T; Nakamura, H; Ohmori, S; Ohtsuka, T, 2001) | 0.68 |
| " Therefore, the purpose of this study was to compare the effectiveness of standard once per day dosing of oral levofloxacin with a standard parenteral antibiotic regimen (nafcillin four times daily) for the treatment of experimental MSSA osteomyelitis in rabbits." | ( Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. Calhoun, JH; Mader, JT; Shirtliff, ME, 2001) | 0.8 |
| " With the resistant isolates, the MICs for ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, and trovafloxacin were above the maximal serum drug concentrations reported for standard dosage regimens." | ( Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. Drlica, K; Mariano, N; Rahal, JJ; Rahman, N; Segal-Maurer, S; Urban, C; Zhao, X, 2001) | 0.8 |
| "We have assessed levofloxacin penetration in cerebrospinal fluid (CSF) and the liquor-to-plasma ratio (C(L)/C(P)) at 2 hours after dosing in 5 patients with spontaneous acute bacterial meningitis." | ( Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Baraldo, M; Furlanut, M; Giobbia, M; Pea, F; Scotton, PG; Vaglia, A, 2001) | 0.91 |
| " Sequential therapy is easily administered due to its high oral bioavailability, and the dosing schedule can be a convenient once-daily dose." | ( Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients. Norrby, SR, 2001) | 0.31 |
| "Thirty-one cases were randomly assigned to two drug regimens using WHO dosage schedules: (i) regimen A (n = 15): isoniazid, rifampicin and ethambutol for 2 months, followed by isoniazid and rifampicin for a further 7 months; and (ii) regimen B (n = 16): isoniazid, pyrazinamide, ethambutol and ofloxacin for 2 months, followed by isoniazid, ethambutol and ofloxacin for a further 10 months." | ( Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. Agarwal, SR; Nandeesh, HP; Saigal, S; Sarin, SK, 2001) | 0.86 |
| " Although clinical trials have shown that gemifloxacin is effective for the treatment of uncomplicated urinary tract infections, whether an oral dosage of 320 mg of gemifloxacin once daily is also adequate for the treatment of complicated urinary tract infections has yet to be confirmed." | ( Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Bygate, EA; Fairless, AJ; Hammer, M; Kinzig-Schippers, M; Machka, K; Naber, CK; Naber, KG; Sauber, C; Sörgel, F, 2001) | 0.55 |
| " Gatifloxacin should be avoided in the same patient population, and the recommended dosage of 400 mg/day should not be exceeded." | ( Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Frothingham, R, 2001) | 0.57 |
| "Marked extracorporeal elimination of levofloxacin occurs, requiring a dosage adjustment that can be calculated from the characteristics of CVVH and CVVHDF." | ( Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Boos, C; Bruch, HP; Guenter, SG; Iven, H; Muhl, E, 2002) | 0.89 |
| "The main pharmacokinetic parameters af ter the first dosing were as follows: Cmax was (2." | ( Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects. Li, JT; Li, MN; Li, TY; Liu, Y; Lu, Y; Zhang, JW; Zhang, L; Zhang, YL, 2002) | 0.56 |
| "To probe the pharmacokinetic basis for the use of levofloxacin for complicated skin and skin-structure infections (SSSIs) at a once-daily dosage of 750 mg by investigating its penetration into skin tissue." | ( Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. Chen, A; Chow, AT; Fowler, C; Lattime, H; Morgan, N; Williams, RR; Wong, F, 2002) | 0.9 |
| " Since this dosing regimen does not reflect the therapeutic situation, we studied the effects of a 5- or 7-day treatment with ofloxacin at lower oral doses (10, 30, and 100 mg/kg twice a day [b." | ( Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Lozo, E; Riecke, K; Schwabe, R; Stahlmann, R; Vormann, J, 2002) | 0.84 |
| " Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence." | ( The expanding role of fluoroquinolones. Schaeffer, AJ, 2002) | 0.31 |
| " Given the severity of some of the adverse events, a better understanding of dosing and clearer guidelines for monitoring therapy are imperative if these drugs are to be prescribed together." | ( Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Dolovich, LR; Holbrook, A; Loeb, M; Papastavros, T; Whitehead, L, 2002) | 0.57 |
| " A higher dosage of sequential levofloxacin 750mg once daily proved as effective as intravenous ticarcillin/clavulanic acid (+/- oral switch to amoxicillin/clavulanic acid) in the treatment of complicated skin and skin structure infections." | ( Levofloxacin: an updated review of its use in the treatment of bacterial infections. Figgitt, DP; Hurst, M; Lamb, HM; Scott, LJ, 2002) | 1.22 |
| " Animals were killed on Days 2, 3, 4, 5 or 8 (the dosing day was designated as Day 1), and the incidence of micronucleus in the epidermis was determined." | ( In vivo photochemical micronucleus induction due to certain quinolone antimicrobial agents in the skin of hairless mice. Furuhama, K; Itoh, S; Katoh, M, 2002) | 0.31 |
| "Most integral endpoints of antimicrobial effect, including area between the control growth and time-kill curves (ABBC), area above the curve (AAC) and area under the time-kill curve (AUBC) are determined over a dosing interval (tau), regardless of the actual effect duration." | ( AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2002) | 0.52 |
| "05) from those observed after intravenous dosing in the same patients; other pharmacokinetic parameters were similar." | ( Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Abraham, E; Fish, DN; Rebuck, JA, 2002) | 0.58 |
| "The dosage regimen of intravenous levofloxacin 500 mg once/day appears adequate for most pathogens found in critically ill patients with normal renal function." | ( Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Abraham, E; Fish, DN; Rebuck, JA, 2002) | 0.85 |
| "This in vitro study evaluated the pharmacodynamic performance of levofloxacin using different dosing strategies against both a levofloxacin-sensitive (MIC = 1 mg/liter) and -resistant (MIC = 16 mg/liter) strain of Streptococcus pneumoniae." | ( Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae. Gunderson, B; Hovde, LB; Ibrahim, KH; Ross, G; Rotschafer, JC; Wright, DH, 2002) | 0.55 |
| " Owing to a concern regarding noncompliance and the adverse effect of bleeding, warfarin dosage was adjusted in one patient even though his first INR value was in the high end of the therapeutic range (2." | ( Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. Burrows, MM; Enlow, AM; Greenwood, MC; Kilpatrick, DM; Lower, DL; Yamreudeewong, W, 2003) | 0.69 |
| " AUC0-t/MIC was strongly associated with bacterial kill throughout the dosing interval." | ( AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA, 2003) | 0.32 |
| " Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33." | ( Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Baldassarre, M; Brollo, L; Cusenza, A; Di Qual, E; Furlanut, M; Pea, F, 2003) | 0.57 |
| " Dosing regimens and consequent drug exposures that amplify or suppress the emergence of resistant bacterial subpopulations were identified and prospectively validated." | ( Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. Bachhawat, R; Bush, K; Deziel, MR; Drusano, GL; Dudley, MN; Freeman, C; Jumbe, N; Kahn, JB; Leary, R; Liu, W; Louie, A; Miller, MH; Tam, VH, 2003) | 0.32 |
| " For example, the cost implications of using manufacturers' recommendations for dosing in patients with renal dysfunction may be important, depending on the distribution of various levels of renal function within a patient population." | ( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003) | 0.32 |
| " Also, costs of failing to adjust dosing regimens for decreased renal function were determined." | ( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003) | 0.32 |
| " Costs potentially incurred by failing to adjust dosing for renal function were substantial." | ( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003) | 0.32 |
| "Formulary decisions can be facilitated by considering factors such as patient characteristics and related dosing in addition to simple acquisition costs." | ( A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Bosso, JA; Enzweiler, KA; White, RL, 2003) | 0.32 |
| " Objectives of this study are to determine the pharmacokinetics and dialytic clearance of levofloxacin and develop dosing strategies in these patients." | ( Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. Hamburger, RJ; Kays, MB; Lucksiri, A; Mueller, BA; Scott, MK; Sowinski, KM, 2003) | 1.16 |
| "Direct measurement of the concentration of antimicrobial agents in bronchial epithelial lining fluid (ELF) would allow for a more informed approach to appropriate dosing of antimicrobial agents for respiratory tract infections." | ( Bronchoscopic microsampling method for measuring drug concentration in epithelial lining fluid. Ishizaka, A; Nishimura, M; Ogura, S; Oh-hara, T; Yamazaki, K, 2003) | 0.32 |
| " Recent reports demonstrate enhanced activity associated with a higher 750 mg dosage of levofloxacin." | ( Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Garrison, MW, 2003) | 0.81 |
| " In classical fractionated dose-response studies with animals, it is difficult to differentiate between the AUC/MIC ratio and the peak/MIC ratio because of colinearity." | ( Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Fraschini, F; Mattina, R; Mouton, JW; Scaglione, F, 2003) | 0.63 |
| " Plasma samples were collected prior to dosing and for up to 48 hours after." | ( Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. Amsden, GW; Johnson, PW; Whitaker, AM, 2003) | 0.61 |
| " The areas under the concentration-time curves during the 12-h dosing interval (AUC(0-tau)s) were 47." | ( Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Benetton, C; Furlanut, M; Nascimben, E; Pavan, F; Pea, F; Scotton, PG; Vaglia, A, 2003) | 0.94 |
| "The impact of the pharmacokinetic/pharmacodynamic (PK/PD) parameters (the 24h area under the concentration-time curve [AUC24h]/minimum inhibitory concentration [MIC] and maximum concentration in serum [Cmax]/MIC ratio) after single oral dosing of gatifloxacin on its bactericidal activity and resistance selectivity against quinolone-susceptible clinical isolates of Streptococcus pneumoniae J-69 was investigated using an in vitro PK model." | ( The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae. Ebisu, H; Fukuda, H; Kishii, R; Takei, M, 2003) | 0.32 |
| "In treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course." | ( [Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine]. Jiao, Q; Wang, BG; Zhang, RL, 2003) | 0.32 |
| " Additional groups of rats were orally dosed with 600 mg/kg ofloxacin and ciprofloxacin." | ( Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. Baumann-Wilschke, I; Bello, A; Kastner, M; Rahm, U; Stahlmann, R, 2004) | 0.57 |
| " In a second study, two dosage regimens of sitafloxacin were compared with placebo in Oriental subjects." | ( A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM, 2003) | 0.55 |
| "An in vitro pharmacodynamic model was used to simulate standard dosing regimens of linezolid, levofloxacin, and vancomycin against the isolates 79, R921, and P9802-020." | ( Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Akins, RL; Cha, R; Rybak, MJ, 2003) | 0.9 |
| " With dosing regimens B and C, levofloxacin concentrations in the aqueous humor were above the MIC90 for most common ocular pathogens, including Staphylococcus and Streptococcus species." | ( An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. Bucci, FA, 2004) | 0.85 |
| " for ventilator associated pneumonia to evaluate if this high dosage regimen might ensure appropriate exposure in the treatment of severe UTIs in ICU patients." | ( Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. Baldassarre, M; Brollo, L; Di Qual, E; Furlanut, M; Nascimben, E; Pavan, F; Pea, F, 2003) | 0.55 |
| "To determine the steady-state, extracellular, and intracellular pulmonary disposition of moxifloxacin (MXF), levofloxacin (LEVO), and azithromycin (AZI) relative to that of the plasma over a 24-h dosing interval." | ( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004) | 0.77 |
| "0 micro g/mL) throughout the dosing interval." | ( Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C, 2004) | 0.56 |
| " The once daily dosage regimen is more applicable, convenience and has better compliance." | ( An open label, randomized comparative study of levofloxacin and amoxicillin/clavulanic acid in the treatment of purulent sinusitis in adult Thai patients. Bunnag, C; Dhiraputra, C; Fooanant, S; Jareoncharsri, P; Srifuengfung, S; Tunsuriyawong, P; Voraprayoon, S, 2004) | 0.58 |
| " g(-1) at 24 h after dosing and declined slowly with a terminal half-life of 468." | ( Absorption, distribution and excretion of 14C-levofloxacin after single oral administration in albino and pigmented rats: binding characteristics of levofloxacin-related radioactivity to melanin in vivo. Ono, C; Tanaka, M; Yamada, M, 2004) | 0.58 |
| " Periodic and continuous ECGs were recorded before and after subjects were dosed with placebo and increasing doses of levofloxacin (500 mg, 1000 mg, 1500 mg) that included doses twice the maximum recommended dose of 750 mg in a double-blind, randomized, four-period, four-sequence crossover trial." | ( Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. Chien, S; Goodman, DB; Natarajan, J; Noel, GJ; Padmanabhan, M; Solanki, B, 2004) | 0.78 |
| " Based on the range of clinical indications, safety profile, local susceptibility, cost, and dosing convenience, levofloxacin was chosen over ciprofloxacin and gatifloxacin as the sole fluoroquinolone." | ( Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital. Armitstead, JA; Empey, KL; Evans, ME; Martin, C; Ofotokum, I; Rapp, RP, 2004) | 0.53 |
| " Areas between the control growth and the time--kill curves (ABBC in single dose simulations and the sum of ABBCs determined after the first, second and third dosing in multiple dose simulations--ABBC(1+2+3)) were higher with ABT492 than levofloxacin." | ( ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. Arzamastsev, AP; Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH, 2004) | 0.87 |
| "Ofloxacin was administered to six male goats intravenously (5 mg/kg) to determine its kinetic behavior, tissue residue, in vitro plasma protein binding and to compute a rational dosage regimen." | ( Pharmacokinetics, tissue residue and plasma protein binding of ofloxacin in goats. Baruah, H; Khonikor, HN; Roy, DC; Roy, RK, 2004) | 2.01 |
| "The aqueous penetration of the commercial preparations of the fluoroquinolone antibiotics ofloxacin, ciprofloxacin, levofloxacin, and gatifloxacin were compared following topical dosing in a rabbit model." | ( Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. Blanchard, J; Lane, LC; Levine, JM; Noecker, RJ; Rapedius, M; Snyder, RW, 2004) | 0.81 |
| " The concentration and the extent of accumulation of radioactivity not only in melanin-containing ocular tissues but also in other non-pigmented ocular tissues, such as retina, after chronic oral administration of 14C-levofloxacin once daily for 84 days were much lower than those after multiple dosing with 14C-chloroquine under the same conditions." | ( Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of 14C-levofloxacin and 14C-chloroquine in pigmented rats. Takashina, H; Tanaka, M; Tsutsumi, S, 2004) | 0.71 |
| " This is one of the first studies to demonstrate a significant effect of a computerized intervention on dosing route within an antibiotic class." | ( Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. Arbogast, PG; Bansal, P; Hargrove, F; Hulgan, T; Kernodle, DS; Miller, RA; Rosenbloom, ST; Talbert, DA, 2004) | 0.32 |
| " Pharmacokinetics of levofloxacin simulated after 500 mg, 750 mg and 1000 mg once daily dosing resulted in levofloxacin volume of distribution: elderly patients = younger patients, while levofloxacin clearance was: elderly patients < younger patients." | ( Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Chan, CK; Hoban, DJ; Marras, TK; Noreddin, AM; Sanders, K; Zhanel, GG, 2004) | 0.85 |
| " To provide dosing guidance for children, 3 single-dose, multicenter pharmacokinetic studies were conducted in 85 children in 5 age groups: 6 months to <2 years, 2 to <5 years, 5 to <10 years, 10 to <12 years, and 12 to 16 years." | ( Levofloxacin pharmacokinetics in children. Blumer, JL; Bocchini, JA; Bradley, JS; Chien, S; Kearns, GL; Maldonado, S; Natarajan, J; Noel, GJ; Wells, TG, 2005) | 0.95 |
| " The percentage of patients who required a warfarin dosage adjustment based on the post-INR (secondary outcome measure) was 41% (9 of 22 patients) in the levofloxacin group and 33% (7 of 21 patients) in the felodipine group." | ( Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Anderson, HG; McCall, KL; Scott, JC, 2005) | 0.76 |
| "A standard dosage regimen of 500 mg/day was administered to nine Caucasian patients included in the study, irrespective of their demographic characteristics." | ( Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Alvarez Lerma, F; Colino Gandarillas, CI; Domínguez-Gil, A; Menacho, YA; Sánchez Navarro, A, 2005) | 0.59 |
| "The aim was to confirm which was the better regimen for second-line therapy after treatment failure with a standard triple therapy in Japan, a high dosage of levofloxacin- or metronidazole-based therapy." | ( Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Aoyama, N; Kasuga, M; Matsumoto, Y; Miki, I; Mitani, T; Miyachi, H; Morita, Y; Shirasaka, D; Tamura, T; Toyoda, M; Watanabe, Y, 2005) | 1.15 |
| " Dosing regimens for gatifloxacin were 400 mg once daily (qd) administered to younger patients (<65 years) and gatifloxacin 200 mg qd to elderly patients (> or =65 years)." | ( Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Hoban, DJ; Noreddin, AM; Zhanel, GG, 2005) | 0.61 |
| " Serum levofloxacin disposition after intravenous and oral dosing was best fitted to a bicompartmental and a monocompartmental open models with first-order elimination, respectively." | ( Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats. Albarellos, GA; Ambros, LA; Landoni, MF, 2005) | 1.04 |
| " The ECL was satisfactorily applied to the determination of the two FQs in dosage form and urine sample." | ( Electrochemiluminescence of terbium (III)-two fluoroquinolones-sodium sulfite system in aqueous solution. Chen, SL; Ding, F; Liu, Y; Zhao, HC, 2006) | 0.33 |
| " Efforts should be directed at modifying hospital policies for dosing of levofloxacin and DTCCs to prevent coadministration." | ( Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Barton, TD; Fishman, NO; Lautenbach, E; Quain, RD; Weiner, MG, 2005) | 0.85 |
| " Levofloxacin dosage adjustments based on sex should be considered on an individual basis." | ( Pharmacokinetics of intravenously administered levofloxacin in men and women. Goldman, M; Kays, MB; Lagvankar, S; Mueller, BA; Overholser, BR; Sowinski, KM, 2005) | 1.14 |
| "Sustained release (SR)-gastroretentive dosage forms (GRDF) enable prolonged and continuous input of the drug to the upper parts of the gastrointestinal (GI) tract and improve the bioavailability of medications that are characterized by a narrow absorption window." | ( Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Chaudhari, S; Chavanpatil, M; Jain, P; Shear, R; Vavia, P, 2005) | 0.56 |
| "Levofloxacin is a fluoroquinolone antimicrobial agent for which pharmacodynamic relationships between the maximum serum antibiotic concentration (Cmax)/minimum inhibitory concentration (MIC) ratio and/or the area under the serum concentration-time curve during a 24-h dosing period (AUC(0-24))/MIC ratio and clinical and/or microbiological outcomes have been developed." | ( Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Blasi, F; Cazzola, M; Donnarumma, G; Marchetti, F; Matera, MG; Sanduzzi, A; Tufano, MA, 2005) | 1.26 |
| " By using a simulated animal pharmacokinetic profile, a once-daily dosing regimen that provided a human-equivalent exposure failed to sterilize the cultures." | ( Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Basset, J; Bush, K; Byrne, WR; Deziel, MR; Drusano, GL; Heine, H; Kao, M; Kelly, M; Louie, A; Miller, L, 2005) | 0.33 |
| " The unbound AUC/MIC ratio revealed that levofloxacin used in the described manner was borderline sufficient for the treatment of nosocomial pneumonia caused by Klebsiella pneumoniae and insufficient for the treatment of pneumonia caused by Pseudomonas aeruginosa, because the breakpoint of 30 to 40 for AUC/MIC could not be reached by the conventionally used dosage schema in our post-CS setting." | ( In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Burgmann, H; Hutschala, D; Jaksch, P; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, EM; Wisser, W; Wolner, E; Zuckermann, A, 2005) | 0.89 |
| " pneumoniae, MPC results were below susceptible breakpoints and within clinically achievable and sustainable drug concentrations for >24 hours of the dosing interval against." | ( Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. Blondeau, JM; Hansen, GT, 2005) | 0.54 |
| "The aim of this work is to provide a methodology to predict the potential efficacy of standard dosage schedules established for antimicrobials when used in clinical practice and administered to patients with different demographic characteristics." | ( [Pharmacokinetic/pharmacodynamic analysis to optimize antibacterial treatments: prediction of efficacy by using Montecarlo simulation techniques]. Sánchez Navarro, A, 2005) | 0.33 |
| "Compare two dosage strengths of levofloxacin in the treatment of acute bacterial sinusitis." | ( A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) | 0.88 |
| " The safety profile of the 2 dosage strengths was similar." | ( A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Anon, J; Kahn, J; Khashab, M; Paglia, M; Poole, M; Xiang, J, 2006) | 0.6 |
| " Recommendations for agent selection, agent concentration, length of treatment, dosing schedule, and methods of irrigation are presented." | ( Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis. Elliott, KA; Stringer, SP, ) | 0.13 |
| " dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%])." | ( Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P, 2006) | 1.32 |
| " Adherence to the prescribed regimen is affected by a number of variables including dosing interval, treatment duration, adverse effects, and palatability in pediatric patients." | ( Value of short-course antimicrobial therapy in community-acquired pneumonia. Blasi, F; Tarsia, P, 2005) | 0.33 |
| "Oral sustained release gastroretentive dosage forms offer many advantages for drugs having absorption from upper gastrointestinal tract and improve the bioavailability of medications that are characterized by a narrow absorption window." | ( Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Chaudhari, S; Chavanpatil, MD; Jain, P; Shear, R; Vavia, PR, 2006) | 0.55 |
| " This subgroup analysis attempted to compare the safety and efficacy of a short-course levofloxacin regimen with traditional levofloxacin dosing for PSI Class III/IV patients." | ( Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Kahn, JB; Khashab, MM; Shorr, AF; Tennenberg, AM; Xiang, JX, 2006) | 1.18 |
| " These differences can pose challenges in developing appropriate dosing guidelines." | ( Do intensive care patients need an individualized dosing regimen for levofloxacin? Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) | 0.57 |
| " For patients with higher levofloxacin clearance, the resulting efficacy for different strains of bacteria (expressed as free AUC/MIC ratios) suggested that for less sensitive pathogens, a dosage adjustment may be needed." | ( Do intensive care patients need an individualized dosing regimen for levofloxacin? Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) | 0.86 |
| " This may have significant implications in the clinical setting for identifying optimal dosage regimens for ICU patients." | ( Do intensive care patients need an individualized dosing regimen for levofloxacin? Barth, J; Hochhaus, G; Jäger, D; Kaufmann, S; Tayab, ZR, 2006) | 0.57 |
| " Three males and three female Rhesus monkeys were dosed with a single oral dose of 14C-levofloxacin at 15 mg kg-1 (2 MBq kg-1)." | ( Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey. Bottacini, M; Hemeryck, A; Kao, M; Kelley, MF; Macpherson, D; Mamidi, RN, 2006) | 0.78 |
| "5 points above the INR before fluoroquinolone use; major or minor bleeding events; requirement for vitamin K administration; warfarin dosage reduction or withholding doses; and warfarin-related hospital, emergency, or urgent care admissions or visits." | ( Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. Cole, J; Mathews, S; Ryono, RA, 2006) | 0.56 |
| " Both the dosage forms follow Higuchi model for release from formulations." | ( Formulation and development of gastroretentive drug delivery system for ofloxacin. Ali, J; Ali, M; Hasan, S, 2006) | 0.57 |
| "Given similar adverse event profiles and the advantages of higher dose therapy, including shorter courses of therapy and potential impact on preventing resistance, clinicians should consider utilizing the 750 mg dose of levofloxacin when choosing between dosage strengths for treatment of indicated infections." | ( Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Kahn, JB; Khashab, MM; Xiang, J, 2006) | 0.78 |
| " The value of dosing of antimicrobial agents based on MPC thresholds results in a rapid reduction in viable cells--even at higher inocula which are more reflective of organism burden in pneumonia." | ( Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C, 2006) | 0.33 |
| " Computer simulations to match plasma concentration profile, area under the concentration-time curve (AUC), and time above MIC for a human oral dose of 500 mg levofloxacin once a day identified a dosing regimen in rhesus monkeys that would most closely match human exposure: 15 mg/kg followed by 4 mg/kg administered 12 h later." | ( Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW, 2006) | 0.78 |
| "The mutant selection window hypothesis, originally based on agar plate assays, may lead to new antimicrobial dosing strategies that severely restrict the acquisition of resistance." | ( The mutant selection window in rabbits infected with Staphylococcus aureus. Cui, J; Drlica, K; Liu, Y; Tong, W; Wang, R; Zhao, X, 2006) | 0.33 |
| " It can be concluded that overall the doses of the two tested fluoroquinolones may be considered equivalent with regard to treatment of complicated urinary tract infections, although the recommended dosing is twice daily for ciprofloxacin and once daily for levofloxacin." | ( Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Kinzig-Schippers, M; Naber, KG; Sörgel, F; Wagenlehner, FM; Weidner, W, 2006) | 0.75 |
| " Area under the concentration time curve to minimum inhibitory concentration (AUC/MIC) values for tigecycline ranged from 79 to 158 microg h/mL and tigecycline concentrations remained above the MIC (T>MIC) throughout the simulated dosing interval." | ( In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison, MW; Nuemiller, JJ, 2007) | 0.34 |
| " Standard levofloxacin dosing (especially monotherapy) is unlikely to produce maximum therapeutic effectiveness." | ( Levofloxacin pharmacokinetics in adult cystic fibrosis. Boyle, MP; Brass-Ernst, L; Diener-West, M; Lee, CKK; Noschese, M; Zeitlin, PL, 2007) | 1.33 |
| " and the possible emergence of resistant bacterial strains in a ten rats group receiving levofloxacin at the dosage of 10mg/kg one a day for 5 consecutive days." | ( [Changes in intestinal microflora following levofloxacin administration in laboratory animals]. Ciarcia, R; Esposito, S; Ianniello, F; Leone, S; Lucisano, A; Noviello, S, 2005) | 0.81 |
| "A rapid and sensitive reverse phase high performance liquid chromatographic (RP-HPLC) method for the analysis of levofloxacin from bulk materials, dosage formulations and human serum is described." | ( Optimization of levofloxacin analysis by RP-HPLC using multivariate calibration technique. Arayne, MS; Siddiqui, FA; Sultana, N, 2007) | 0.88 |
| " The purpose of this paper is to review the concepts pertinent to drug removal by hemodialysis and discuss the issues related to these new dialysis techniques and how they may have a impact on drug removal and the design of dosing regimens." | ( Drug dosing considerations in alternative hemodialysis. Decker, BS; Mueller, BA; Sowinski, KM, 2007) | 0.34 |
| " pylori treatment: effectiveness (>80%), simplicity (twice-daily dosing and excellent compliance) and safety (low incidence of adverse effects)." | ( First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Fernández-Bermejo, M; Gisbert, JP; González-García, G; Mateos-Rodríguez, JM; Molina-Infante, J; Pérez-Gallardo, B; Prieto-Bermejo, AB; Robledo-Andrés, P, 2007) | 0.62 |
| "To identify the optimal dosage of levofloxacin to eradicate persistent Helicobacter pylori when triple therapy with amoxicillin, clarithromycin, and omeprazole fails." | ( Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB, 2007) | 1.23 |
| " According to these findings, anuric critically ill patients who are undergoing EDD should be treated with the standard dosage of moxifloxacin (400 mg/d intravenously)." | ( Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S, 2006) | 0.6 |
| " Included studies also had to meet 3 minimum criteria: evaluation of clinically relevant dosing regimens, use of rigorous study methods, and provision of mean (SD) values for the pharmacokinetic parameters of interest." | ( Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Burgess, DS; Hall, RG, 2007) | 0.59 |
| " Improper dosage adjustment based on renal function was not associated with higher rates of hypoglycemia and hyperglycemia for either drug." | ( Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. Graves, J; Lodise, T; Lomaestro, B; Miller, C; Mohr, JF; Smith, RP, 2007) | 0.63 |
| " For eradication, European, Canadian, and American guidelines recommend a regimen consisting of a proton pump inhibitor, clarithromycin, and metronidazole or amoxicillin dosed twice daily for at least 7 days." | ( An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure. Cantu, M; Ferguson, D; Page, RL, 2008) | 0.35 |
| " no change in warfarin dosing in 40 chronically anticoagulated patients initiating trimethoprim-sulfamethoxazole (TMP-SMX) or levofloxacin." | ( Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. Ahmed, A; Fay, WP; Kaus, CA; Stephens, JC, 2008) | 0.76 |
| " An expectant strategy consisting of no change in warfarin dosing with short-term INR follow-up appears reasonable in patients treated with levofloxacin." | ( Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. Ahmed, A; Fay, WP; Kaus, CA; Stephens, JC, 2008) | 0.76 |
| "Information about the elimination and the adequate dosing of levofloxacin during renal replacement therapy is scarce." | ( Clearance of levofloxacin by an in vitro model of continuous venovenous hemodialysis (CVVHD). Drewelow, B; Mueller, SC; Siewert, S, 2007) | 0.92 |
| " Based on the pharmacokinetic parameters, an appropriate intravenous dosage regimen for levofloxacin would be 5 mg/kg repeated at 24 h intervals when prescribed with paracetamol in calves." | ( Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves. Dumka, VK, 2007) | 0.82 |
| "A simple, rapid, and accurate high-performance thin-layer chromatography (HPTLC) method is described for the simultaneous determination of levofloxacin hemihydrate and ornidazole in tablet dosage form." | ( Validated HPTLC method for simultaneous estimation of levofloxacin hemihydrate and ornidazole in pharmaceutical dosage form. Bari, SB; Chepurwar, SB; Fursule, RA; Shirkhedkar, AA; Surana, SJ, 2007) | 0.79 |
| " Multivariate analysis demonstrated that lack of downward dosage adjustment based on creatinine clearance (odds ratio [OR] 10." | ( Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE, 2008) | 0.57 |
| " Lack of downward fluoroquinolone dosage adjustment for renal function, presence of diabetes, and treatment with insulin or sulfonylureas each independently increased the risk of dysglycemia." | ( Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. LaPlante, KL; Mersfelder, TL; Quilliam, BJ; Ward, KE, 2008) | 0.57 |
| " In patients with these risk factors, especially among people with a combination of said risk factors - which is frequently the case with nephrologic and dialysis patients, especially -, fluoroquinolones should be administered only after critical evaluation and with a dosage that is adapted to renal function." | ( [Fluoroquinolone-induced Achilles tendon rupture]. Maurin, N, 2008) | 0.35 |
| " To prevent the emerging of resistance resulting from its abuse, an optimal method and dosage are needed." | ( Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008) | 0.63 |
| " is predicted to be the most effective dosage and method." | ( Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008) | 0.63 |
| " Our findings suggest the re-evaluation of clinical dosing schemas of antibiotic therapy in a variety of diseases associated with atelectasis formation." | ( The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Hutschala, D; Kinstner, C; Mayer-Helm, BX; Müller, M; Skhirtladze, K; Tschernko, E; Wisser, W; Zeitlinger, M, 2008) | 0.35 |
| " A hollow-fiber infection model (HFIM) simulating various clinical (fluctuating concentrations over time) dosing exposures was used to selectively validate our quantitative assessment of the combined killing effect." | ( Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Chang, KT; Hou, JG; Kwa, AL; Ledesma, KR; Lim, TP; Nikolaou, M; Prince, RA; Quinn, JP; Tam, VH, 2008) | 0.35 |
| "Being a sustained release dosage form, pellets allow ofloxacin to exhibit improved release and absorption profiles." | ( In vitro and in vivo evaluation of ofloxacin sustained release pellets. Cui, Y; Tang, X; Zhang, Y, 2008) | 0.87 |
| " The efficacy of the rifampin-levofloxacin combination is not significantly improved by the dosage of levofloxacin." | ( Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Ariza, J; Cabellos, C; Cabo, J; Euba, G; Gudiol, F; Murillo, O; Pachón, ME; Tubau, F; Verdaguer, R, 2008) | 0.87 |
| " Azithromycin use was associated with more nausea in the 30 min after dosing (azithromycin group, 8% of patients; levofloxacin group, 1% of patients; Pp." | ( Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) | 0.8 |
| " Although nausea after dosing is uncommon, it is more frequently associated with azithromycin than with levofloxacin." | ( Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) | 0.81 |
| " The methods developed were applied successfully to the determination of the subject drugs in their pharmaceutical dosage forms with good precision and accuracy compared to official and reported methods as revealed by t- and F-tests." | ( Study of fluorescence characteristics of the charge-transfer reaction of quinolone agents with bromanil. Chen, XF; Li, WY; Xuan, CS, 2009) | 0.35 |
| "The manuscript describes validated reversed-phase column high-performance liquid chromatographic (RP-HPLC) and first-derivative UV spectrophotometric methods for the estimation of levofloxacin (LFX) and ornidazole (ORNI) in combined dosage forms." | ( Development and validation of column high-performance liquid chromatographic and derivative spectrophotometric methods for determination of levofloxacin and ornidazole in combined dosage forms. Patel, NJ; Patel, PU; Patel, SA; Prajapati, AM; Vaghmasi, JB, ) | 0.52 |
| "This is the first study to measure AH levels of levofloxacin after postoperative pulsed dosing in humans." | ( Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. Gardner, S; Geldsetzer, K; Lokkila, J; Ropo, A; Seal, D; Stenevi, U; Sundelin, K, 2009) | 0.85 |
| " Therapy was initiated at 2 h postinoculation with 5-640 mg/kg per d fractionated for different dosing regimens." | ( Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. Xiao, XM; Xiao, YH, 2008) | 0.61 |
| " However, dosage and length of levofloxacin-based regimens have not been established." | ( Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Di Caro, S; Franceschi, F; Gasbarrini, A; La Rocca, E; Mariani, A; Masci, E; Raimondo, D; Testoni, A; Thompson, F, 2009) | 0.98 |
| " Dosage of levofloxacin did not affect the eradication rates (77." | ( Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Di Caro, S; Franceschi, F; Gasbarrini, A; La Rocca, E; Mariani, A; Masci, E; Raimondo, D; Testoni, A; Thompson, F, 2009) | 1.07 |
| "1% dosing approach the calculated value was 116 microg/cm2." | ( Cleaning validation of ofloxacin on pharmaceutical manufacturing equipment and validation of desired HPLC method. Ali, SS; Arayne, MS; Sajid, SS; Sultana, N, ) | 0.44 |
| "Emerging evidence suggests that current fluoroquinolone dosing strategies may be inadequate to treat bloodstream infections caused by organisms classified as sensitive." | ( Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Defife, R; Feinglass, JM; Postelnick, MJ; Scarsi, KK; Scheetz, MH, 2009) | 0.55 |
| "5% eyedrops with the classic, more frequent dosing in patients with bacterial conjunctivitis." | ( Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Kaminska, A; Szaflik, J; Szaflik, JP, ) | 0.39 |
| "5% levofloxacin eyedrops three times daily to each eye for 5 days (experimental dosage group), or every 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to four times per day) (classic dosage group)." | ( Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Kaminska, A; Szaflik, J; Szaflik, JP, ) | 0.87 |
| "3% in classic dosage group, p=0." | ( Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Kaminska, A; Szaflik, J; Szaflik, JP, ) | 0.39 |
| " Subsequent studies should be performed to evaluate antibiotic resistance, doses, dosing intervals, duration of treatment, and safety of these two regimes." | ( Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Coelho, L; Moretzsohn, L; Sanches, B; Vieira, G, 2008) | 0.35 |
| " Concentrations of all agents are predicted to exceed the MPC for ATCC 49226 for the entire dosage interval, while concentrations of moxifloxacin alone will exceed the MPC for m-49226." | ( Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. Allen, GP; Hankins, CD, 2009) | 0.35 |
| " The proposed method has been applied for the analysis of ofloxacin and ornidazole both individually and in a combined dosage tablet formulation." | ( Simultaneous determination of ofloxacin and ornidazole in pharmaceutical preparations by capillary zone electrophoresis. Aboul-Enein, HY; Ali, AS; Elbashir, AA; Saad, B; See, KL, 2009) | 0.89 |
| " In case of macrolides higher dosage is indicated, because there is a risk of clinical failure at lower doses." | ( [Voice on the treatment of ureaplasmas infections]. Biernat-Sudolska, M; Drzewiecki, A; Rojek-Zakrzewska, D, 2009) | 0.35 |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | ( Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) | 0.63 |
| "The objective of current study was to develop a validated specific stability indicating reversed-phase liquid chromatographic method for the quantitative determination of levofloxacin as well as its related substances determination in bulk samples, pharmaceutical dosage forms in the presence of degradation products and its process related impurities." | ( A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant. Chandrasekhar, KB; Lalitha Devi, M, 2009) | 0.79 |
| "The efficacy of drug candidates is frequently limited by their inability to reach the target site of action, especially when they are administered through conventional dosage forms or drug delivery systems." | ( Ofloxacin targeting to lungs by way of microspheres. Harsha, S; R, C; Rani, S, 2009) | 1.8 |
| " The results indicate that LVFX dosage adjustment should be individualized on the basis of the CL(cr), especially in those with CL(cr) less than 50 ml/min." | ( Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY, 2009) | 0.62 |
| " This study concluded that the dosage regimen of LVFX 500 mg once daily was effective and tolerable for the treatment of LRTIs and UTIs." | ( Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. Chen, BY; Ding, GH; Duan, J; Gu, JM; Guo, DY; Hao, QL; Huang, HH; Huang, JA; Li, HY; Li, QH; Liu, A; Lü, XJ; Ma, H; Ren, ZY; Shen, HH; Shi, MH; Si, B; Sun, SH; Sun, TY; Wu, GM; Xia, QM; Xiao, W; Xiao, ZK; Xiu, QY; Yang, HF; Yang, HP; Yao, WZ; Ying, KJ; Yu, YS; Yue, HM; Zhang, W; Zhang, YY; Zheng, HG, 2009) | 0.64 |
| " Different dosing regimens were simulated to match adult exposure (area under the concentration-time curve from 0 to 24 h at steady state, maximum concentration of drug in serum at steady state, and minimum concentration of drug in serum at steady state) following the approved adult dose of 500 mg once a day." | ( Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) | 0.62 |
| " These results, including in vitro antibacterial activity against clinical isolates and therapeutic efficacy of a humanized dosing regimen, provide good evidence to support the use of LVFX at 500 mg once a day for treating patient with legionnaires disease." | ( [Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice]. Fujikawa, K; Karibe, Y; Kashimoto, Y; Kurosaka, Y; Namba, K; Otani, T; Uoyama, S; Yamaguchi, K, 2009) | 0.65 |
| " Subjects were dosed every 2 hours while awake and 4 and 6 hours after retiring (Days 1-3) and four times daily while awake (Days 4-14)." | ( Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers. Holdbrook, M; Krebs, W; Rinehart, M; Walters, T, 2010) | 0.64 |
| "3% ophthalmic solution after topical dosing in human eyes." | ( [Human aqueous humor levels of levofloxacin 0.5%, gatifloxacin 0.3% and levofloxacin 0.3% ophthalmic solution after topical dosing]. Chen, WJ; Huang, XD; Yao, K; Yuan, JQ; Zhang, Z, 2009) | 0.63 |
| " Subsequently, a neutropenic murine pneumonia model with simulated clinical dosing exposures was used to validate our quantitative assessment of combined killing." | ( Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. Hou, J; Ledesma, KR; Prince, RA; Singh, R; Tam, VH; Yuan, Z, 2010) | 0.36 |
| " The proposed procedure was applied successfully for the detection of the investigated drugs in their pharmaceutical dosage forms, in spiked plasma, spiked urine, and urine samples, with good precision and accuracy." | ( Determination of ofloxacin and gatifloxacin by mixed micelle-mediated cloud point extraction-fluorimetry combined methodology. Du, LM; Wu, H; Zhao, GY, 2010) | 0.7 |
| "0 hours after the dosing of ofloxacin tablets to 24 rabbits and analyzed by high performance liquid chromatography." | ( The effect of binders on the bioavailability of ofloxacin tablets in animal model. Ahmad, M; Akhtar, N; Khan, HM; Murtaza, G; Rasool, F, ) | 0.68 |
| " A biphasic extended release profile at an appropriate dose can inhibit the biofilm growth for four days, therefore reducing the dosing frequency." | ( Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Chang, MW; Cheow, WS; Hadinoto, K, 2010) | 0.63 |
| " In particular, the deeper knowledge of kinetic-dynamic characteristics has allowed to highlight that high dosage approach in short term therapy might reveal as extremely interesting in a setting of critical patients." | ( [PK/PD profile and post-marketing surveillance of levofloxacin]. Pea, F, 2009) | 0.6 |
| "A questionnaire regarding what antitubercular drugs, their dosage and for how long was asked to attending faculty in an International Conference on musculoskeletal infections." | ( A survey of prescribing pattern for osteoarticular tuberculosis: orthopaedic surgeons' and infectious disease experts' perspective. Agarwal, A; Arora, A; Kumar, S, 2009) | 0.35 |
| " To overcome these problems of conventional dosage form, novel drug delivery systems are explored like nanoparticles." | ( Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. Ali, A; Aqil, M; Bhatnagar, A; Gupta, H; Khar, RK; Mittal, G, 2011) | 0.71 |
| " In the CCB, the pharmacokinetics of different ofloxacin dosing regimens were simulated." | ( Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections. Elkhatib, WF; Noreddin, AM, 2009) | 0.87 |
| " aeruginosa biofilm and the shedding planktonic cells in response to different ofloxacin dosing regimens were not parallel and this may explain the non-coincidence of microbiological and clinical outcomes with biofilm associated infections." | ( Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections. Elkhatib, WF; Noreddin, AM, 2009) | 0.84 |
| " The single method thus developed is applied for the quantification of levofloxacin both in aqueous humour as well as pharmaceutical dosage forms (i." | ( A single reversed-phase UPLC method for quantification of levofloxacin in aqueous humour and pharmaceutical dosage forms. Ali, A; Aqil, M; Chander, P; Gupta, H; Khar, RK, 2010) | 0.83 |
| " Aerosol administration of levofloxacin as in the form of the investigational formulation MP-376 results in higher concentrations in lung tissues that are higher than those that can be attained with oral or intravenous dosing of levofloxacin." | ( Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. Dudley, MN; Griffith, DC; Lomovskaya, O; Sabet, M; Tarazi, Z; Tsivkovskii, R, 2011) | 1.28 |
| " This trial is based on the hypothesis that current anti-mycobacterial treatment schedules for TBM are not potent enough and that outcomes will be improved by increasing the CSF penetrating power of this regimen by optimising dosage and using additional drugs with better CSF penetration." | ( Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Bang, ND; Caws, M; Chau, TT; Day, J; Dung, NH; Farrar, J; Heemskerk, D; Merson, L; Olliaro, P; Pouplin, T; Wolbers, M; Yen, NT, 2011) | 0.62 |
| " Accumulating elimination rate of antofloxaxin from urine within 120 hours after the last dosing was 60." | ( Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers. Kang, ZS; Li, TY; Liu, Y; Lü, Y; Xiao, YH; Zhang, M; Zhu, Y, 2011) | 0.6 |
| "Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing levofloxacin as the only active pharmaceutical ingredient (API) are reviewed." | ( Biowaiver monographs for immediate release solid oral dosage forms: levofloxacin. Barends, DM; Cristofoletti, R; Dressman, JB; Fernandes, EF; Junginger, HE; Koeppe, MO; Kopp, S; Midha, KK; Shah, VP; Stavchansky, S; Storpirtis, S, 2011) | 0.79 |
| " We had previously developed a mathematical modelling framework to describe the dynamics of bacterial populations under the effect of antimicrobials, which could facilitate the design of optimal dosing regimens." | ( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011) | 0.37 |
| " Based on the best-fit model parameters, the likelihood of resistance development associated with various dosing regimens was predicted." | ( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011) | 0.37 |
| "Bacterial regrowth and resistance development were observed with suboptimal dosing regimens." | ( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011) | 0.37 |
| "Our model was found to be reasonable in characterizing biphasic killing of fluoroquinolones and predicting dosing regimens to suppress resistance development." | ( Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH, 2011) | 0.37 |
| " C3H/HeOuJ mice were dosed by oral gavage with diclofenac (DF), APAP, AMAP, OFLX, MET, or CMZ." | ( Oral exposure to drugs with immune-adjuvant potential induces hypersensitivity responses to the reporter antigen TNP-OVA. Bleumink, R; Boon, L; Fiechter, D; Hassing, I; Kwast, LM; Ludwig, IS; Pieters, RH, 2011) | 0.37 |
| "The purpose of the study was to evaluate pharmacokinetic characteristics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, during a multiple, intravenous dosing regimen." | ( Pharmacokinetics of antofloxacin hydrochloride in healthy male subjects after multiple intravenous dose administration. Kang, Z; Li, T; Liang, J; Liu, Y; Lu, Y; Wang, J; Xiao, Y; Zhang, M, 2011) | 0.91 |
| " This was despite a longer duration of treatment at a higher dosage in patients infected with isolates with an MIC≥0." | ( The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. Baker, S; Campbell, JI; Chinh, NT; Farrar, JJ; Hien, TT; Parry, CM; Vinh, H; Wain, J, 2011) | 0.58 |
| "Being controlled release dosage forms, tablets allow an improved absorption and release profiles of Ofloxacin." | ( Formulation and in vitro evaluation of ofloxacin-ethocel controlled release matrix tablets prepared by wet granulation method: influence of co-excipients on drug release rates. Ahmad, K; Hussain, A; Jan, SU; Khan, GM; Rehman, A; Shah, K; Shah, S, 2011) | 0.85 |
| " An in vitro infection model was used to simulate free pulmonary fluctuating concentrations expected after multiple dosing regimens of both drugs in humans or constant multiples of the minimum inhibitory concentration." | ( Pharmacokinetic/pharmacodynamic modelling of the bactericidal activity of free lung concentrations of levofloxacin and gatifloxacin against Streptococcus pneumoniae. Dalla Costa, T; de Andrade, C; Tasso, L, 2011) | 0.58 |
| " Due to the high antibiotic dosage requirement in anti-biofilm therapy, the most suitable formulation for this purpose is the antibiotic nanoparticles themselves, instead of the more extensively studied antibiotic-loaded nano-carriers, which often exhibit low drug loading." | ( Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate. Cheow, WS; Hadinoto, K, 2012) | 0.38 |
| " Using a similar dosing selection pressure, the emergence of levofloxacin resistance was delayed in a strain with acrAB deleted compared to the isogenic parent." | ( Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Hu, M; Ledesma, KR; Singh, R; Swick, MC; Tam, VH; Yang, Z; Zechiedrich, L, 2012) | 0.62 |
| "The series is part of an ongoing randomised controlled trial assessing rechallenge dosing following TB-associated cutaneous ADR." | ( Multiple drug hypersensitivity reactions to anti-tuberculosis drugs: five cases in HIV-infected patients. Dheda, K; Lehloenya, RJ; Todd, G; Wallace, J, 2012) | 0.38 |
| "We performed plasma dosage for each antibiotic in patients with a bone and joint infection requiring treatment with a levofloxacin and rifampicin combination." | ( Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. Bensalem, M; Bland, S; Bru, JP; Gaillat, J; Garraffo, R; Guillaume, M; Janssen, C, 2012) | 0.85 |
| " Just after dosing of OFLX, hindlimb unloading was performed for 0, 2, 4, or 8 h by a tail-suspension method." | ( Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats. Goto, K; Goto, M; Imaoka, M; Jindo, T; Kikuchi, I; Suzuki, T; Takasaki, W, 2013) | 0.39 |
| "Levofloxacin dosing regimens with low AUC/MIC ratios select for efflux pump overexpression, leading to fluoroquinolone resistance." | ( Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. Bowker, KE; Garvey, MI; Macgowan, AP; Noel, AR; Tomaselli, SG, 2013) | 1.26 |
| " Patients were administered LVFX 500mg, orally, once a day and the dosage period was seven days." | ( [Efficacy and safety of levofloxacin to non-gonorrheal urethritis]. Hosobe, T; Kato, T; Onodera, S; Onoe, Y; Yoshida, M, 2012) | 0.68 |
| " Moreover, in this study, smart control over the pH conditions of the oxidation system via different modes of Oxone dosage resulted in the selective degradation of the functional sites of OFX molecule, where it was shown that the SO4 (-•)-driven destruction of the quinolone moiety of OFX molecule favored the neutral pH conditions." | ( Oxidation of ofloxacin by Oxone/Co(2+): identification of reaction products and pathways. Feng, J; Pi, Y; Song, M; Sun, J, 2014) | 0.77 |
| " The designed ofloxacin niosomes with span 60 showed good physicochemical properties, good stability, improved pharmacokinetic parameters, prolonged action and improved bioavailability than the commercially available conventional dosage form which might be a potential carrier system to improve the patient compliance and reduce the side effects." | ( Design and characterization of ofloxacin niosomes. Balasundaram, J; Dhandayuthapani, B; Natesan, G; Natesan, S; Perumal, P; Ramalingam, N, 2013) | 1.04 |
| " (99m)Tc-Ofloxacin served as a good tracer for studying the pharmacokinetics of three controlled release mucoadhesive dosage forms by gamma scintigraphy studies." | ( Preparation and evaluation of three mucoadhesive dosage forms using (99m)Tc-Ofloxacin. Chakraborti, CK; Mukherjee, A; Sahoo, S; Samuel, G; Sarma, HD, 2014) | 1.05 |
| "To prolong the residence time of dosage forms within gastrointestinal trace until all drug released at desired rate was one of the real challenges for oral controlled-release drug delivery system." | ( Floating tablets for controlled release of ofloxacin via compression coating of hydroxypropyl cellulose combined with effervescent agent. Chen, H; Ma, N; Qi, X; Rui, Y; Wu, Z; Yang, F, 2015) | 0.68 |
| " It is not known whether the current internationally recommended pediatric dosage of 15 to 20 mg/kg of body weight achieves exposures reached in adults with tuberculosis after a standard 800-mg dose (adult median area under the concentration-time curve from 0 to 24 h [AUC0-24], 103 μg · h/ml)." | ( Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Castel, S; Dooley, KE; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Seddon, JA; Thee, S; Wiesner, L, 2015) | 0.7 |
| "Two sensitive, accurate, and precise spectrophotometric methods have been developed and validated for the simultaneous estimation of ofloxacin (OFX), clotrimazole (CLZ), and lignocaine hydrochloride (LGN) in their combined dosage form (ear drops) without prior separation." | ( Simultaneous Estimation of Ofloxacin, Clotrimazole, and Lignocaine Hydrochloride in Their Combined Ear-Drop Formulation by Two Spectrophotometric Methods. Bodiwala, K; Kalyankar, G; Marolia, B; Patel, Y; Prajapati, P; Shah, S, 2017) | 0.96 |
| " The aim of our study was to establish the kinetics of dissolution rate process of ofloxacin optical isomers (S-(-) and R-(+)-ofloxacin) from solid oral dosage forms using flow-through cell method (USP 4 method)." | ( STUDY OF OFLOXACIN ENANTIOMERS DISSOLUTION FROM SELECTED SOLID DOSAGE FORMS USING HIGH PERFORMANCE CAPILLARY ELECTROPHORESIS METHOD. Kokot, ZJ; Lulek, J; Milanowski, B; Urbaniak, B, 2017) | 1.1 |
| "The effect of AT on QT interval prolongation may not have been significant at the dosage of 400 mg." | ( Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate. He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS, 2020) | 0.87 |
| "Bacterial regrowth was observed under exposure to clinically relevant dosing regimens in the dynamic in vitro infection model." | ( Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. Kloft, C; Michelet, R; Seeger, J, 2021) | 0.62 |
| " The mimicked dosing regimens did not eradicate the resistant isolates and enhanced persister formation to a strain-specific extent." | ( Quantification of persister formation of Escherichia coli leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. Kloft, C; Michelet, R; Seeger, J, 2021) | 0.62 |
| " Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens." | ( Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study. Arvieux, C; Bellissant, E; Comets, E; Fily, F; Foulquier, JB; Huten, D; Jullien, V; Laviolle, B; Lemaitre, F; Petitcollin, A; Polard, JL; Revest, M; Tattevin, P; Tron, C; Verdier, MC, 2021) | 0.62 |
| " The fast capillary action of the porous structure enabled controllable loading and sustained release of ofloxacin and bovine albumin at a high loading dosage of 79." | ( Fabrication of "Spongy Skin" on Diversified Materials Based on Surface Swelling Non-Solvent-Induced Phase Separation. Fang, Y; Huang, WP; Ji, J; Qian, HL; Ren, KF; Wang, J; Xu, ZK; Yu, WJ; Zou, LY, 2021) | 0.84 |
| " The optimal removal for ozone dosing range was nitrate (9." | ( Efficient removal of ibuprofen and ofloxacin pharmaceuticals using biofilm reactors for hospital wastewater treatment. Ahmed, S; Alam, SS; Ali, I; Bokhari, A; Farooqi, IH; Khan, AH; Khan, NA; Mubashir, M, 2022) | 1 |
| " Recently, the combination of nanomaterial-loaded antibiotics with photothermal therapy showed the efficient antibacteria ability under a low dosage of antibiotics." | ( Ofloxacin-loaded HMPB NPs for Klebsiella pneumoniae eradication in the surgical wound with the combination of PTT. Fan, J; Liu, B; Liu, T; Liu, X; Tang, D; Tong, C; Yang, X; Yang, Y; Zhong, G; Zhong, X, 2022) | 2.16 |
| " The Day-1 dosing rates for ciprofloxacin and ofloxacin should be considered separately, and the regimes suggested in published guidelines and case studies may need be re-considered in light of the findings of this review." | ( The clinical treatment of bacterial keratitis: A review of drop instillation regimes. Essex, RW; Maddess, T; Pearce, JG, 2022) | 1 |
| "Uniformity of dosage unit (UDU) test is widely used to assess the quality, safety, and effectiveness of dosage forms in unit doses." | ( Measurement uncertainty for < 905 > Uniformity of Dosage Units tests using Monte Carlo and bootstrapping methods - Uncertainties arising from sampling and analytical steps. Lourenço, FR; Martins, MT, 2024) | 1.44 |
| Class | Description |
|---|---|
| 3-oxo monocarboxylic acid | |
| N-methylpiperazine | |
| N-arylpiperazine | |
| oxazinoquinoline | Any organic heterotricyclic compound based on a skeleton comprised of an oxazine ring fused onto a quinoline system. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 112.2020 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 17.5595 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 17.5595 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 17.3955 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID2323 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 29.7506 | 0.1000 | 20.8793 | 79.4328 | AID488772; AID588453; AID588456 |
| TDP1 protein | Homo sapiens (human) | Potency | 19.7611 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.5648 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 20.9310 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253 |
| arylsulfatase A | Homo sapiens (human) | Potency | 4.2562 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 32.5733 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 14.1406 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 32.6427 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 79.4328 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 37.6858 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 566.5000 | 0.1100 | 7.1903 | 10.0000 | AID1449628; AID1473738 |
| DNA gyrase subunit A | Escherichia coli K-12 | IC50 (µMol) | 1.5000 | 0.0239 | 0.5629 | 5.2300 | AID530379 |
| DNA gyrase subunit B | Escherichia coli K-12 | IC50 (µMol) | 1.5000 | 0.0050 | 0.4398 | 5.2300 | AID530379 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5057 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.4973 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.4988 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5046 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5065 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5057 | 10.0000 | AID71980; AID71981 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 28.0000 | 0.0150 | 2.4676 | 10.0000 | AID530368 |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 28.0000 | 0.0150 | 3.4773 | 10.0000 | AID530368 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 1,414.0320 | 0.0009 | 1.9014 | 10.0000 | AID161281; AID243151; AID408340; AID576612; AID755684 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | IC50 (µMol) | 55.5000 | 0.0001 | 0.5075 | 10.0000 | AID71980; AID71981 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 3.6940 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| Albumin | Homo sapiens (human) | Kd | 12.0000 | 0.0893 | 3.3135 | 8.0000 | AID557095 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| STE24 | Saccharomyces cerevisiae (brewer's yeast) | AC50 | 1.9500 | 1.9500 | 6.6870 | 11.8600 | AID488815 |
| CAAX prenyl protease | Saccharomyces cerevisiae S288C | AC50 | 100.0000 | 1.0790 | 17.9906 | 68.9400 | AID488788 |
| Trypsin | Sus scrofa (pig) | AC50 | 9.2640 | 3.3400 | 16.7050 | 77.2200 | AID488789 |
| DNA gyrase subunit A | Escherichia coli K-12 | CC25 | 0.2000 | 0.2000 | 0.3500 | 0.5000 | AID530391 |
| DNA gyrase subunit B | Escherichia coli K-12 | CC25 | 0.2000 | 0.2000 | 0.3500 | 0.5000 | AID530391 |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | CC25 | 7.0000 | 2.0000 | 4.5000 | 7.0000 | AID530380 |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | CC25 | 7.0000 | 2.0000 | 4.5000 | 7.0000 | AID530380 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID447218 | Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID562930 | Antimicrobial activity against Clostridium difficile CD07-259 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID209087 | Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-2 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID127505 | In vitro antibacterial activity against glucose nonfermenter Moraxella bovis P-7101 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID391988 | Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23::qnr-cat promoter mutant by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1163980 | Antimycobacterial activity against isoniazid, rifampicin, ofloxacin and kanamycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 clinical isolate after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. |
| AID1230207 | Antibacterial activity against Bacillus cereus N258 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID530388 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID562782 | Antimicrobial activity against Chlamydia trachomatis L2/oflR harboring ompA gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID70428 | Compound was tested for antibacterial activity against gram negative Escherichia coli ML4707 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID510156 | Antimicrobial activity against Staphylococcus aureus ATCC 35218 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID1368746 | Antibacterial activity against Escherichia coli MTCC 443 at 1 ug/ml under overnight incubation condition by paper disc method | 2018 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2 | Synthesis and biological evaluation of 1-amino isochromans from 2-bromoethyl benzaldehyde and amines in acid medium. |
| AID200881 | Tested in vitro against Salmonella Typhimurium IID971 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID563502 | Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID371460 | Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID64885 | Tested for inhibitory activity against DNA gyrase supercoiling in Escherichia coli (KL-16) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID524824 | Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID1230227 | Antibacterial activity against Enterococcus gallinarum N489 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID572525 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2017 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID531337 | Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID678717 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID371464 | Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID1193922 | Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method | 2015 | Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7 | Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. |
| AID428985 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 104 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID733008 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID128018 | Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID395361 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID532981 | Antibacterial activity against Escherichia coli DH5alpha | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID1331878 | Antibacterial activity against Salmonella enterica ATCC 14028 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID206437 | In vitro antibacterial activity against clinical isolates of Staphylococcus aureus 18773 (gram-positive) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID1695812 | Antibacterial activity against Escherichia coli assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. |
| AID1324013 | Permeability of the compound at 100 ug/ml after 16 hrs by PAMPA-BBB method | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease. |
| AID293582 | Antibacterial activity against Klebsiella pneumoniae isolate assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID1274482 | Antibacterial activity against Escherichia coli JM 109 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID287371 | Antibacterial activity against Escherichia coli after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID203039 | Minimum inhibitory concentration required in vitro against Shigella | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID207258 | Tested in vitro for antibacterial activity against Staphylococcus aureus (FDA 209P JC-1) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1743440 | Antibacterial activity against Mycobacterium smegmatis measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID520423 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU18 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID1516026 | Antibacterial activity against Acinetobacter baumannii AB1901 clinical isolate incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID572516 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2944 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID530424 | Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID164395 | Antimicrobial activity against the Pseudomonas aeruginosa K 799/61 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID322314 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1224525 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID498787 | Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID352091 | Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID530384 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID540227 | Volume of distribution at steady state in monkey after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID163228 | Compound was tested for antibacterial activity against gram negative Proteus vulgaris No.33 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID1662846 | Antibacterial activity against Staphylococcus aureus ATCC 209p | 2020 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13 | Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action. |
| AID1823665 | Apparent permeability across basolateral to apical side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10 | Discovery of New Imidazo[2,1- |
| AID316447 | Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID530383 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID70860 | Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 2646 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID429013 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT60 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID562927 | Antimicrobial activity against Clostridium difficile ATCC 43603-M1 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID164709 | Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-18 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1653574 | Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.375 ug/ml in presence of 0.05 ug/ml rifabutin measured at 4 weeks | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID562797 | Antimicrobial activity against Chlamydia trachomatis L2/tetR1 harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1577333 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 9449/2007 after 21 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID572511 | Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate s2878 harboring wild type ParC gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID562928 | Antimicrobial activity against Clostridium difficile ATCC 43603 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID550048 | Antibacterial activity against Escherichia coli assessed as inhibition of visible growth after 48 hrs by agar dilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds. |
| AID1167608 | Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis XDR-TB after 28 days by two-fold agar dilution method | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA. |
| AID563228 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1274479 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID1331879 | Antimycobacterial activity against Mycobacterium smegmatis MC2 155 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID581497 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D500N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID530409 | Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1230214 | Antibacterial activity against Enterococcus durans CIP 104999 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1485937 | Permeability of the compound in PBS/EtOH after 16 hrs by PAMPA-BBB assay | 2017 | Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14 | Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease. |
| AID1570739 | Antimicrobial activity against Listeria monocytogenes clinical isolate at 5 ug/disk incubated for 20 +/- 4 hrs by agar disk diffusion method | 2019 | Bioorganic & medicinal chemistry, 11-01, Volume: 27, Issue:21 | Synthesis and evaluation of 1,3,4-oxadiazole derivatives for development as broad-spectrum antibiotics. |
| AID524790 | Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10 | Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID1907629 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC2858 incubated for 18 to 20 hrs by double dilution method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA. |
| AID476929 | Human intestinal absorption in po dosed human | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Neural computational prediction of oral drug absorption based on CODES 2D descriptors. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1331872 | Antibacterial activity against vancomycin-resistant Enterococcus | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID144565 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID530245 | Antimicrobial activity against apaH deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. |
| AID352095 | Antimicrobial activity against ceftriazone-resistant Bacillus subtilis after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID679031 | TP_TRANSPORTER: inhibition of DNP-SG uptakee (DNP-SG: 1 uM, OFLX: 10000 uM) in bile canalicular membrane vesicles from SD rat | 1998 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3 | Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. |
| AID203167 | Tested in vitro against Serratia marcescens IAM1184 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID520871 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU57 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID9222 | Activity against Acinetobacter calcoaceticus (AC54) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID1377751 | Effective permeability of the compound after 2.5 hrs at 25 degC by PAMPA assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. |
| AID371462 | Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID1743467 | Inhibition of DNA gyrase in Escherichia coli ATCC 25922 assessed as elongation of bacterial cells at 2 ug/ml measured after 1.5 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID694231 | Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition by BACTEC method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22 | The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives. |
| AID1138550 | In vivo antibacterial activity against Staphylococcus aureus in New zealand rabbit keratitis model assessed as suppression of conjuctival congestion, conjuctival chemosis, infiltration, operative ulcer area and depth at 3 mg/ml administered topically ever | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I. |
| AID1653556 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.0062 ug/ml KRM-1648 measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID445446 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID385166 | Antimicrobial activity against Enterococcus faecalis by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID532988 | Antibacterial activity against Klebsiella aerogenes NCIM 2281 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID532987 | Antibacterial activity against Pseudomonas aeruginosa NCIM 5029 in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID1412154 | Bactericidal activity against methicillin-resistant Staphylococcus aureus 15 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID322316 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID95540 | Tested in vitro for antibacterial activity against Klebsiella pneumoniae (B54) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID535837 | Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID562783 | Antimicrobial activity against Chlamydia suis S45/rifR harboring rpoB gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1435653 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 7357/1998 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID69782 | Antibacterial activity against Escherichia coli (H560) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID429017 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG7 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID424879 | Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID429022 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG152 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID67531 | Inhibition of growth of Entero. cloacae | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID557096 | Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID209225 | In vitro antibacterial activity against Streptococcus faecalis 2473 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID1516028 | Antibacterial activity against Pseudomonas aeruginosa 25349 clinical isolate incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID206368 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus faecalis MGH-2 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID581502 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94A mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID542140 | Antimicrobial activity against Salmonella enterica HN-GSS2007-0.033 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID1378880 | Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease. |
| AID542146 | Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrS1 gene by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID1557280 | Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID559366 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID581500 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB A90V and T539P mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID203037 | Minimum bactericidal concentration required in vitro against Shigella | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID209061 | In vitro antibacterial activity against Streptococcus epidermis 8 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID581510 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and D500A mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1557279 | Antibacterial activity against Escherichia coli by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID656233 | Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID1557287 | Antibacterial activity against Enterococcus by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID563225 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1653573 | Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.75 ug/ml in presence of 0.2 ug/ml rifampin measured at 4 weeks | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID133980 | In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered subcutaneously | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID395365 | Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID205965 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus UC-76 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID352837 | Antimicrobial activity against Aspergillus fumigatus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID70947 | In vitro antibacterial activity against clinical isolates of Escherichia coli 15 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID1412149 | Antibacterial activity against Staphylococcus epidermidis ATCC 35984 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID1502712 | Antimycobacterial activity against Mycobacterium avium isolate MAV3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID574808 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID562241 | Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID279820 | Antimicrobial activity against Mycobacterium tuberculosis H3Rv on day 7 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID563031 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1301203 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis harbouring Beijing genotype with combination of mutations of Ser 53-Leu 315 and Ser-Thr in rpoB and katG genes after 10 days by micro broth dilution method | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. |
| AID1230244 | Antibacterial activity against Staphylococcus haemolyticus CIP 8156 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID530619 | Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1188153 | Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. |
| AID1743471 | Inhibition of DNA gyrase in Mycobacterium smegmatis assessed as segmentation of bacterial cells at 2 ug/ml measured after 6 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID530410 | Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID207385 | Inhibition of growth of Staphylococcus aureus (sensitive) | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID67215 | Compound was tested for antibacterial activity against gram positive Enterococcus faecalis 1373 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID559579 | Antimicrobial activity against Parachlamydia acanthamoebae infected in Acanthamoeba castellanii amoeba cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID396101 | Antibacterial activity against Pseudomonas aeruginosa OCR1 overexpressing mexAB by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID530413 | Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1463957 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 4 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID530422 | Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID559561 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID162775 | In vitro minimum inhibitory concentration against Pseudomonas aeruginosa (ATCC 27853) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID316451 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse spleen assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID530617 | Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID529671 | Antimicrobial activity against azide-resistant Escherichia coli J53 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli. |
| AID530426 | Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID206283 | In vitro antibacterial activity against Staphylococcus aureus 209P JC-1 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID562939 | Effect on fbp69 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID43924 | Compound was tested for antibacterial activity against gram negative Burkholderia cepacia 23 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID562784 | Antimicrobial activity against Chlamydia trachomatis J/6276/rifR harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID562245 | Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID562788 | Antimicrobial activity against Chlamydia muridarum MoPn/rifRoflR harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID523002 | Cytotoxicity against human 5637 cells assessed as mild induction of cell death by LDH release assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID349880 | Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. |
| AID678722 | Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID563055 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1309353 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 24 hrs by microbroth dilution method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines. |
| AID534424 | Antibacterial activity against Mycobacterium bovis BCG-Pasteur | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID557093 | Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID557094 | Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID521968 | Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID563043 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID524825 | Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID563032 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1743462 | Antitubercular activity against Mycobacterium tuberculosis XDR measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID68846 | In vitro minimum inhibitory concentration against Escherichia coli KC-14 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID406846 | Antibacterial activity against Escherichia coli TOP10 containing pS1A plasmid expressing quinolone resistance determinant QnrB4 by E-test | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1171213 | Antibacterial activity against tolC-deficient Escherichia coli | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID151536 | Tested in vitro against Pseudomonas aeruginosa IFO3445 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1152758 | Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 27294 after 16 to 18 days by BACTEC 7H12B microdilution method | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID1672289 | Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay | |||
| AID1823666 | Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10 | Discovery of New Imidazo[2,1- |
| AID563040 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1695811 | Antibacterial activity against Pseudomonas aeruginosa assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. |
| AID131700 | Effective dose against Escherichia coli KC14 strain in mouse | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID1230225 | Antibacterial activity against Enterococcus faecium N823 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID70926 | In vitro antibacterial activity against Escherichia coli P-5101 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID535838 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID530403 | Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID161281 | Inhibition of human Potassium channel HERG expressed in mammalian cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. |
| AID562242 | Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID295112 | Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID574589 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID406845 | Antibacterial activity against Escherichia coli TOP10 containing pS1B plasmid expressing quinolone resistance determinant QnrS1 by E-test | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. |
| AID498188 | Antibacterial activity against Stenotrophomonas maltophilia MBS108 containing both chromosomally and plasmid encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID572513 | Antimicrobial activity against Salmonella enterica serovar Mbandaka isolate s2159 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID293583 | Antibacterial activity against Pseudomonas aeruginosa isolate assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID1421886 | Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method | 2018 | European journal of medicinal chemistry, Oct-05, Volume: 158 | Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. |
| AID1562257 | Antimycobacterial activity against Mycobacterium smegmatis atR2 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines. |
| AID1435650 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID206643 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID408340 | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | 2008 | Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11 | Support vector machines classification of hERG liabilities based on atom types. |
| AID1174112 | Antimycobacterial activity against isoniazid, rifampin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID1478786 | Permeability of the compound at 200 uL after 16 hrs by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. |
| AID391987 | Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23 promoter by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1743457 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID433403 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID563048 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID164385 | Antibacterial activity against Pseudomonas aeruginosa (UI-18) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID1347980 | Permeability of the compound in PBS/EtOH at 100 ug/ml after 12 hrs by PAMPA-BBB assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. |
| AID530615 | Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1264447 | Permeability of the compound by PAMPA method | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. |
| AID293590 | Antibacterial activity against Bacillus subtilis ATCC 6633 assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID1230212 | Antibacterial activity against Enterococcus casseliflavus N487 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID405120 | Antimicrobial activity against Escherichia coli TOP10 harbouring p0 plasmid expressing pCR-BluntII-TOPO | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID1152777 | Antimycobacterial activity against 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID117675 | Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (sc) | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID563017 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID433400 | Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID498190 | Antibacterial activity against Stenotrophomonas maltophilia MBS82 deficient in Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID205546 | Minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 13709 | 2003 | Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10 | Antibacterial activity of quinolone-macrocycle conjugates. |
| AID1730991 | Antitubercular activity against drug susceptible Mycobacterium tuberculosis V4207 by MABA assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID563046 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563219 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425069 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID316445 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID1653575 | Antimicrobial activity against Mycobacterium leprae assessed as fractional inhibitory concentration index at 0.375 ug/ml in presence of 0.0125 ug/ml KRM-1648 measured at 4 weeks | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID542147 | Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrD gene by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID1230243 | Antibacterial activity against Staphylococcus epidermidis CIP 53124 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID396097 | Antibacterial activity against Staphylococcus aureus K1758-P by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID765109 | Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition at 2 ug/mL relative to control | 2013 | Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17 | Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides. |
| AID530616 | Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1113447 | Antibacterial activity against Proteus vulgaris assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID1174108 | Antimycobacterial activity against isoniazid, rifampin, ethambutol, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID532038 | Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfPS012 harboring PMQR determinant qnrB22 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID581509 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1653552 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.75 ug/ml in presence of 0.1 ug/ml rifampin measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID563503 | Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens. |
| AID532982 | Antibacterial activity against Escherichia coli W3110 in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID52937 | Compound was tested for antibacterial activity against gram negative Citrobacter freundii KP-29 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID94051 | Tested in vitro against Klebsiella pneumoniae PCI-602 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID295121 | Antibacterial activity against Micrococcus luteus La 2971 at 5 ug by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID425072 | Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID563027 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID450458 | Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID559358 | Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID562829 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID696005 | Permeability of the compound after 4 hrs by PAMPA assay | 2012 | European journal of medicinal chemistry, Dec, Volume: 58 | Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress. |
| AID162914 | In vitro antibacterial activity against clinical isolates of Proteus morganii 27 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID530405 | Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID352089 | Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID406844 | Antibacterial activity against Escherichia coli TOP10 by E-test | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. |
| AID559552 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1823664 | Apparent permeability across apical to basolateral side in human Caco-2 cells at 5 uM measured every 15 mins for 1 hr by LC-MS/MS analysis | 2021 | Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10 | Discovery of New Imidazo[2,1- |
| AID1113448 | Antibacterial activity against Escherichia coli assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID122923 | Minimum inhibitory concentration against gram-positive MI, Micrococcus luteus ATCC 9341. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID520873 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU69 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID450460 | Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID1167550 | Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay | 2014 | European journal of medicinal chemistry, Nov-24, Volume: 87 | Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1743461 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Asp-94-Gly/gyrB Asp-500-Asn mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1349194 | Antichlamydial activity against Chlamydia trachomatis serovar L2 infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID1502710 | Antimycobacterial activity against Mycobacterium avium isolate MAV1 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID763998 | Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 15 mm) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. |
| AID562798 | Antimicrobial activity against Chlamydia muridarum MoPn/tetR14 harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID428998 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1516020 | Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID542148 | Antimicrobial activity against Escherichia coli DH10B harboring p2007057 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID445445 | Permeability at pH 6.5 by PAMPA method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID164712 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa E-2 (Pa(E)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID532035 | Antimicrobial activity against azide-resistant Escherichia coli J53 TrcPS012 harboring PMQR determinant qnrB22 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID559364 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1705959 | Effective permeability of compound at 100 ug/ml incubated for 20 hrs by PAMPA-BBB assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID78715 | Inhibition constant against DNA Gyrase isolated from Micrococcus luteus | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID1360040 | Antimicrobial activity against Escherichia coli after 18 to 20 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID206890 | Antibacterial activity against Staphylococcus aureus UC76 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID532033 | Antimicrobial activity against Citrobacter werkmanii PS012 expressing PMQR determinant qnrB22 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID428990 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 45 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID498781 | Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID164703 | Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa PAO1 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID1662849 | Bactericidal activity against Bacillus cereus | 2020 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13 | Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action. |
| AID562931 | Antimicrobial activity against Clostridium difficile 6269 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID205651 | Compound was tested for antibacterial activity against gram positive Staphylococcus aureus JS-1 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID41268 | In vitro minimum inhibitory concentration against Bacteroides fragilis (ATCC 25285) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID395360 | Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID530406 | Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1055941 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 hrs | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain. |
| AID656231 | Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID164702 | Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa KP-254 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID535833 | Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID542141 | Antimicrobial activity against Salmonella enterica HN-GSS2007-0.056 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID279821 | Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 1 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID559578 | Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID559367 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID209279 | Antimicrobial activity against the streptococcus pyogenes EES 61 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID572147 | Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli. |
| AID324747 | Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID1171217 | Antibacterial activity against wild-type Pseudomonas aeruginosa | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1743458 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Gly-88-Cys mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1412156 | Bactericidal activity against methicillin-resistant Staphylococcus epidermidis 57 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID206174 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID1907643 | Antibiofilm activity against methicillin-resistant Staphylococcus aureus ATCC2858 assessed as minimal biofilm eradication concentration incubated for 24 hrs by crystal violet staining based assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA. |
| AID143122 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 90% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID1463956 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 1 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID70735 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Escherichia coli Vogel | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID428994 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 32 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID133813 | Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID563050 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID198343 | Tested in vitro against Staphylococcus aureus FDA209P JC-1 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID352833 | Antimicrobial activity against Rhodotorula rubra NCIM 3174 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID208131 | In vitro minimum inhibitory concentration against Streptococcus pneumoniae (ATCC 6301) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID1557295 | Cmax in human at 0.4 g, po bid | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID205596 | In vitro minimum inhibitory concentration against gram-positive Se, Staphylococcus epidermidis IAM 1296. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID665368 | Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate at 10 ug/mL by radiometric growth assay | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antimycobacterial activity of novel 1,3-dimethylisocyanurate derivatives. |
| AID481442 | Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? |
| AID498782 | Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID563012 | Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID423635 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs | 2009 | Journal of natural products, Apr, Volume: 72, Issue:4 | Terpenoids from Toona ciliata. |
| AID1331871 | Antibacterial activity against methicillin-resistant Staphylococcus aureus | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1173784 | Inhibition of Mycobacterium tuberculosis DNA gyrase using relaxed pBR322 as substrate after 30 mins by supercoiling assay | 2014 | Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23 | An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition. |
| AID581504 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID63896 | Activity against Enterobacter aerogenes (ATCC 13048) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID428993 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 51 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID316449 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse lungs assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID151670 | Minimum inhibition concentration against Pseudomonas aeruginosa U-31 strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID733007 | Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID163048 | Inhibition of growth of Proteus rettgeri | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID563338 | Induction of Cwp84 protease expression in Clostridium difficile CD196 M1 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1662848 | Antibacterial activity against Bacillus cereus | 2020 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13 | Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action. |
| AID563337 | Induction of Cwp84 protease expression in Clostridium difficile CD196 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID78688 | Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID581506 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA G88A mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID510170 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID576612 | Inhibition of human ERG | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. |
| AID1171215 | Antibacterial activity against wild-type Escherichia coli | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID427197 | Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. |
| AID352621 | Antimicrobial activity against Salmonella Typhimurium NCIM 2501 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID1274481 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID285161 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID1437026 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by agar dilution method | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis. |
| AID559359 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID151530 | Tested in vivo against Pseudomonas aeruginosa E-2 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1224521 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID530408 | Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID559564 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1193921 | Inhibition of Mycobacterium smegmatis DNA GyrB domain assessed as inhibition of inorganic phosphate release after 100 mins at room temperature by ATPase assay | 2015 | Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7 | Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. |
| AID352629 | Antimicrobial activity against Pseudomonas aeruginosa NCIM 2200 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1557286 | Antibacterial activity against Streptococcus pyogenes by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1173786 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23 | An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition. |
| AID133979 | In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered perorally | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID428900 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID131401 | Oral efficacy against Streptococcus pyogenes A65 on Systemic Infections in Mice | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID1511118 | Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. |
| AID581494 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94G mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID287379 | Antibacterial activity against Pseudomonas aeruginosa after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID28899 | Calculated partition coefficient (clogP) | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID117674 | Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (po) | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID574790 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID209067 | Antibacterial activity against Streptococcus faecalis MGH-2 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID1331876 | Antibacterial activity against Klebsiella pneumoniae ATCC 27736 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1055939 | Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 20 hrs | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID71794 | Percentage of GABA-induced chloride currents with 10e-4 M 4-biphenylacetic acid | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID209462 | In vitro antibacterial activity against Streptococcus pyogenes A65 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID164704 | In vitro minimum inhibitory concentration against gram-negative Pa(E), Pseudomonas aeruginosa E-2. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID429023 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG168 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID562945 | Upregulation of cwp84 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID165055 | In vitro antibacterial activity against clinical isolates of Pseudomonas aeruginosa 2437 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID40925 | Tested in vitro against Bacillus subtilis ATCC 6633 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID70564 | Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(K), Escherichia coli KC-14. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID563224 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID293589 | Antibacterial activity against Escherichia coli ATCC 25922 assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID574809 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID209730 | Inhibition of growth of Streptococcus pneumonia | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID1557284 | Antibacterial activity against Staphylococcus aureus by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1188156 | Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. |
| AID572523 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2052 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID1352674 | Effective permeability at 25 ug/ml after 16 hrs by PAMPA | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease. |
| AID1174110 | Antimycobacterial activity against isoniazid, rifampin, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID563332 | Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1295091 | Tuberculostatic activity against multi-drug resistant Mycobacterium tuberculosis isolates assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity. |
| AID1309354 | Antimycobacterial activity against Mycobacterium avium after 24 hrs by microbroth dilution method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines. |
| AID285684 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 with pvdS mutation after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID562800 | Antimicrobial activity against Chlamydia trachomatis F/70/rifR-tetR harboring rpoB gene and tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1743442 | Antibacterial activity against Mycobacterium marinum measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID530379 | Inhibition of Escherichia coli DNA gyrase GyrA/GyrB | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID559361 | Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID530402 | Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID429033 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT76 harboring wild type DNA gyrase A by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1230223 | Antibacterial activity against Enterococcus faecium N507 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID428995 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 33 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1193920 | Inhibition of Mycobacterium tuberculosis DNA GyrA/B heterotetramer assessed as inhibition of pBR322 supercoiling after 30 mins by gel electrophoresis | 2015 | Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7 | Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. |
| AID530421 | Antimicrobial activity against Helicobacter pylori harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID534344 | Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID71980 | Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID1188155 | Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. |
| AID532985 | Antibacterial activity against Escherichia coli MG1655 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID563018 | Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559362 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID530378 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID531336 | Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID530411 | Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID293588 | Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID429034 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1163982 | Cytotoxicity against mouse RAW264.7 cells at 50 uM after 72 hrs by MTT assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. |
| AID656227 | Antimycobacterial activity against isoniazid-, rifampin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID535836 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID450459 | Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID164396 | Antimicrobial activity against the Pseudomonas aeruginosa K 799/WT by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID447216 | Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID559576 | Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Acanthamoeba castellanii amoeba cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID433404 | Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID687497 | Clearance in rat | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID542145 | Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrA1 gene by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID733004 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB G89C mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID1730995 | Antitubercular activity against extensively drug resistance Mycobacterium tuberculosis R506 XDR by MABA | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. |
| AID510157 | Antimicrobial activity against cephalosporin-resistant Acinetobacter baumannii by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID285682 | Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID405121 | Antimicrobial activity against Escherichia coli TOP10 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID562244 | Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID1279155 | Permeability of the compound at 25 ug/ml at pH 7.4 after 18 hrs by PAMPA | 2016 | Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7 | Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease. |
| AID295100 | Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID534337 | Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1907630 | Antibacterial activity against Escherichia coli incubated for 18 to 20 hrs by double dilution method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA. |
| AID69619 | Antibacterial activity against Escherichia coli H560 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID94363 | In vitro antibacterial activity against Klebsiella pneumoniae K-1966 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID530394 | Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID208737 | Minimum inhibitory concentration required in vitro against Streptococcus D | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID322313 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID295097 | Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID498191 | Antibacterial activity against Stenotrophomonas maltophilia MBS101 containing plasmid encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID70571 | Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID532980 | Antibacterial activity against Escherichia coli DH5alpha in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID71795 | Percentage of GABA-induced chloride currents with compound alone at 10 e-4 M | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID529159 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID105366 | Concentration required to reduce the viability of mock-infected MT-4 cells by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID429006 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT37 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID699541 | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID205665 | In vitro minimum inhibitory concentration against gram-positive Sa (I), Staphylococcus aureus IID803. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID563215 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID53311 | Inhibitory effect on DNA gyrase supercoiling activity from Escherichia coli K-12 C600 | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID428987 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate nar 108 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563015 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID520875 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolates isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID205924 | Antimicrobial activity against the faecium ATCC 8043 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID1907628 | Antibacterial activity against Staphylococcus aureus ATCC6538 incubated for 18 to 20 hrs by double dilution method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA. |
| AID429026 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG182 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559365 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1174107 | Antimycobacterial activity against isoniazid, rifampin, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID665367 | Antitubercular activity against Mycobacterium tuberculosis H37Rv at 10 ug/mL by radiometric growth assay | 2012 | European journal of medicinal chemistry, Jul, Volume: 53 | Synthesis and antimycobacterial activity of novel 1,3-dimethylisocyanurate derivatives. |
| AID687499 | Drug excretion in rat urine | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID285683 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 with rpoN mutation after 24 hrs | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID395778 | Antibacterial activity against ceftriaxone-resistant Bacillus subtilis isolate after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID1557281 | Antibacterial activity against Klebsiella by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID391979 | Antibacterial activity against Enterococcus faecalis JH2-2-delta-pG1KT mutant by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID563051 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID293584 | Antibacterial activity against Escherichia coli isolate assessed after 24 hrs by by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID1730992 | Antitubercular activity against multi drug resistance Mycobacterium tuberculosis V2475 by MABA assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. |
| AID395364 | Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID498189 | Antibacterial activity against Stenotrophomonas maltophilia MBS109 containing chromosomally encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID428984 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 102 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID207175 | Antibacterial activity against Staphylococcus aureus (H228) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID559557 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1743441 | Antibacterial activity against Mycobacterium aurum measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1412157 | Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID287377 | Antibacterial activity against Mycobacterium smegmatis after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID164706 | In vitro minimum inhibitory concentration against gram-negative Pa(I), Pseudomonas aeruginosa IFO 3445. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID529456 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID391981 | Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT/pORI23::qnr-cat mutant with qnr gene complementation by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID65384 | Minimum inhibition concentration against Enterococcus faecalis LS-101 strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID392220 | Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23 promoter by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID560590 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID535841 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID352805 | Antimicrobial activity against Bacillus cereus NCIM 2155 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID563212 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID637605 | Permeability of the compound by PAMPA | 2012 | European journal of medicinal chemistry, Feb, Volume: 48 | A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. |
| AID563023 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene and deletion of codons 678 and 679 in gyrB mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID96075 | Antimicrobial activity against the klebsiella pneumoniae 8045 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID530417 | Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID559558 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID762022 | Antibacterial activity against Pseudomonas aeruginosa 9027 measured every 24 hrs for 5 days by conventional dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety. |
| AID559581 | Antimicrobial activity against Chlamydophila pneumoniae infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID563339 | Induction of Cwp84 protease expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID535840 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID1230215 | Antibacterial activity against Enterococcus faecalis CIP 103214 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID534418 | Antibacterial activity against Mycobacterium bovis BCG-Russia | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID550047 | Antibacterial activity against Staphylococcus aureus assessed as inhibition of visible growth after 48 hrs by agar dilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds. |
| AID563026 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1230247 | Antibacterial activity against Staphylococcus saprophyticus CIP 76125 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1694879 | Permeability of compound after 16 hrs by PAMPA-BBB assay | 2020 | RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2 | Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. |
| AID562792 | Antimicrobial activity against Chlamydophila caviae GPIC/rifR harboring rpoB gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID559555 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID96228 | Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Kp, Klebsiella pneumoniae B54. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID1557283 | Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID206854 | Minimum bactericidal concentration required in vitro against Staphylococcus aureus | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID529160 | Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID396104 | Antibacterial activity against Escherichia coli AG100 by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID1152781 | Ratio of MIC for 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant to MIC for wild-type Mycobacterium tuber | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID1230220 | Antibacterial activity against Enterococcus faecium CIP 103014 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1360043 | Bactericidal activity against Bacillus cereus after 24 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID1909448 | Permeability of the compound by PAMPA-BBB assay | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. |
| AID1516027 | Antibacterial activity against Acinetobacter baumannii AB1902 clinical isolate incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID1230226 | Antibacterial activity against Enterococcus gallinarum CIP 105985 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1743444 | Antibacterial activity against Pseudomonas aeruginosa measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID295109 | Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID395363 | Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID1743456 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1377752 | Effective permeability of the compound at 25 ug/ml by PAMPA assay | 2017 | European journal of medicinal chemistry, Sep-29, Volume: 138 | Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. |
| AID1516086 | Resistance index, ratio of MIC for antibacterial activity against ciprofloxacin-resistant Escherichia coli to MIC for Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID53321 | Inhibition of DNA gyrase supercoiling in Escherichia coli. | 1998 | Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1 | DNA gyrase inhibitory activity of ellagic acid derivatives. |
| AID67545 | Activity against Enterobacter aerogenes | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Search compounds with antimicrobial activity by applying molecular topology to selected quinolones. |
| AID530372 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID352092 | Antimicrobial activity against multidrug-resistant Escherichia coli after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID1463958 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate Praha 131 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID529670 | Antimicrobial activity against Escherichia coli J53 transconjugate by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli. |
| AID1274477 | Antibacterial activity against Methicillin-resistant Staphylococcus aureus N 315 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID429003 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT9 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID133954 | In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered subcutaneously | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID510168 | Antimicrobial activity against extended spectrum beta lactamase expressing Klebsiella pneumoniae by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID1295090 | Tuberculostatic activity against Mycobacterium terrae assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity. |
| AID1230213 | Antibacterial activity against Enterococcus casseliflavus CIP 103018 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID532037 | Antimicrobial activity against azide-resistant Escherichia coli J53 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID203276 | Antimicrobial activity against the Staphylococcus aureus 45 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID563039 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1577331 | Antimycobacterial activity against XDR Mycobacterium tuberculosis Praha 131 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID540231 | Dose normalised AUC in dog after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID557099 | Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at >145 ug/ml by SPR | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID429012 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT54 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1173785 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay | 2014 | Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23 | An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID428979 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate E86 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID532034 | Antimicrobial activity against Citrobacter freundii S008 expressing PMQR determinant qnrB23 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID450461 | Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID1662847 | Bactericidal activity against Staphylococcus aureus ATCC 209p | 2020 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13 | Design and synthesis of amphiphilic 2-hydroxybenzylphosphonium salts with antimicrobial and antitumor dual action. |
| AID542142 | Antimicrobial activity against Salmonella enterica HN-GSS-2007-057 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID1224527 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1412158 | Bactericidal activity against Pseudomonas aeruginosa isolate 1 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID1516019 | Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID1230221 | Antibacterial activity against Enterococcus faecium CIP 107387 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID562932 | Antimicrobial activity against Clostridium difficile 6425 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID429016 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG6 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID530385 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID95885 | Antibacterial activity against Klebsiella pneumonia (MGH-2) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID163554 | Tested in vitro against Proteus vulgaris OX-19 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID781326 | pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X | 2014 | Pharmaceutical research, Apr, Volume: 31, Issue:4 | Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. |
| AID559360 | Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID395717 | Antibacterial activity against Escherichia coli DH10B containing ORI23 promoter by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID386623 | Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy | 2008 | Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19 | Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. |
| AID162777 | In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IFO 3445 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID206284 | In vitro antibacterial activity against Staphylococcus aureus 50774 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1309358 | Acute toxicity in po dosed mouse | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines. |
| AID135327 | BBB penetration classification | 2000 | Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11 | Predicting blood-brain barrier permeation from three-dimensional molecular structure. |
| AID562240 | Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID198342 | Tested in vivo against Staphylococcus aureus IID803 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1230241 | Antibacterial activity against Staphylococcus aureus CIP 7625 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID293587 | Antibacterial activity against Klebsiella pneumoniae RSHM 574 assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID162740 | Compound was tested for antibacterial activity against gram negative Proteus mirabilis JY-10 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID429028 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG259 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID96098 | Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae KC-1 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID574796 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID733009 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration causing =<1% reduction in bacterial growth incubated for 21 to 30 days by proportion method | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID1335284 | Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as inhibition of DNA supercoiling activity using relaxed pBR322 as substrate incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1557285 | Antibacterial activity against Streptococcus pneumoniae by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1480942 | Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Apr-21, Volume: 130 | Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. |
| AID530392 | Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID324745 | Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID521967 | Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID1349196 | Antichlamydial activity against Chlamydia trachomatis serovar A 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID540225 | Volume of distribution at steady state in dog after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID206812 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pyogenes C203 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID69626 | Antibacterial activity against Escherichia coli Vogel | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID205652 | Compound was tested for antibacterial activity against gram positive Staphylococcus aureus KP-90-3 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID1463962 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 8666/2010 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID530623 | Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID510167 | Antimicrobial activity against Klebsiella pneumoniae RSKK 574 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID1730994 | Antitubercular activity against isoniazid/rifampin/levofloxacin/ofloxacin/kanamycin extensively drug resistance Mycobacterium tuberculosis TF274 XDR by MABA assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. |
| AID271563 | Residual activity of human CK2 at 30 uM | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. |
| AID694360 | Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition by BACTEC method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22 | The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID563341 | Induction of Cwp84 protease expression in Clostridium difficile 6269 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID207260 | Tested in vitro for antibacterial activity against Staphylococcus aureus (IID 803) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID395775 | Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID563340 | Effect on Cwp84 protease expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID562785 | Antimicrobial activity against Chlamydia muridarum MoPn/oflR harboring ompA gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID534341 | Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID429027 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG258 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID198344 | Tested in vitro against Staphylococcus aureus IID803 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID131003 | Compound was tested for oral efficacy on systemic infections caused by Staphylococcus aureus IID803 in mice | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID1593376 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in extensively drug-resistant Mycobacterium tuberculosis TF274 assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID540226 | Clearance in monkey after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID532036 | Antimicrobial activity against azide-resistant Escherichia coli J53 TrcS008 harboring PMQR determinant qnrB23 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID144017 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID283088 | Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA at 5 ug by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. |
| AID352841 | Antimicrobial activity against Aspergillus parasiticus NCIM 904 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID572151 | Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli. |
| AID521966 | Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID534346 | Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID450457 | Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID1177575 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by microdilution method | 2014 | Journal of natural products, Aug-22, Volume: 77, Issue:8 | Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus. |
| AID562943 | Upregulation of slpA gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID200334 | Minimum bactericidal concentration required in vitro against Salmonella | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID1143269 | Antimycobacterial activity against ethambutol-resistant Mycobacterium tuberculosis 17003 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID1295088 | Tuberculostatic activity against Mycobacterium tuberculosis H37Rv assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity. |
| AID1762620 | Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as reduction in bacterial growth after 6 to 8 days by green fluorescent protein microplate assay | |||
| AID163732 | Antibacterial activity against Providencia rettgeri M1771 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID1511119 | Permeability of the compound at 25 ug/ml by PAMPA-BBB assay | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. |
| AID131400 | Oral efficacy against Pseudomonas aeruginosa 12 on Systemic Infections in Mice | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID122920 | Antimicrobial activity against the micrococcus luteus 9341 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID1623120 | Effective permeability of the compound by BBB-PAMPA method | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease. |
| AID574583 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID530618 | Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID65203 | Minimum inhibitory concentration against Escherichia coli KC14 strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID694359 | Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22 | The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives. |
| AID1174106 | Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID540233 | Dose normalised AUC in human after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID67219 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Enterococcus faecalis IID682 (Ef) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID733005 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB A91V mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID95891 | Inhibition of growth of Klebsiella pneumonia | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID1360037 | Antimicrobial activity against Staphylococcus aureus after 18 to 20 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID1230238 | Antibacterial activity against Staphylococcus aureus CIP 53154 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1773264 | Permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease. |
| AID1296388 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 131 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID405115 | Antimicrobial activity against Vibrio splendidus LGP32 expressing plasmid-mediated QnrS-like quinolone resistance determinants | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID563330 | Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1653555 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.05 ug/ml rifabutin measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID352096 | Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID207390 | In vitro antibacterial activity against Staphylococcus aureus 209P JC-1 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1404015 | Permeability of the compound after 2.5 hrs by PAMPA | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. |
| AID205805 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus IID 803 (Sa(I)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID572519 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2425 harboring wild type ParC gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID520870 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU47 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID70429 | Compound was tested for antibacterial activity against gram negative Escherichia coli NIHJ JC-2 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID681306 | TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 0.03 uM, Ofloxacin: 21.7 mg/mL) in HL60R cells: flow cytometric analysis | 2000 | Antimicrobial agents and chemotherapy, Jun, Volume: 44, Issue:6 | Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. |
| AID1595267 | Antibacterial activity against Escherichia coli assessed as inhibition zone incubated for 24 hrs by disk diffusion method relative to control | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore. |
| AID563024 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID297186 | Antibacterial activity against multidrug resistant Staphylococcus aureus 49589 | 2007 | Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17 | Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. |
| AID755684 | Inhibition of human ERG current by patch clamp assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13 | The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel. |
| AID699540 | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1503776 | Antichlamydial activity against Chlamydia pneumoniae K7 infected in HL cells after 70 hrs by fluorescent microscopic analysis | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Identification of Privileged Antichlamydial Natural Products by a Ligand-Based Strategy. |
| AID562787 | Antimicrobial activity against Chlamydia suis R19/tetR harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID163738 | Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H1771 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID433580 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID442658 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives. |
| AID69479 | Minimum inhibitory concentration against Escherichia coli ATCC 25922 | 2003 | Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10 | Antibacterial activity of quinolone-macrocycle conjugates. |
| AID200869 | In vitro minimum inhibitory concentration against Salmonella Typhimurium IID 971 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1174109 | Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID765104 | Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17 | Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides. |
| AID205964 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus H228 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID530419 | Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID133812 | Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1301204 | Cytotoxicity against human FEH cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. |
| AID534338 | Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID209894 | Antibacterial activity against Streptococcus pneumoniae SV-1 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID1143266 | Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis 136570 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID1174111 | Antimycobacterial activity against isoniazid, rifampin, ethambutol-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay | 2015 | European journal of medicinal chemistry, Jan-07, Volume: 89 | Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis. |
| AID1435648 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID429010 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT48 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID542139 | Antimicrobial activity against Salmonella enterica HN-GSS2006-142 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID17991 | Bioavailability | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Search compounds with antimicrobial activity by applying molecular topology to selected quinolones. |
| AID1743448 | Antibacterial activity against Staphylococcus aureus measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID206632 | Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 50% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range) | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID574784 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID563041 | Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID530620 | Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID562940 | Effect on fbp69 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1279139 | Permeability of the compound at 25 ug/ml at pH 7.4 after 16 hrs by PAMPA | 2016 | Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7 | Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease. |
| AID530390 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID656232 | Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID293585 | Antibacterial activity against Bacillus subtilis isolate assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID530414 | Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID352845 | Antimicrobial activity against Penicillium chrysogenum NCIM 707 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID498192 | Antibacterial activity against Stenotrophomonas maltophilia MBS100 deficient in Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID1695809 | Antibacterial activity against Bacillus subtilis assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. |
| AID763999 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 16 mm) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID559556 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1129167 | Permeability of the compound by PAMPA | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6 | Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. |
| AID287375 | Antibacterial activity against Micrococcus luteus after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID581505 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94Y mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID529161 | FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa. |
| AID429004 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT15 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID206825 | Compound was tested for antibacterial activity against gram positive Staphylococcus pyogenes cook | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID285687 | Increase in GFP tagged vqsR protein expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml by flow cytometry relative to wild type | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID202106 | Minimum inhibition concentration against Streptococcus pneumoniae Type I strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID1201746 | Permeability of the compound after 16 hrs by PAMPA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. |
| AID1113446 | Antibacterial activity against Salmonella enterica subsp. enterica serovar Typhi assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID429030 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate BL 21801 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID530423 | Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID279818 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774A.1 macrophages | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID557091 | Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID433581 | Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A G89C mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID1230210 | Antibacterial activity against Corynebacterium striatum N840 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID78707 | MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID428901 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1264455 | Permeability of the compound by high throughput PAMPA method | 2015 | European journal of medicinal chemistry, Nov-13, Volume: 105 | Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID563209 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563029 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID572150 | Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli. |
| AID405118 | Antimicrobial activity against Escherichia coli TOP10 harbouring pS1 plasmid expressing quinolone resistant QnrS1 gene | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID395772 | Antibacterial activity against Klebsiella pneumoniae isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID1730993 | Antitubercular activity against isoniazid/rifampin resistance Mycobacterium tuberculosis KZN494 by MABA assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. |
| AID563334 | Upregulation of slpA gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID691688 | Antibacterial activity against Bartonella henselae infected in african green monkey Vero cells by immunofluorescence staining | 2012 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20 | Studies on the antimicrobial properties of N-acylated ciprofloxacins. |
| AID524826 | Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID1331869 | Antibacterial activity against Bacillus subtilis 168 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID203190 | In vitro antibacterial activity against Shigella flexneri 2a EW-10 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID449435 | Antimycobacterial activity against Mycobacterium tuberculosis XDR infected in MDBK by BACTEC analysis | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents. |
| AID404304 | Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). |
| AID352825 | Antimicrobial activity against Aspergillus niger NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID74727 | Antibacterial activity against five Gram-negative bacteria | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. |
| AID1743449 | Antibacterial activity against Klebsiella pneumoniae measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID530391 | Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID574802 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID765112 | Bacteriostatic activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition | 2013 | Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17 | Inhibition of Mycobacterium tuberculosis strains H37Rv and MDR MS-115 by a new set of C5 modified pyrimidine nucleosides. |
| AID1152776 | Antimycobacterial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA A74V mutant | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID763997 | Antibacterial activity against Shigella flexneri ATCC 15391 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 17 mm) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. |
| AID524827 | Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents. |
| AID562828 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID535842 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID133807 | Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID530369 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID581503 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID67217 | In vitro minimum inhibitory concentration against gram-positive Ef Enterococcus faecalis IID 682. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID1230219 | Antibacterial activity against Enterococcus faecalis N520 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID429024 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG169 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID498187 | Antibacterial activity against Stenotrophomonas maltophilia D457 containing chromosomally encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID510169 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID563218 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1557282 | Antibacterial activity against Bacteroides fragilis by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1390097 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 50 ug/ml after 48 hrs by MTT assay | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | Synthesis and evaluation of 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis. |
| AID1315652 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv measured daily for 8 days by GFP-based fluorescence assay | 2016 | Journal of natural products, 06-24, Volume: 79, Issue:6 | Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178. |
| AID535834 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID428982 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT29 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID295853 | Antimicrobial activity against Streptococcus pyogenes KUKEM676 by disk diffusion method at 10 ug/disc | 2007 | European journal of medicinal chemistry, Jul, Volume: 42, Issue:7 | Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. |
| AID678712 | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID395780 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID206370 | In vitro minimum inhibitory concentration against Streptococcus faecalis (ATCC 29212) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID694367 | Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22 | The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives. |
| AID96099 | Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae No.42 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID687496 | Half life in rat | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID428978 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate B111 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID562794 | Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR1 harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1502706 | Antimycobacterial activity against Mycobacterium avium 104 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID687493 | Oral bioavailability in rat | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID96230 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Klebsiella pneumoniae B54 (Kp) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID530427 | Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID534421 | Antibacterial activity against Mycobacterium bovis BCG-Denmark | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID70427 | Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RK1 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID207201 | In vitro minimum inhibitory concentration against Staphylococcus aureus (ATCC 29213) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID163786 | Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (IFO 3445) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1231418 | Antibacterial activity against Bacillus cereus ATCC 14579 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID295115 | Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID396099 | Antibacterial activity against Staphylococcus aureus K1902 by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID1593377 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in extensively drug-resistant Mycobacterium tuberculosis R506 assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID447215 | Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID572520 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Virginia isolate s2219 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID1231420 | Antibacterial activity against Escherichia coli ATCC 35218 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID206877 | Antibacterial activity against Staphylococcus aureus H-228 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID433402 | Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID530407 | Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID396103 | Antibacterial activity against Escherichia coli AG102 overexpressing acrAB by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1577327 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 1 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID70781 | In vitro antibacterial activity against Escherichia coli NIH JC-2 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1672290 | Antibacterial activity against Pseudomonas aeruginosa assessed as bacterial growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay | |||
| AID1412153 | Bactericidal activity against Staphylococcus aureus ATCC 6538 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID322318 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID352821 | Antimicrobial activity against Proteus vulgaris NCIM 2027 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID535845 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID352801 | Antimicrobial activity against Bacillus subtilis NCIM 2063 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID1319973 | Permeability of the compound by PAMPA assay | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21 | Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents. |
| AID429005 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID207207 | In vitro minimum inhibitory concentration against Staphylococcus aureus IID 803 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID563010 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID560259 | Antimicrobial activity against Salmonella enterica serovar Typhimurium STYM61/9 expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium. |
| AID540229 | Volume of distribution at steady state in human after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID681771 | TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, OFLX: 2000 uM) in Xenopus laevis oocytes | 1999 | The Journal of pharmacology and experimental therapeutics, Aug, Volume: 290, Issue:2 | The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. |
| AID1230224 | Antibacterial activity against Enterococcus faecium N733 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1562256 | Antimycobacterial activity against Mycobacterium smegmatis atR40 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines. |
| AID560592 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID563331 | Upregulation of slpA gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1413649 | Ratio of MIC for methicillin-resistant Staphylococcus aureus JCSC 4788 re-passaged at 24 hrs intervals for 20 times to MIC for methicillin-resistant Staphylococcus aureus JCSC 4788 | 2018 | MedChemComm, Oct-01, Volume: 9, Issue:10 | Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains. |
| AID67549 | Antimicrobial activity against the enterobacter aerogenes ATCC 13048 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID510161 | Antimicrobial activity against Proteus mirabilis ATCC 7002 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID532990 | Antibacterial activity against Klebsiella pneumoniae NCIM 2883 assessed as growth inhibition in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID279841 | Drug level in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID64252 | Activity against Escherichia coli (K-12 C600) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID1478796 | Permeability of the compound by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. |
| AID164873 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas aeruginosa UI-18 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID1324014 | Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB method | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease. |
| AID535846 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID279817 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv in 7H9 broth | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID207206 | In vitro minimum inhibitory concentration against Staphylococcus aureus FDA 209P JC-1 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID65221 | Minimum inhibition concentration against Escherichia coli NIHJ JC-2 strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID1390094 | Antimycobacterial activity against active form of Mycobacterium tuberculosis H37Rv measured after 7 days by alamar blue assay | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | Synthesis and evaluation of 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis. |
| AID687494 | Cmax in rat at 10 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID428986 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 107 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1516024 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID68976 | Minimum concentration of the drug needed to produce linear DNA at an intensity relative to oxolinic acid(at 10 ug/mL) | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID530387 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID534339 | Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID1056992 | Permeability of the compound by PAMPA | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids. |
| AID1273398 | Anti-tubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294T after 7 days by mircodilution method | 2016 | European journal of medicinal chemistry, Jan-01, Volume: 107 | Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis. |
| AID285686 | Increase in vqsR gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml relative to wild type | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID133817 | Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1335283 | Inhibition of Mycobacterium smegmatis DNA gyrase B expressed in BL21(DE3)pLysS cells assessed as inhibition of DNA supercoiling activity in presence of ATP measured after 30 mins by malachite green dye based assay | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. |
| AID70570 | Compound was tested for inhibition of the gram-negative organism Escherichia coli H560 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID405117 | Antimicrobial activity against Escherichia coli TOP10 harbouring pVS2 expressing quinolone resistant Vibrio splendidus LGP32 QnrVS2 gene | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID71070 | Concentration required to produce linear DNA from closed circular DNA by the denaturation of the drug-gyrase-DNA complex | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID68013 | Antibacterial activity against Enterobacter cloacae MA2646 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID572522 | Antimicrobial activity against qnrA-positive Salmonella enterica serovar Mbandaka isolate s2093 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID94137 | Activity against Klebsiella pneumoniae (PCI-602) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID563208 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID531332 | Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID391985 | Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL by agarose gel electrophoresis | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID203278 | Antimicrobial activity against the Staphylococcus epidermis 3519 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID581513 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94G mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID530244 | Antimicrobial activity against Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. |
| AID69951 | Antimicrobial activity against the Escherichia coli H560 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID534343 | Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID678721 | Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID563045 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID206197 | Tested in vitro for antibacterial activity against Staphylococcus epidermidis (IAM 1296) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID535844 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID68849 | In vitro minimum inhibitory concentration against Escherichia coli (ATCC 1-25922) | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID530377 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1557288 | Antibacterial activity against Clostridium perfringens by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID279839 | Ratio of fraction AUC in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID530412 | Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID531334 | Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID1412155 | Bactericidal activity against Staphylococcus epidermidis ATCC 35984 incubated for 24 hrs followed by replating on Mueller hinton agar plates and measured after 24 hrs | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID563030 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID447080 | Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID1163979 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. |
| AID563216 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID447219 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID1113451 | Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID1421885 | Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method | 2018 | European journal of medicinal chemistry, Oct-05, Volume: 158 | Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. |
| AID114660 | Compound was evaluated for oral Pseudomonas aeruginosa E-2 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID371463 | Antimicrobial activity against Escherichia coli isolate after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID532039 | Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfS008 harboring PMQR determinant qnrB23 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID1516029 | Antibacterial activity against Staphylococcus aureus 11011 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID520872 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU67 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID572517 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Braenderup isolate s2856 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID559363 | Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID208946 | Inhibition of growth of Streptococcus pyogenes | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID563009 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID78692 | 50% inhibitory concentration against DNA-gyrase | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID1516023 | Antibacterial activity against Escherichia coli ATCC 25922 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID562944 | Upregulation of fbp68 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID429007 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT40 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1230216 | Antibacterial activity against Enterococcus faecalis CIP 104676 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID64889 | Tested in vitro for antibacterial activity agains Escherichia coli (NIHJ JC-2) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1412150 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 57 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID395715 | Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23::qnr-cat promoter mutant by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID563016 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID208740 | Antimicrobial activity against the streptococcus agalactiae CMX 508 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID428991 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 46 harboring DNA gyrase A D87G mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563333 | Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID424862 | Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID1295089 | Tuberculostatic activity against Mycobacterium avium assessed as induction of penetration size stunting incubated for 10 days by vertical diffusion method | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity. |
| AID678715 | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID151057 | Activity against Pseudomonas aeruginosa (E-2) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID563336 | Induction of Cwp84 protease expression in Clostridium difficile 6425 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID427198 | Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. |
| AID352094 | Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID198023 | Activity against Streptococcus faecalis (IID 682) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID524796 | Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay | 2009 | Nature chemical biology, Oct, Volume: 5, Issue:10 | Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. |
| AID1480849 | Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Apr-21, Volume: 130 | Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment. |
| AID70770 | Inhibition of growth of Escherichia coli H560 | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID429036 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID201406 | Minimum inhibitory concentration against Staphylococcus aureus Smith | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID68172 | Compound was tested for antibacterial activity against gram negative Enterobacter cloacae Nek39 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID429001 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT2 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1577329 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis Praha 4 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID562926 | Antimicrobial activity against Clostridium difficile CD196 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1301202 | Antimycobacterial activity against Mycobacterium terrae after 10 days by micro broth dilution method | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. |
| AID371461 | Antimicrobial activity against Bacillus subtilis isolate after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID1463961 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 7357/1998 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID563056 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID429002 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT3 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1171223 | Ratio of MIC for wild-type Escherichia coli to MIC for tolC-deficient Escherichia coli | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID559563 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID542144 | Antimicrobial activity against Escherichia coli DH10B harboring pBR322 by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID540230 | Dose normalised AUC in rat after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID563042 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID498872 | Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. |
| AID1224523 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID656230 | Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID557092 | Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID562933 | Upregulation of slpA gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID532986 | Antibacterial activity against Pseudomonas aeruginosa NCIM 5029 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID391984 | Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL in presence of 0.9 uM histidine6-tagged Enterococcus faecalis qnr protein preincubated before compound administration by agarose gel electrophoresis | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID395774 | Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID433401 | Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID535835 | Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID279830 | Half life in BALB/c mouse at 37.5 to 2400 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID352097 | Antimicrobial activity against multidrug-resistant Staphylococcus aureus after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID562937 | Upregulation of cwp84 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID68848 | In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID96249 | In vitro antibacterial activity against Klebsiella pneumoniae 13 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID510159 | Antimicrobial activity against extended spectrum beta lactamase expressing Proteus mirabilis by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID530376 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1562258 | Antimycobacterial activity against Mycobacterium smegmatis atR19 assessed as decrease in drug resistance development at 2 ug/disc after 2 to 3 days by paper disc method | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines. |
| AID433578 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID95916 | Antibacterial activity against Klebsiella pneumoniae MGH-2 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID285685 | Increase in pvdS gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml after 3 hrs relative to wild type | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | rpoN gene of Pseudomonas aeruginosa alters its susceptibility to quinolones and carbapenems. |
| AID540224 | Clearance in dog after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID562942 | Upregulation of cwp84 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1143264 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID560261 | Antimicrobial activity against Escherichia coli CSH26RifR receiving qnrB19 gene variant carried by IncL/M-like plasmid from Salmonella enterica serovar Typhimurium STYM61/9 by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium. |
| AID1743447 | Antibacterial activity against Enterobacter cloacae measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID279819 | Fraction unbound ligand in mouse plasma at 0.01 to 50 mg/litre | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID424863 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID209302 | Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203. | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1230246 | Antibacterial activity against Staphylococcus lugdunensis ATCC 43809 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID395359 | Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID510163 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 10145 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID540223 | Volume of distribution at steady state in rat after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID529457 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID114659 | Compound was evaluated for oral efficacy on systemic infections in mice by Escherichia coli KC-14 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1230236 | Antibacterial activity against Staphylococcus aureus ATCC 9144 oxford after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID562793 | Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR2 harboring ampA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID678714 | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID534345 | Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID28851 | The compound was evaluated for the solubility in water at 25 degrees Centigrade | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID352817 | Antimicrobial activity against Staphylococcus albus NCIM 2178 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID560591 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID395776 | Antibacterial activity against Escherichia coli isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID659472 | Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. |
| AID206794 | Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID293591 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID405119 | Antimicrobial activity against Escherichia coli TOP10 harbouring pS2 plasmid expressing quinolone resistant QnrS2 gene | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID200345 | Minimum inhibitory concentration required in vitro against Salmonella | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID279823 | Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 14 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID521220 | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 2007 | Nature chemical biology, May, Volume: 3, Issue:5 | Chemical genetics reveals a complex functional ground state of neural stem cells. |
| AID559368 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID540222 | Clearance in rat after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID562786 | Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR1 harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1230235 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID534342 | Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID164268 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas rettgeri H1771 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID352090 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID96229 | Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-2 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID530398 | Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID110152 | Percentage of mice with convulsion (400 mg/kg fenbufen) | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID687498 | Volume of distribution in rat | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID208735 | Minimum bactericidal concentration required in vitro against Streptococcus D | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID562929 | Antimicrobial activity against Clostridium difficile CD196 M1 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1743469 | Inhibition of DNA gyrase in Mycobacterium smegmatis assessed as elongation of bacterial cells at 2 ug/ml measured after 6 hrs by DAPI/FM 4-64 staining based confocal fluorescence microscopic analysis | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1331873 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1435654 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID1274478 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID198018 | Activity against Staphylococcus epidermidis (IAM 1296) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID635079 | Permeability of the compound after 2.5 hrs by PAMPA-BBB assay | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model. |
| AID532983 | Antibacterial activity against Escherichia coli W3110 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID562934 | Upregulation of slpA gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID207384 | Inhibition of growth of Staphylococcus aureus (resistant) | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID205389 | Compound was tested for antibacterial activity against gram negative Serratia marcescens No.16-2 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID694227 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22 | The synthesis and antituberculosis activity of 5'-nor carbocyclic uracil derivatives. |
| AID530371 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID563036 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID64884 | Tested in vitro for antibacterial activity against Escherichia coli (KC-14) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID164701 | Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa K-13 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID385168 | Antimicrobial activity against Staphylococcus aureus by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID1485936 | Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay | 2017 | Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14 | Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease. |
| AID279837 | Reduction of Mycobacterium tuberculosis H37Rv in orally dosed BALB/c mouse lung | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID385164 | Antimicrobial activity against Candida albicans by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID1743460 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ala-90-Val/gyrB Glu-540-Val mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID563038 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID581499 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying mutation | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1230245 | Antibacterial activity against Staphylococcus intermedius N987 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1435652 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID425073 | Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID1113450 | Antibacterial activity against Klebsiella pneumoniae assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID1693561 | Effective permeability of compound in PBS/EtOH buffer (7:3) at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay | 2021 | Bioorganic & medicinal chemistry, 01-15, Volume: 30 | Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease. |
| AID1143270 | Antimycobacterial activity against ofloxacin-resistant Mycobacterium tuberculosis 12119 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID687495 | AUC (0 to infinity) in rat at 10 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20 | Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties. |
| AID1703921 | Permeability of the compound by PAMPA-BBB assay | 2020 | European journal of medicinal chemistry, Oct-15, Volume: 204 | Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. |
| AID1437020 | Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis clinical isolate after 4 days by Alamar blue assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives. |
| AID1230217 | Antibacterial activity against Enterococcus faecalis N491 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID95735 | Compound was tested for antibacterial activity against gram negative Klebsiella oxytoca GN 10650 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID510164 | Antimicrobial activity against extended spectrum beta lactamase expressing Escherichia coli by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1230229 | Antibacterial activity against Enterococcus hirae CIP 5855 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID563058 | Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559371 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID205806 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus FDA 209P JC-1 (Sa(F)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID574806 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID143107 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID532984 | Antibacterial activity against Escherichia coli MG1655 in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID530370 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID395366 | Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID131701 | Effective dose against Staphylococcus aureus smith strain in mouse | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID1577339 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID1623078 | Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease. |
| AID1653557 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.0125 ug/ml KRM-1648 measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID352853 | Antimicrobial activity against Trichoderma viride NCIM 1195 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID1230228 | Antibacterial activity against Enterococcus gallinarum N492 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID762020 | Antibacterial activity against Bacillus cereus 8035 measured every 24 hrs for 5 days by conventional dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety. |
| AID243151 | Inhibitory concentration against potassium channel HERG | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. |
| AID540232 | Dose normalised AUC in monkey after po administration | 2005 | Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2 | Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. |
| AID1171218 | Antibacterial activity against MeXABCDXY-deficient Pseudomonas aeruginosa | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID762019 | Antibacterial activity against Escherichia coli F-50 measured every 24 hrs for 5 days by conventional dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety. |
| AID1143267 | Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 912253 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID1230250 | Antibacterial activity against Streptococcus agalactiae CIP 103227 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID562935 | Upregulation of slpA gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID510158 | Antimicrobial activity against Acinetobacter baumannii RSKK 02026 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID469403 | Permeability across PAMPA membrane | 2009 | Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22 | Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. |
| AID520869 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU33 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID532040 | Antimicrobial activity against azide-resistant Escherichia coli DH5alpha by Etest | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel variants of the qnrB gene, qnrB22 and qnrB23, in Citrobacter werkmanii and Citrobacter freundii. |
| AID205881 | In vitro minimum inhibitory concentration against Staphylococcus epidermidis IAM 1296 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID352809 | Antimicrobial activity against Vibrio fischeri NCIM 2154 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID1143265 | Antimycobacterial activity against Mycobacterium tuberculosis D-211 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID563049 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID395718 | Antibacterial activity against Escherichia coli DH10B containing ORI23::qnr-cat promoter mutant by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID163961 | In vitro antibacterial activity against Pseudomonas aeruginosa E-2 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID563217 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1412148 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 15 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID143859 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID1171224 | Ratio of MIC for wild-type Pseudomonas aeruginosa to MIC for MeXABCDXY-deficient Pseudomonas aeruginosa | 2014 | Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23 | Trends and exceptions of physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. |
| AID542143 | Antimicrobial activity against Escherichia coli DH10B by broth microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. |
| AID1335286 | Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM measured after 72 hrs by MTT assay relative to control | 2016 | European journal of medicinal chemistry, Nov-29, Volume: 124 | Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID581511 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and T539P mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID562243 | Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. |
| AID572512 | Antimicrobial activity against Salmonella enterica serovar Montevideo isolate s2317 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID210196 | Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-1 | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID395781 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID581493 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94A mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID96264 | In vitro antibacterial activity against clinical isolates of Klebsiella pneumoniae-4 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID406847 | Antibacterial activity against Enterobacter cloacae S1 isolate expressing quinolone resistance determinant QnrB4 by E-test | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant. |
| AID396100 | Antibacterial activity against Pseudomonas aeruginosa K1536 overexpressing mexCD by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID678716 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID523001 | Cytotoxicity against human 5637 cells assessed as mild induction of cell death by trypan blue exclusion assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID1230249 | Antibacterial activity against Staphylococcus sciuri N993 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID68201 | In vitro antibacterial activity against clinical isolates of Enterobacter cloacae 041 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID70575 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli KC-14 (Ec(K)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID1593375 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in multidrug-resistant Mycobacterium tuberculosis KZN494 assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID559580 | Antimicrobial activity against Chlamydia trachomatis infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID557098 | Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 18 to 36 ug/ml by SPR | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID1126743 | Antibacterial activity against 0.5 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay | 2014 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8 | Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents. |
| AID386887 | Antimicrobial activity against Candida albicans ATCC 2091 by cup plate method | 2008 | European journal of medicinal chemistry, Oct, Volume: 43, Issue:10 | Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid. |
| AID563052 | Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID574810 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID1593373 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in drug-susceptible Mycobacterium tuberculosis V4207 assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID71981 | Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID352813 | Antimicrobial activity against Corynebacterium rubrum NCIM 2252 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID429035 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID51918 | Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity) | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. |
| AID530386 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID572510 | Antimicrobial activity against Salmonella enterica serovar Braenderup isolate s2906 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID133810 | Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1055943 | Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 hrs | 2013 | Journal of natural products, Nov-22, Volume: 76, Issue:11 | Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain. |
| AID70576 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli NIHJ JC-2 (Ec(N)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID1301201 | Antimycobacterial activity against Mycobacterium avium after 10 days by micro broth dilution method | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. |
| AID562824 | Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID498780 | Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID530380 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID559550 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID559554 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1230208 | Antibacterial activity against Bacillus cereus N349 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID563059 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1347981 | Permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. |
| AID144567 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 90% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID206034 | Tested in vitro against Staphylococcus epidermidis IAM12896 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID572514 | Antimicrobial activity against Salmonella enterica serovar Corvallis isolate s2064 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID1230218 | Antibacterial activity against Enterococcus faecalis N518 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1890598 | Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method | 2022 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 63 | WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections. |
| AID203277 | Antimicrobial activity against the Staphylococcus aureus ATCC 6538 P by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID560601 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID144019 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 90% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID385165 | Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID581507 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D500N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID324749 | Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 150 mg/kg/day after 9 months | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID563222 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1866897 | Permeability for across blood brain barrier by PAMPA | 2022 | European journal of medicinal chemistry, Apr-15, Volume: 234 | Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors. |
| AID1331874 | Antibacterial activity against Enterobacter cloacae ATCC 13047 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1360039 | Antimicrobial activity against Pseudomonas aeruginosa after 18 to 20 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID563500 | Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens. |
| AID563033 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID405114 | Antimicrobial activity against Vibrio splendidus 12B01 expressing plasmid-mediated QnrS-like quinolone resistance determinants | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID279840 | Ratio of fraction Cmax in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID574807 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID429011 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT49 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID763993 | Antibacterial activity against Shigella flexneri ATCC 15391 after 24 hrs by two-fold serial dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. |
| AID530396 | Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID563221 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563035 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID209126 | Antibacterial activity against Streptococcus pyogenes C203 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID1502709 | Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID295103 | Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID530622 | Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1672292 | Antifungal activity against Candida albicans assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay | |||
| AID287376 | Antibacterial activity against Proteus vulgaris after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID352829 | Antimicrobial activity against Aspergillus flavus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID428988 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate ipt 2 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID205663 | Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-positive Sa (F) Staphylococcus aureus FDA 209P JC-1 | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID208910 | Antimicrobial activity against the streptococcus bovis A 5169 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID429025 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG176 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID429021 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG17 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1173783 | Inhibition of purified Mycobacterium smegmatis GyrB at 50 to 100 uM after 100 mins by ATPase assay | 2014 | Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23 | An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID563211 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene assessed as microbial susceptibility and deletion of codons 678 and 679 in gyrB mutant gene assessed as microbial susceptibility by agar proportion m | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1413530 | Toxicity in Staphylococcus aureus after 18 to 24 hrs by two-fold serial dilution method | 2018 | MedChemComm, Aug-01, Volume: 9, Issue:8 | Design, synthesis, and biological evaluation of |
| AID678713 | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID396098 | Antibacterial activity against Staphylococcus aureus K2361 overexpressing norA by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID295850 | Antimicrobial activity against Proteus vulgaris A161 by disk diffusion method at 10 ug/disc | 2007 | European journal of medicinal chemistry, Jul, Volume: 42, Issue:7 | Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. |
| AID68183 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Enterobacter cloacae HA 2646 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID395358 | Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID433583 | Selectivity index, ratio of CC25 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to CC25 for Mycobacterium leprae wild type DNA gyrase A2B2 by DNA cleavage assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID510171 | Antimicrobial activity against cephalosporin-resistant Enterococcus faecalis by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID428999 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT145 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID680399 | TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, OFLX: 1000 uM) in Xenopus laevis oocytes | 1999 | The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2 | Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. |
| AID559559 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1331870 | Antibacterial activity against Listeria monocytogenes ATCC 19115 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID151194 | Activity against Pseudomonas cepacia (IID-1341) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID560593 | Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID563025 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1412152 | Antibacterial activity against Pseudomonas aeruginosa isolate 1 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID563007 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1753998 | Permeability of the compound in PBS/EtOH buffer (7:3) incubated for 16 hrs by UV plate reader based PAMPA-BBB assay | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease. |
| AID1177574 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by microdilution method | 2014 | Journal of natural products, Aug-22, Volume: 77, Issue:8 | Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus. |
| AID133815 | Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1230211 | Antibacterial activity against Enterococcus avium CIP 104053 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID197875 | Minimum inhibition concentration against Staphylococcus aureus FDA209P strain | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID530418 | Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1295093 | Toxicity in healthy mouse administered as single peroral dose measured after 14 days | 2016 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10 | A convenient and efficient approach to polyfluorosalicylic acids and their tuberculostatic activity. |
| AID1326673 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay | 2016 | European journal of medicinal chemistry, Oct-21, Volume: 122 | Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. |
| AID540228 | Clearance in human after iv administration | 2006 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7 | Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. |
| AID78695 | Gyrase inhibitory activity against Escherichia coli | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID588208 | Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset | 2010 | Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5 | Predicting phospholipidosis using machine learning. |
| AID396102 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID429018 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG8 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID529669 | Antimicrobial activity against Escherichia coli R4525 expressing gyrA S83L and D87Y and parC S80I and E84G mutant gene by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | ISEcp1-mediated transposition of qnrB-like gene in Escherichia coli. |
| AID530389 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID520868 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU28 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID1296386 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 1 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID530399 | Antimicrobial activity against Helicobacter pylori 1 harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID279842 | Toxicity in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID352849 | Antimicrobial activity against Lipomyces lipofer NCIM 3252 at 5 ug/disk after 72 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID530401 | Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1113449 | Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm) | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID78709 | Inhibition of DNA gyrase of Escherichia coli H560 cells | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID165048 | In vitro antibacterial activity against Pseudomonas aeruginosa IFO 3445 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID352093 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs | 2009 | European journal of medicinal chemistry, Feb, Volume: 44, Issue:2 | Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. |
| AID563028 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1230237 | Antibacterial activity against Staphylococcus aureus CIP 483 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1161578 | Permeability of the compound by PAMPA-BBB assay | 2014 | Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19 | Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties. |
| AID1163978 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. |
| AID534340 | Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | The BpeAB-OprB efflux pump of Burkholderia pseudomallei 1026b does not play a role in quorum sensing, virulence factor production, or extrusion of aminoglycosides but is a broad-spectrum drug efflux system. |
| AID316444 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID699539 | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | 2012 | Journal of medicinal chemistry, May-24, Volume: 55, Issue:10 | Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. |
| AID563223 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563037 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID69952 | Antimicrobial activity against the Escherichia coli JUHL by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID386886 | Antibacterial activity against sEscherichia coli ATCC 25922 by cup plate method | 2008 | European journal of medicinal chemistry, Oct, Volume: 43, Issue:10 | Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid. |
| AID563047 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID535843 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID581492 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA A90V mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID428996 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT118 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1319976 | Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21 | Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents. |
| AID1230242 | Antibacterial activity against Staphylococcus aureus CRBIP 2121 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID143121 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 90% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID1557297 | Half life in human at 0.4 g, po bid | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1636268 | Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay | 2016 | Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20 | Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors. |
| AID563226 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID64253 | Activity against Escherichia coli (KC-14) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID428992 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 50 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1309356 | Antimycobacterial activity against rifampin and isoniazid resistant-Mycobacterium tuberculosis Beijing harboring Ser 531 to Leu 315 and Ser to Thr in rpoB and katG genes mutation after 24 hrs by microbroth dilution method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines. |
| AID447082 | Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID1173449 | Effective permeability of the compound by PAMPA assay | 2014 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23 | Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines. |
| AID395097 | Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. |
| AID30399 | Compound was tested for antibacterial activity against gram negative Acinetobacter calcoaceticus No.4 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID510166 | Antimicrobial activity against Escherichia coli ATCC 35218 by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID1230206 | Antibacterial activity against Bacillus cereus N190 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID574811 | Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. |
| AID197994 | Activity against Staphylococcus aureus (FDA207PJC-1) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID287378 | Antibacterial activity against Listeria monocytogenes after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID1274480 | Antibacterial activity against Proteus vulgaris ATCC 8427 after 24 hrs by two-fold serial dilution method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Synthesis and biological evaluation of novel phosphoramidate derivatives of coumarin as chitin synthase inhibitors and antifungal agents. |
| AID322317 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID563220 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID531335 | Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID530397 | Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID467863 | Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs | 2009 | Journal of natural products, Dec, Volume: 72, Issue:12 | Structurally diverse limonoids from the fruits of Swietenia mahagoni. |
| AID405116 | Antimicrobial activity against Escherichia coli TOP10 harbouring pVS1 expressing quinolone resistant Vibrio splendidus 12B01 QnrVS1 gene | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants. |
| AID1435651 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID295118 | Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID122925 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Micrococcus luteus ATCC 9341 (MI) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID1143263 | Antimycobacterial activity against Mycobacterium tuberculosis Beijing (E-47/94) assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID581508 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D540D mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1743439 | Antitubercular activity against Mycobacterium tuberculosis H37Rv measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID206216 | Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus epidermidis IAM 1296 (Se) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID391989 | Antibacterial activity against Lactococcus lactis IL-1419 by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID559562 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID429031 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 21095 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1463960 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 234/2005 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID279824 | Cmax in BALB/c mouse at 37.5 to 2400 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID1143268 | Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis 19000 assessed as growth inhibition after 2 to 3 weeks by turbidometry | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. |
| AID656228 | Antimycobacterial activity against isoniazid-, rifampin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID395779 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID530395 | Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID30416 | Antimicrobial activity against the acinetobacter sp. CMX 669 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID371459 | Antimicrobial activity against Staphylococcus aureus isolate after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID429009 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT47 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1224519 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID581512 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94A mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1378879 | Effective permeability of the compound at 100 mg/ml after 16 hrs by UV based PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease. |
| AID163227 | Compound was tested for antibacterial activity against gram negative Proteus vulgaris KS-134 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID70566 | Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(N), Escherichia coli NIHJ JC-2. | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID1360038 | Antimicrobial activity against Bacillus cereus after 18 to 20 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID581498 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D540D mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID563214 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID206652 | Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 90% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range) | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID131001 | Compound was tested for oral efficacy on systemic infections caused by Escherichia coli KC-14 in mice | 1994 | Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterials. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1231419 | Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID530373 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID562791 | Antimicrobial activity against Chlamydia trachomatis F/70/rifR harboring rpoB gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID285159 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID1502711 | Antimycobacterial activity against Mycobacterium avium isolate MAV2 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1201747 | Permeability of the compound by PAMPA | 2015 | European journal of medicinal chemistry, May-05, Volume: 95 | Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. |
| AID1296384 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 9449/2007 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID386885 | Antibacterial activity against Staphylococcus aureus ATCC 19433 by cup plate method | 2008 | European journal of medicinal chemistry, Oct, Volume: 43, Issue:10 | Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid. |
| AID391982 | Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23::qnr-cat promoter mutant overexpressing qnr by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1743443 | Antibacterial activity against Mycobacterium bovis BCG measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID1653553 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.75 ug/ml in presence of 0.2 ug/ml rifampin measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID1152780 | Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates after 2 to 4 weeks by BACTEC 460 radiometric assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID1435649 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 14 days by micromethod | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | S-substituted 3,5-dinitrophenyl 1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. |
| AID385167 | Antimicrobial activity against Bacillus cereus by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID682301 | TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, OFLX: 500 uM) in OCTN2-expressing HEK293 cells | 1999 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2 | Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. |
| AID1230233 | Antibacterial activity against Listeria monocytogenes N836 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID557095 | Binding affinity to first site on human serum albumin by SPR | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID1743445 | Antibacterial activity against Acinetobacter baumannii measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID206684 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pneumoniae SV-1 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID530416 | Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID562796 | Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR2 harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID530246 | Antimicrobial activity against surA deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Role of global regulators and nucleotide metabolism in antibiotic tolerance in Escherichia coli. |
| AID1230222 | Antibacterial activity against Enterococcus faecium N490 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID562799 | Antimicrobial activity against Chlamydia muridarum MoPn/tetR1 harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID428980 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate A102 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID557097 | Protein binding in serum | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID1352675 | Effective permeability at 25 ug/ml after 18 hrs by PAMPA | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease. |
| AID713896 | Antimycobacterial activity against Mycobacterium tuberculosis isolate CIBIN/UMF 15:19 | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Recent advances in antitubercular natural products. |
| AID69826 | Tested in vitro against Escherichia coli NIHJ JC-2 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1349195 | Antichlamydial activity against Chlamydia trachomatis serovar D 454/Bu infected in human HeLa 299 cells assessed as reduction in number of inclusion bodies measured after 44 to 48 hrs by DAPI staining-based HCS assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. |
| AID316446 | Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. |
| AID428983 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT61 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID713895 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Recent advances in antitubercular natural products. |
| AID520874 | Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU90 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Methicillin-resistant Staphylococcus saprophyticus isolates carrying staphylococcal cassette chromosome mec have emerged in urogenital tract infections. |
| AID1557296 | AUC in human at 0.4 g, po bid | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID572518 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2705 harboring wild type ParC gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID559372 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1071344 | Permeability of the compound by BBB-PAMPA | 2014 | European journal of medicinal chemistry, Feb-12, Volume: 73 | 1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies. |
| AID1915642 | Antimycobacterial activity against Mycobacterium tuberculosis My 331/88 (H37Rv) assessed as reduction in bacterial growth incubated for 14 days by microdilution method | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review. |
| AID1230230 | Antibacterial activity against Listeria innocua E044 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID530382 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1577335 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 234/2005 after 14 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID143862 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 90% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID563014 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1230240 | Antibacterial activity against Staphylococcus aureus CIP 5710 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID1516021 | Antibacterial activity against Salmonella enterica serovar typhimurium C77-31 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID530400 | Antimicrobial activity against Helicobacter pylori 2 harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1695810 | Antibacterial activity against Staphylococcus aureus assessed as inhibition zone at 1 mg/ml measured after overnight incubation by disc diffusion method | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. |
| AID68191 | In vitro antibacterial activity against Enterobacter cloacae 963 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID498786 | Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID1230239 | Antibacterial activity against Staphylococcus aureus CIP 53156 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID203317 | In vitro antibacterial activity against Serratia marcescens IFO 3736 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1193923 | Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7 | Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. |
| AID395773 | Antibacterial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID530393 | Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID429014 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG3 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1412147 | Antibacterial activity against Staphylococcus aureus ATCC 6538 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID1230205 | Antibacterial activity against Bacillus cereus CIP 6624 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID425070 | Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID287372 | Antibacterial activity against Staphylococcus aureus after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID559551 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1393806 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by broth dilution assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Fluoroquinolone derivatives and their anti-tubercular activities. |
| AID1907631 | Antibacterial activity against Pseudomonas aeruginosa incubated for 18 to 20 hrs by double dilution method | 2022 | European journal of medicinal chemistry, Jun-05, Volume: 236 | Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA. |
| AID429015 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG5 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID433579 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID78705 | Inhibition constant against DNA Gyrase isolated from Escherichia coli | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID163785 | Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (E-2) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID133953 | In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered perorally | 1988 | Journal of medicinal chemistry, Sep, Volume: 31, Issue:9 | Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative. |
| AID131005 | Compound was tested for oral efficacy on systemic infections on mice by peroral administration | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID639368 | Permeability of the compound by PAMPA assay | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. |
| AID1703887 | Permeability of the compound incubated for 165 mins by PAMPA-BBB assay | 2020 | European journal of medicinal chemistry, Oct-15, Volume: 204 | Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID143108 | Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 50% | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID510162 | Antimicrobial activity against trimethoprim-sulfamethoxazole and tazobactum-induced Pseudomonas aeruginosa by spectrophotometry | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID395362 | Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis, Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of mixed aza-oxo-thia macrocyclic compounds. |
| AID391977 | Antibacterial activity against Enterococcus faecalis JH2-2 by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1188154 | Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17 | Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis. |
| AID481439 | Absolute bioavailability in human | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? |
| AID530368 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID762021 | Antibacterial activity against Staphylococcus aureus 209p measured every 24 hrs for 5 days by conventional dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium moiety. |
| AID530415 | Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1227981 | Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Ra assessed as microbial growth inhibition incubated at 37 degC for 7 days by fluorescence based assay | 2015 | Journal of natural products, Apr-24, Volume: 78, Issue:4 | Eremophilane Sesquiterpenes and Diphenyl Thioethers from the Soil Fungus Penicillium copticola PSU-RSPG138. |
| AID352625 | Antimicrobial activity against Klebsiella aerogenes NCIM 2239 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID1056993 | Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA | 2013 | Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23 | Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids. |
| AID285160 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID442657 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives. |
| AID352633 | Antimicrobial activity against Escherichia coli NCIM 2065 at 5 ug/disk after 24 hrs by disk diffusion method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Microwave-induced synthesis and anti-microbial activities of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. |
| AID425071 | Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID287374 | Antibacterial activity against Bacillus cereus after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID74853 | Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB) | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. |
| AID71793 | Percentage of GABA-induced chloride currents with 10 e-5 M 4-biphenylacetic acid | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID396096 | Antibacterial activity against Staphylococcus aureus K1758-A overexpressing mepA by broth microdilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. |
| AID429019 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG15 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID69784 | Antibacterial activity against Escherichia coli (vogel) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID1743459 | Antitubercular activity against FQ resistant Mycobacterium tuberculosis H37Rv harboring gyrA Ser-91-Pro mutant measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID205650 | Compound was tested for antibacterial activity against gram positive Staphylococcus aureus FDA 209P JC-1 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID581501 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID38471 | Activity against Bacillus subtilis (ATCC 6633) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID1412151 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by microbroth dilution method | 2018 | MedChemComm, Jan-01, Volume: 9, Issue:1 | Design, synthesis and antibacterial evaluation of a polycationic calix[4]arene derivative alone and in combination with antibiotics. |
| AID279827 | AUC(0-infinity) in BALB/c mouse at 37.5 to 2400 mg/kg, po | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID1230234 | Antibacterial activity against Listeria monocytogenes N851 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID563210 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID447083 | Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID515780 | Intrinsic solubility of the compound in water | 2010 | Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19 | QSAR-based solubility model for drug-like compounds. |
| AID1360042 | Bactericidal activity against Staphylococcus aureus after 24 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID563057 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID162776 | In vitro minimum inhibitory concentration against Pseudomonas aeruginosa E-2 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID535848 | Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID562790 | Antimicrobial activity against Chlamydia trachomatis J/6276/tetR harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1321386 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2016 | Journal of medicinal chemistry, 10-13, Volume: 59, Issue:19 | The Rational Design, Synthesis, and Antimicrobial Properties of Thiophene Derivatives That Inhibit Bacterial Histidine Kinases. |
| AID279822 | Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 7 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. |
| AID1502713 | Antimycobacterial activity against Mycobacterium avium isolate MAV4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID1437019 | Antimycobacterial activity against isoniazid/rifampicin/ethambutol-sensitive Mycobacterium tuberculosis H37Rv after 4 days by Alamar blue assay | 2017 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4 | Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives. |
| AID1672291 | Antifungal activity against Candida tropicalis assessed as fungal growth inhibition after 24 hrs by CLSI protocol based broth microdilution assay | |||
| AID70426 | Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RE45 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID433582 | Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID523004 | Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID763994 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by two-fold serial dilution method | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis, biological evaluation and molecular docking studies of some pyrimidine derivatives. |
| AID498785 | Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. |
| AID70804 | Inhibition of growth of Escherichia coli vogel | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID65376 | Tested in vitro for antibacterial activity agains Enterococcus faecalis (IID 682) | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID1480943 | Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay | 2017 | European journal of medicinal chemistry, Apr-21, Volume: 130 | Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. |
| AID322315 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID581514 | Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G and D94A mutant genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID563020 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID209278 | Antimicrobial activity against the streptococcus pyogenes 2548 by 2-fold agar dilution method using brain-heart infusion agar. | 1987 | Journal of medicinal chemistry, Dec, Volume: 30, Issue:12 | Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin). |
| AID96239 | Evaluated for minimum inhibitory concentration against gram-negative bacteria Klebsiella pneumoniae MGH-2 | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID562795 | Antimicrobial activity against Chlamydia muridarum MoPn/oflR-rifR harboring ompA and rpoB genes | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID1463959 | Antimycobacterial activity MDR/XDR against Mycobacterium tuberculosis isolate 9449/2007 incubated for 14 days by micromethod | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. |
| AID1163981 | Cytotoxicity against mouse RAW264.7 cells at 100 uM after 72 hrs by MTT assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID164565 | Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa AK109 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID1502707 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID563213 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1224517 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | 1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria. |
| AID1331877 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1368749 | Antibacterial activity against Bacillus subtilis MTCC 441 at 1 ug/ml under overnight incubation condition by paper disc method | 2018 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2 | Synthesis and biological evaluation of 1-amino isochromans from 2-bromoethyl benzaldehyde and amines in acid medium. |
| AID371458 | Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID563021 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID295851 | Antimicrobial activity against Proteus vulgaris KUKEM1329 by disk diffusion method at 10 ug/disc | 2007 | European journal of medicinal chemistry, Jul, Volume: 42, Issue:7 | Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. |
| AID1296387 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis Praha 4 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID162792 | Inhibition of growth of Pseudomonas aeruginosa | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID287373 | Antibacterial activity against Klebsiella pneumoniae after 72 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Feb, Volume: 42, Issue:2 | Synthesis, characterization and antimicrobial activity of Fe(II), Zn(II), Cd(II) and Hg(II) complexes with 2,6-bis(benzimidazol-2-yl) pyridine ligand. |
| AID1413648 | Antibacterial activity against methicillin-resistant Staphylococcus aureus JCSC 4788 at sub-MIC re-passaged at 24 hrs intervals for 5 times by micro dilution susceptibility test | 2018 | MedChemComm, Oct-01, Volume: 9, Issue:10 | Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains. |
| AID164245 | Antibacterial activity against Pseudomonas aeruginosa UI-18 | 1988 | Journal of medicinal chemistry, Mar, Volume: 31, Issue:3 | 7-substituted 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids: synthesis and biological activity of a new class of quinolone antibacterials. |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID295852 | Antimicrobial activity against Streptococcus pyogenes ATCC 176 by disk diffusion method at 10 ug/disc | 2007 | European journal of medicinal chemistry, Jul, Volume: 42, Issue:7 | Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. |
| AID208893 | Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228. | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID1331875 | Antibacterial activity against Escherichia coli MC1061 | 2017 | Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1 | Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents. |
| AID1413531 | Toxicity in Escherichia coli after 18 to 24 hrs by two-fold serial dilution method | 2018 | MedChemComm, Aug-01, Volume: 9, Issue:8 | Design, synthesis, and biological evaluation of |
| AID203326 | In vitro antibacterial activity against Serratia marcescens S-9 | 1990 | Journal of medicinal chemistry, Jun, Volume: 33, Issue:6 | Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. |
| AID562826 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID428997 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT142 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563053 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID285162 | Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. |
| AID1516025 | Antibacterial activity against Escherichia coli 20411 clinical isolate incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID52938 | Compound was tested for antibacterial activity against gram negative Citrobacter freundii No.7 | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID1593374 | Inhibition of Pks13 D1644G/N1640K double mutant thioesterase domain in multidrug-resistant Mycobacterium tuberculosis V2475 assessed as reduction in bacterial growth by microplate alamar blue assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7 | Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. |
| AID371466 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID535839 | Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID563044 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID562789 | Antimicrobial activity against Chlamydia trachomatis L2/tetR13 harboring tet(C) allele | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. |
| AID391978 | Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT mutant with inactivated qnr gene by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID559553 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID563019 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID197995 | Activity against Staphylococcus aureus (IID 803) | 1990 | Journal of medicinal chemistry, Jul, Volume: 33, Issue:7 | Synthesis and antibacterial activity of thiazolo-, oxazolo-, and imidazolo[3,2-a][1,8]naphthyridinecarboxylic acids. |
| AID562946 | Upregulation of slpA gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID563022 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563335 | Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID572515 | Antimicrobial activity against Salmonella enterica serovar Stanley isolate s2043 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID532989 | Antibacterial activity against Klebsiella aerogenes NCIM 2281 in presence of 10 mM N-Acetylcysteine | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. |
| AID563054 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID395716 | Antibacterial activity against Escherichia coli DH10B by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1360044 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by micro broth dilution method | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Free radical rearrangement synthesis and microbiological evaluation of novel 2-sulfoether-4-quinolone scaffolds as potential antibacterial agents. |
| AID1577337 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis 7357/1998 after 21 days | 2019 | Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17 | Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. |
| AID562825 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID550049 | Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of visible growth after 48 hrs by agar dilution method | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID530404 | Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrA QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID151535 | Tested in vitro against Pseudomonas aeruginosa E-2 by agar dilution method | 1993 | Journal of medicinal chemistry, Sep-17, Volume: 36, Issue:19 | Synthesis of antimicrobial agents. 5. In vivo metabolism of 7-(4-hydroxypiperazin-1-yl)quinolones. |
| AID1516085 | Antibacterial activity against ciprofloxacin-resistant Escherichia coli ATCC 25922 incubated for 18 to 24 hrs | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID562936 | Upregulation of cwp84 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID563008 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID562938 | Upregulation of cwp84 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID581496 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94Y mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1326672 | Growth inhibition of mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Oct-21, Volume: 122 | Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. |
| AID1765292 | Permeability of compound by PAMPA-BBB assay | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. |
| AID425074 | Antimicrobial activity against Escherichia coli DH10B in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID1309355 | Antimycobacterial activity against Mycobacterium terrae after 24 hrs by microbroth dilution method | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidines. |
| AID1557298 | Protein binding in human at 0.4 g, po bid | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1653554 | Antimicrobial activity against Mycobacterium leprae assessed as microbial growth at 0.375 ug/ml in presence of 0.025 ug/ml rifabutin measured at 4 weeks (Rvb = 147 +/- 19.1%) | 2019 | Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13 | Insights of synthetic analogues of anti-leprosy agents. |
| AID1326670 | Inhibition of Mycobacterium smegmatis 155 6His-tagged DNA gyrase B catalytic domain ATPase activity expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as inorganic phosphate release after 120 mins in presence of ATP by malachite green dye based | 2016 | European journal of medicinal chemistry, Oct-21, Volume: 122 | Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. |
| AID324746 | Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID530374 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID557090 | Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. |
| AID391980 | Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23 promoter by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID572509 | Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate SL1344 harboring wild type ParC gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID405477 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 5 ug by disc diffusion method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. |
| AID530381 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant assessed as concentration required for inducing cleavage | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1172969 | Antibacterial activity against Escherichia coli TG1 | 2014 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23 | Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity. |
| AID656229 | Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay | 2012 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8 | Antimycobacterial activity of bisbenzylisoquinoline alkaloids from Tiliacora triandra against multidrug-resistant isolates of Mycobacterium tuberculosis. |
| AID429020 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG16 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1230231 | Antibacterial activity against Listeria monocytogenes CIP 103575 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID562941 | Effect on fbp69 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID530375 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID391975 | Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID559369 | Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID572521 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2209 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID1449628 | Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12 | Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. |
| AID1516022 | Antibacterial activity against Escherichia coli UB1005 incubated for 18 to 24 hrs by broth microdilution method | 2019 | Journal of medicinal chemistry, 08-08, Volume: 62, Issue:15 | Design of Trp-Rich Dodecapeptides with Broad-Spectrum Antimicrobial Potency and Membrane-Disruptive Mechanism. |
| AID531333 | Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID405478 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 30 ug by disc diffusion method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID427196 | Membrane permeability by PAMPA-BBB assay | 2009 | Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17 | Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. |
| AID1890597 | Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth incubated for 18 hrs by CLSI based serial agar dilution method | 2022 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 63 | WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1296383 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 234/2005 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID395777 | Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by twofold serial dilution technique | 2008 | European journal of medicinal chemistry, Nov, Volume: 43, Issue:11 | Synthesis, antimicrobial activity, pharmacophore analysis of some new 2-(substitutedphenyl/benzyl)-5-[(2-benzofuryl)carboxamido]benzoxazoles. |
| AID208894 | Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76. | 1986 | Journal of medicinal chemistry, Apr, Volume: 29, Issue:4 | 1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity. |
| AID293586 | Antibacterial activity against Staphylococcus aureus isolate assessed after 24 hrs by serial dilution method | 2007 | Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5 | Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5)-nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. |
| AID391986 | Antibacterial activity against Staphylococcus aureus RN4220 by twofold dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID563101 | Upregulation of fbp68 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID428977 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate D43 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID385163 | Antimicrobial activity against Escherichia coli by broth microdilution method | 2008 | Journal of natural products, Apr, Volume: 71, Issue:4 | Antimicrobial triterpenoids from Vladimiria muliensis. |
| AID535832 | Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID563227 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1743446 | Antibacterial activity against Enterobacter aerogenes measured after 7 days by resazurin microtiter assay | 2020 | European journal of medicinal chemistry, Dec-01, Volume: 207 | Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. |
| AID442659 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2010 | European journal of medicinal chemistry, Jan, Volume: 45, Issue:1 | Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives. |
| AID563342 | Induction of Cwp84 protease expression in Clostridium difficile CD07-259 at 0.5 times MIC by immunoblot analysis | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID562827 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1231421 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13 | Synthesis and biological evaluation of caracasine acid derivatives. |
| AID1230232 | Antibacterial activity against Listeria monocytogenes N783 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID447081 | Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID205653 | Compound was tested for antibacterial activity against gram positive Staphylococcus aureus smith | 1998 | Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20 | Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4-trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones. |
| AID206009 | Minimum inhibitory concentration required in vitro against Staphylococcus aureus | 1999 | Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12 | Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. |
| AID563501 | Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Mutational upregulation of a resistance-nodulation-cell division-type multidrug efflux pump, SdeAB, upon exposure to a biocide, cetylpyridinium chloride, and antibiotic resistance in Serratia marcescens. |
| AID210022 | Antibacterial activity against Streptococcus pneumoniae (SV-1) | 1986 | Journal of medicinal chemistry, Mar, Volume: 29, Issue:3 | New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. |
| AID1502708 | Antimycobacterial activity against Mycobacterium avium 104 mc'2 4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140 | Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium. |
| AID563034 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1301200 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 10 days by micro broth dilution method | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. |
| AID530420 | Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID209240 | Inhibition of growth of Streptococcus faecalis | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | New "ofloxacin" type antibacterial agents. Incorporation of the spiro cyclopropyl group at N-1. |
| AID559370 | Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID1126742 | Antibacterial activity against 1 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay | 2014 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8 | Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents. |
| AID581495 | Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94N mutant gene | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. |
| AID1230248 | Antibacterial activity against Staphylococcus saprophyticus E260 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID429008 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT42 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID429029 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID405470 | Antibacterial activity against oxacillin-dependent methicillin-resistant Staphylococcus aureus 2884D isolate at 5 ug by disc diffusion method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. |
| AID572524 | Antimicrobial activity against qnrS-positive Salmonella enterica serovar Stanley isolate s2018 harboring ParC QRDR mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype. |
| AID563011 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID123085 | In vitro antibacterial activity against Micrococcus luteus ATCC 9341 | 1992 | Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25 | Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids. |
| AID1296385 | Antimycobacterial activity against multi drug resistant Mycobacterium tuberculosis 8666/2010 after 14 days by microdilution method | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis. |
| AID428981 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate C152 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1167605 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold agar dilution method | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA. |
| AID1230209 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by agar dilution method | 2015 | Journal of natural products, Jun-26, Volume: 78, Issue:6 | Antibacterial Labdane Diterpenoids from Vitex vestita. |
| AID535847 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation. |
| AID522870 | Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 400 to 700 ug/ml after 12 hrs by serial dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. |
| AID428989 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 28 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID96421 | In vitro minimum inhibitory concentration against Klebsiella pneumoniae B54 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID560260 | Antimicrobial activity against Salmonella enterica serovar Typhimurium transconjugant p61/9T expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium. |
| AID534419 | Antibacterial activity against Mycobacterium bovis BCG-Connaught | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. |
| AID447217 | Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by agar disk diffusion assay | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Synthesis, Raman, FT-IR, NMR spectroscopic characterization, antimicrobial activity, cytotoxicity and DNA binding of new mixed aza-oxo-thia macrocyclic compounds. |
| AID67422 | In vitro minimum inhibitory concentration against E. Faecalis IID682 | 1993 | Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18 | Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids. |
| AID164713 | Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa IFO 3445 (Pa(I)) | 1994 | Journal of medicinal chemistry, Aug-19, Volume: 37, Issue:17 | Synthesis and antibacterial activity of thiazolopyrazine-incorporated tetracyclic quinolone antibacterial agents. 2. |
| AID563013 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID530425 | Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1326671 | Inhibition of Mycobacterium tuberculosis DNA gyrase subunit A2B2 supercoiling activity using relaxed pBR322 as substrate after 30 mins in presence of ATP by agarose gel electrophoresis | 2016 | European journal of medicinal chemistry, Oct-21, Volume: 122 | Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. |
| AID733006 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electro | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID1183278 | Permeability of the compound by PAMPA | 2014 | European journal of medicinal chemistry, Sep-12, Volume: 84 | Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies. |
| AID110153 | Percentage of mice with convulsion with compound alone at 400 mg/kg | 1993 | Journal of medicinal chemistry, May-14, Volume: 36, Issue:10 | Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. |
| AID429032 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 3769 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID70721 | Evaluated for minimum concentration needed to produce linear DNA at an intensity relative to oxolinic acid at 10 mg/mL. by gyrase mediated cleavage of DNA in Escherichia coli 560. | 1990 | Journal of medicinal chemistry, Aug, Volume: 33, Issue:8 | Quinolone antibacterial agents substituted at the 7-position with spiroamines. Synthesis and structure-activity relationships. |
| AID559560 | Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. |
| AID371465 | Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by disk diffusion method | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Synthesis and biological activity of some new benzoxazoles. |
| AID530621 | Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrB QRDR | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. |
| AID1177576 | Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs by microdilution method | 2014 | Journal of natural products, Aug-22, Volume: 77, Issue:8 | Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus. |
| AID559582 | Antimicrobial activity against Chlamydophila psittaci infected in Vero cells | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. |
| AID391976 | Antibacterial activity against Escherichia coli ATCC 25922 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones. |
| AID1900247 | Permeability of the compound at pH 7.4 PBS/EtOH buffer (70:30) by PAMPA-BBB assay | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2 | TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. |
| AID295106 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method | 2007 | European journal of medicinal chemistry, Aug, Volume: 42, Issue:8 | Raman, FT-IR, NMR spectroscopic data and antimicrobial activity of bis[micro2-(benzimidazol-2-yl)-2-ethanethiolato-N,S,S-chloro-palladium(II)] dimer, [(micro2-CH2CH2NHNCC6H4)PdCl]2.C2H5OH complex. |
| AID1152778 | Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis harboring DNA gyraseA G88N mutant | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11 | Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1177577 | Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by microdilution method | 2014 | Journal of natural products, Aug-22, Volume: 77, Issue:8 | Lithocarpic Acids A-N, 3,4-seco-Cycloartane Derivatives from the Cupules of Lithocarpus polystachyus. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1224864 | HCS microscopy assay (F508del-CFTR) | 2016 | PloS one, , Volume: 11, Issue:10 | Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 679 (11.20) | 18.7374 |
| 1990's | 1543 (25.45) | 18.2507 |
| 2000's | 2270 (37.45) | 29.6817 |
| 2010's | 1307 (21.56) | 24.3611 |
| 2020's | 263 (4.34) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (126.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 976 (15.05%) | 5.53% |
| Reviews | 333 (5.14%) | 6.00% |
| Case Studies | 782 (12.06%) | 4.05% |
| Observational | 6 (0.09%) | 0.25% |
| Other | 4,387 (67.66%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma [NCT00002850] | Phase 3 | 212 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study [NCT01353339] | Phase 4 | 154 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers [NCT00659646] | Phase 2 | 56 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Standard Treatment [NCT03698682] | Phase 2 | 310 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection-A Randomized Clinical Trial [NCT03658746] | Phase 4 | 420 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for [NCT03739528] | Phase 3 | 808 participants (Actual) | Interventional | 2018-09-03 | Completed | ||
| A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as [NCT02439632] | Phase 3 | 216 participants (Anticipated) | Interventional | 2014-02-28 | Completed | ||
| Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy (PCNL) [NCT03178292] | 300 participants (Anticipated) | Interventional | 2017-06-15 | Not yet recruiting | |||
| Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori [NCT02422706] | Phase 3 | 120 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection and Its Influence on Recurrence Rate: a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study [NCT03658291] | Phase 4 | 252 participants (Anticipated) | Interventional | 2019-01-01 | Not yet recruiting | ||
| Efficacies of Tetracycline-levofloxacin Quadruple Therapy, Standard Bismuth Quadruple Therapy and Amoxicillin-levofloxacin Quadruple Therapy in the Second-line Treatment of H Pylori Infection [NCT05850117] | 240 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Treatment Guided by Markers of Inflammation [NCT02067780] | Phase 3 | 310 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT) [NCT00578474] | Phase 3 | 911 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers [NCT02128308] | Phase 1 | 16 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289] | 1,578 participants (Actual) | Observational | 2003-06-09 | Completed | |||
| Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants [NCT01349738] | 200 participants (Anticipated) | Observational | 2011-05-31 | Enrolling by invitation | |||
| Determination of a Trough Serum Concentration of Ofloxacin Associated to Increase in Side Effects Frequency in Elderly Treated for Bone and Joint Infection [NCT04496024] | 110 participants (Anticipated) | Interventional | 2020-06-02 | Recruiting | |||
| Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis [NCT03472144] | Phase 3 | 60 participants (Anticipated) | Interventional | 2017-07-07 | Recruiting | ||
| VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia [NCT02528123] | 187 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | |||
| High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials [NCT05863858] | Phase 3 | 162 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis [NCT00621387] | 56 participants (Actual) | Interventional | 1993-11-30 | Completed | |||
| Comparison of the Effectiveness of Preurodynamic Single Dose of Levofloxacin With Posturodynamic Levofloxacin for Three Days on the Incidence of Urinary Tract Infections [NCT05219877] | Phase 1/Phase 2 | 134 participants (Actual) | Interventional | 2022-02-04 | Completed | ||
| [NCT02157571] | Phase 3 | 360 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Evaluation of Lactated Ringers for Protection From Cisplatin Ototoxicity. [NCT00584155] | Phase 1 | 0 participants (Actual) | Interventional | 2006-07-31 | Withdrawn(stopped due to PI left the university.) | ||
| A Phase II, Multi-Center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW 1201 Compared to Ofloxacin Eye Drops in the Treatment of Acute Bacterial Conjunctivitis [NCT05816070] | Phase 2 | 129 participants (Actual) | Interventional | 2023-01-05 | Completed | ||
| Evaluation of the Congruity of Methods Used in the Diagnostics of Chronic Endometritis in the Course of Infertility and the Effectiveness of Antibiotic Therapy in the Context of Remission of Symptoms and Obstetric Results [NCT05946655] | 100 participants (Actual) | Interventional | 2021-04-01 | Completed | |||
| A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis [NCT00402688] | Phase 3 | 242 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction [NCT02540785] | 41 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic [NCT00683865] | Phase 3 | 749 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media [NCT02567825] | 250 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery [NCT03655665] | Phase 4 | 125 participants (Anticipated) | Interventional | 2019-05-16 | Recruiting | ||
| A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes [NCT00781521] | Phase 3 | 96 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| A Randomized, Double-masked, Parallel Group Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery (Levofloxacin 0.5% Ophthalmic Solution as a Comparator) - Phase III, Confirmatory Study of Perioperative Bacteria Eradicatio [NCT02573610] | Phase 3 | 576 participants (Actual) | Interventional | 2015-09-21 | Completed | ||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers [NCT00563394] | Phase 3 | 584 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. [NCT00873626] | Phase 4 | 310 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Phase 4 Study of Azitromicin in the Treatment of PID [NCT01241110] | Phase 4 | 100 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation [NCT05743101] | 80 participants (Anticipated) | Interventional | 2023-02-13 | Not yet recruiting | |||
| Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs [NCT00392275] | Phase 4 | 48 participants | Interventional | 2002-11-30 | Completed | ||
| An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections [NCT00516958] | Phase 2 | 65 participants (Anticipated) | Interventional | 2007-05-31 | Completed | ||
| Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis [NCT02551796] | 75 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach [NCT00250718] | Phase 2 | 17 participants (Actual) | Interventional | 2004-10-31 | Terminated(stopped due to Low rate of accrual) | ||
| Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study [NCT05126121] | 60 participants (Anticipated) | Interventional | 2021-11-20 | Not yet recruiting | |||
| Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke [NCT05741905] | 100 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy [NCT04502095] | Phase 4 | 100 participants (Anticipated) | Interventional | 2020-09-02 | Recruiting | ||
| Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial. [NCT02726269] | Phase 3 | 230 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| An Open-label, Randomized, 3-way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects [NCT00602589] | Phase 1 | 72 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers [NCT00563433] | Phase 3 | 342 participants (Actual) | Interventional | 1994-08-31 | Completed | ||
| Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial [NCT05549115] | 500 participants (Anticipated) | Interventional | 2022-09-20 | Recruiting | |||
| Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871] | Phase 3 | 35 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment [NCT02988089] | Phase 4 | 480 participants (Anticipated) | Interventional | 2017-04-20 | Recruiting | ||
| Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate [NCT00480376] | Phase 4 | 160 participants (Anticipated) | Interventional | 2007-06-30 | Not yet recruiting | ||
| A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis [NCT00565123] | Phase 2/Phase 3 | 119 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Effect of Nasal Ointment on Epistaxis of Nasotracheal Intubation in Children: A Randomized Controlled Trial [NCT04426409] | 108 participants (Actual) | Interventional | 2020-07-08 | Completed | |||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial [NCT01537055] | Phase 4 | 600 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) [NCT01537250] | Phase 2 | 192 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxa [NCT00035347] | Phase 4 | 219 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial [NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients [NCT01573910] | Phase 3 | 985 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Treatment of Methicillin-sensitive Staphylococcus Aureus Orthopaedic Infections With Clindamycin in Combination With Rifampin or Levofloxacin: a Randomized Pharmacological and Clinical Study (the CLINDOS Trial) [NCT01500837] | 23 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure [NCT04810793] | 820 participants (Actual) | Observational [Patient Registry] | 2020-07-01 | Completed | |||
| A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade Surgery [NCT03933631] | Phase 3 | 142 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| "A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients." [NCT01761201] | Phase 3 | 68 participants (Actual) | Interventional | 2012-01-31 | Terminated(stopped due to Recruitment rythm not sufficent to reach the simple size needed.) | ||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So [NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment [NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Descemet Endothelial Thickness Comparison Trial [NCT02373137] | Phase 4 | 38 participants (Actual) | Interventional | 2015-01-22 | Active, not recruiting | ||
| Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial [NCT05799326] | 100 participants (Anticipated) | Interventional | 2023-06-30 | Recruiting | |||
| An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia [NCT03551210] | Phase 3 | 342 participants (Actual) | Interventional | 2016-05-04 | Completed | ||
| Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection - a Multi-center Randomized Controlled Trial [NCT03779087] | 112 participants (Actual) | Interventional | 2018-07-11 | Completed | |||
| Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan [NCT03832465] | Phase 4 | 20 participants (Actual) | Interventional | 2019-06-14 | Completed | ||
| [NCT01799356] | Phase 4 | 1,303 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Usefulness of Melatonin Supplementation in Postmenopausal Women With Helicobacter Pylori-associated Dyspepsia [NCT04352062] | 152 participants (Actual) | Interventional | 2011-01-09 | Completed | |||
| A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Trabectome Surgery [NCT04005079] | Phase 3 | 0 participants (Actual) | Interventional | 2019-06-05 | Withdrawn(stopped due to not performing Trabectomes) | ||
| Personalized Treatment for Refractory H Pylori Infection [NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial [NCT02424461] | Phase 3 | 400 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Aqueous Humour Concentrations After Topical apPlication of combinEd Levofloxacin-dexamethasone Eye dRops and of Its Single Components: a randoMized, assEssor-blinded, Parallel-group Study in Patients Undergoing Cataract Surgery - iPERME [NCT03740659] | Phase 2 | 125 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections [NCT03160807] | Phase 4 | 214 participants (Anticipated) | Interventional | 2017-04-15 | Recruiting | ||
| Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model [NCT02357407] | Phase 4 | 31 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori. [NCT01575899] | Phase 4 | 208 participants (Actual) | Interventional | 2007-12-31 | Terminated(stopped due to Early termination due to efficacy) | ||
| Comparison of Ofloxacin and Metronidazole/Amoxicillin on the Treatment of Periodontitis. [NCT04353362] | Phase 4 | 74 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| Bioequivalence Study of Levomerc (Levofloxacin) 500 mg Tablet With Tavanic (Levofloxacin) 500 mg Tablets [NCT05339295] | Phase 1 | 24 participants (Actual) | Interventional | 2012-07-11 | Completed | ||
| Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections [NCT03378427] | 35 participants (Actual) | Interventional | 2018-08-28 | Completed | |||
| Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients [NCT01270347] | Phase 3 | 267 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis [NCT05398679] | Phase 4 | 360 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations [NCT01988779] | Phase 3 | 33 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study [NCT05302531] | Phase 1 | 10 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||